UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-K

ANNUAL REPORT

PURSUANT TO SECTIONS 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Fiscal Year Ended September 30, ~~2022~~2023

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Transition Period from to

Commission File Number 000-56112

GENUFOOD ENERGY ENZYMES CORP.

(Exact name of registrant as specified in its charter)

Nevada		68-0681158
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

1108 S. Baldwin Avenue, Suite 107

Arcadia, California 91007

(Address of principal executive offices, including zip code)

Registrant’s telephone number, including area code: (855) 707-2077

Securities registered pursuant to Section 12(b) of the Act: None

Title of each class		Name of each exchange on which registered

Securities registered pursuant to Section 12(g) of the Act:

Common Stock

Indicate by check mark whether the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No ☒

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No ☒

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of the registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer”, “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☒
Smaller reporting company	☒	Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☐

~~Indicate~~If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the ~~registrant~~financial isstatements aof ~~shell~~the ~~company~~registrant ~~(as~~included ~~defined~~ in ~~Rule~~the ~~12b-2~~filing reflect the correction of ~~the~~an ~~Exchange~~error ~~Act).~~to ~~Yes~~previously ☒issued Nofinancial statements. ☐

AsIndicate ofby ~~January~~check ~~11,~~mark ~~2023, there were 299,686,921 shares outstanding,~~whether ~~$0.001~~any ~~par~~of ~~value~~those ~~per~~error ~~share,~~corrections ofare ~~the~~restatements ~~registrant’s~~that ~~common~~required ~~stock~~a ~~outstanding.~~recovery Noanalysis ~~market~~of ~~value~~incentive-based ~~has~~compensation ~~been~~received ~~computed~~by ~~based~~any ~~upon~~of the ~~fact~~ ~~that~~registrant’s noexecutive ~~active~~officers ~~trading~~during ~~market~~the ~~had~~relevant ~~been~~recovery ~~established~~period aspursuant ofto ~~September 30, 2022~~§240.10D-1(b). ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of January 9, 2024, there were 808,900,041 shares outstanding, $0.001 par value per share, of the registrant’s common stock outstanding. No market value has been computed based upon the fact that no active trading market had been established as of September 30, 2023.

GENUFOOD ENERGY ENZYMES CORP.

FORM 10-K FOR THE FISCAL YEAR ENDED SEPTEMBER 30, ~~2022~~2023

TABLE OF CONTENTS

		Page
PART I
ITEM 1.	BUSINESS	1
ITEM 1A.	RISK FACTORS	43
ITEM 1B.	UNRESOLVED STAFF COMMENTS	43
ITEM 2.	PROPERTIES	43
ITEM 3.	LEGAL PROCEEDINGS	43
ITEM 4.	MINE SAFETY DISCLOSURES	43
PART II
ITEM 5.	MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES	54
ITEM 6.	[RESERVED]	65
ITEM 7.	MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS	65
ITEM 7A.	QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK	1210
ITEM 8.	FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA	1210
ITEM 9.	CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE	1210
ITEM 9A.	CONTROLS AND PROCEDURES	1210
ITEM 9B.	OTHER INFORMATION	1412
ITEM 9C.	DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS	1412
PART III
ITEM 10.	DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE	1513
ITEM 11.	EXECUTIVE COMPENSATION	1715
ITEM 12.	SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS	2018
ITEM 13.	CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE	2119
ITEM 14.	PRINCIPAL ACCOUNTING FEES AND SERVICES	2119
PART IV
ITEM 15.	EXHIBITS AND FINANCIAL STATEMENT SCHEDULES	2220
ITEM 16.	FORM 10-K SUMMARY	2221
SIGNATURES		2322
POWER OF ATTORNEY		2322

GENERAL NOTE

We refer to our business from the period from inception (June 21, 2010) through approximately mid- to late-2016, as our “historic period”, the business conducted during the historic period as our “original business” and the management of our company during the historic period as “Oliver Lin’s management”.

FORWARD-LOOKING STATEMENTS

This document contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934 (the “Exchange Act”). All statements other than statements of historical fact are “forward-looking statements” for purposes of federal and state securities laws, including, but not limited to, any projections of earnings, revenue or other financial items; any statements of the plans, strategies and objectives of management for future operations; any statements concerning proposed new services or developments; any statements regarding future economic conditions or performance; any statements of belief; and any statements of assumptions underlying any of the foregoing.

Forward-looking statements may include the words “may,” “could,” “will,” “estimate,” “intend,” “continue,” “believe,” “expect” or “anticipate” or other similar words. These forward-looking statements present our estimates and assumptions only as of the date of this report. Except for our ongoing obligation to disclose material information as required by the federal securities laws, we do not intend, and undertake no obligation, to update any forward-looking statement.

Although we believe that the expectations reflected in any of our forward-looking statements are reasonable, actual results could differ materially from those projected or assumed in any of our forward-looking statements. Our future financial condition and results of operations, as well as any forward-looking statements, are subject to change and inherent risks and uncertainties. Some of the key factors impacting these risks and uncertainties include, but are not limited to:

●

risks related to our ability to identify, pursue and commence a reverse merger and/or a possible operating business;

●

our ability to obtain adequate funding to complete a reverse merger or commence a possible operating business and meet our operating expenses on a current basis;

●

general economic uncertainty, whether as a result of the COVID-19 pandemic or otherwise;

●

delays in our ability to obtain any necessary business licenses and permits, and commence business operations, whether as a result of the COVID-19 pandemic or otherwise; and

●

current and longer-term economic and other impacts of the COVID-19 pandemic on our operations, results of operations and financial condition, including without limitation changes in consumer spending patterns for non-essential products, resulting from the economic crisis caused by lockdown, shelter-in-place, stay-at-home or similar orders instituted as a result of the pandemic, or otherwise.

ITEM 1. BUSINESS

The discussion of the business of Genufood Energy Enzymes Corp. and its wholly-owned subsidiary (“Genufood” “we” or the “Company”), is as of the date of filing this report, unless otherwise indicated.

Original Business

During our historic period, we were a start-up company whose main focus was to promote, market, distribute and export a range of enzyme products manufactured in the United States for sale for human and animal consumption in certain Asian markets, including the Association of Southeast Asian Nations (“ASEAN”). Our objective was to commence marketing and distribution of a range of enzyme products for human and animal consumption to sole country distributors, wholesalers, dealers and retailers, as well as to the general public following a Multi-Level Marketing – - Franchise Investor Dealer Related (MLM-FIDR) concept, beginning in Taiwan, and then China, Hong Kong, Macau, Thailand, Malaysia, Singapore and Sri Lanka.

At some point, which we believe may have occurred approximately mid- to late-2016, Oliver Lin’s management ceased operating our original business. We have not generated any revenue from operations since that time.

~~Recent~~Genufood Energy Enzymes Corp. ~~Developments~~was incorporated in Nevada on June 21, 2010. Our principal place of business is located at 1108 S. Baldwin Avenue, Suite 107, Arcadia, California 91007 and our telephone number is (855) 707-2077. Our website is www.geecenzymes.com. No part of our website is incorporated into this report.

~~In 2019~~Recent and through the end of fiscal 2021, we explored plans to restart our enzyme products business or develop a new business. In 2019 and through early 2020, we had planned to restart our original enzyme products business, by importing enzyme supplements from the United States for sale in Taiwan. However, due to the COVID-19 pandemic, all non-COVID-19 related matters, including obtaining an import license from Taiwan’s Ministry of Economic Affairs and the Taiwan Food and Drug Administration (“FDA”), were delayed or were taking longer than usual in Taiwan beginning in late-January 2020. For various reasons, including the fact that, without a reasonably foreseeable end of the pandemic and Taiwan government resources being shifted to dealing with the pandemic, we decided to abandon the plan to restart our enzyme products business.Developments

~~During fiscal~~On ~~year~~August ~~2020~~1, we2022, ~~announced~~the ~~that~~board of wedirectors ~~were~~(the in“Board”) of the ~~preliminary~~Company ~~stage~~unanimously ofapproved ~~developing~~to aexpand ~~new~~our business ~~plan~~in tothe ~~sell~~area ~~and~~of ~~distribute~~electric ~~physiological~~vehicle supply ~~sea~~equipment ~~water~~(“EVSE”) and ~~nasal~~will ~~spray~~direct inthe ~~Taiwan~~management ~~and~~team ~~the~~to ~~United~~implement ~~States~~our new business plan in such industry. ~~However~~On August 16, 2022, ~~after~~we ~~exploring~~formally ~~this~~announced ~~possible~~our ~~business~~intention to reposition as aEVSE ~~result~~solutions ofprovider, ~~several~~seeking ~~factors~~to grow business in EVSE industry, including building, ~~but~~owning, ~~not~~and ~~limited~~operating tothe ~~difficulties~~next ingeneration ~~commencing~~of aelectric ~~new~~vehicle ~~business~~charging ~~during~~stations in the ~~ongoing~~U.S. ~~COVID-19~~We ~~pandemic~~intend to bring convenient, wereliable, and ~~decided~~accessible ~~not~~charging experience to ~~pursue the~~electric ~~nasal~~vehicle ~~spray~~drivers, ~~business~~utilizing frictionless technology and carbon-neutral vehicle-charging infrastructure.

~~In September~~On ~~2020~~October 26, we2022, ~~announced that~~ we ~~were~~entered into ~~exploring~~three ~~business~~Charging ~~opportunities~~Station ~~for~~Site ~~medical~~Host ~~mask,~~Agreements ~~medical-grade~~(the ~~gloves~~“Agreements”) ~~and~~with ~~possibly~~two ~~other PPE.~~institutions ~~During~~(the ~~fiscal~~“Site ~~2021~~Hosts”), respectively, ~~due~~pursuant to ~~lack~~which ofthe ~~sufficient~~Site ~~funding,~~Hosts weagree ~~decided~~to ~~not~~allow us to ~~pursue~~install ~~the~~our ~~PPE~~electric ~~business.~~vehicle Wecharging ~~continued~~stations toat ~~explore~~the ~~other~~locations set ~~products~~forth ~~with~~in ~~high~~the ~~demand~~Agreements ~~since~~ (the ~~advent~~“Charging ofStations”). Under the ~~COVID-19 pandemic~~Agreements, ~~specifically~~we ~~rapid~~have ~~test~~agreed ~~kits. However, due~~ to ~~lack~~share ofour ~~funding~~revenue ~~and other~~generated ~~factors, including~~ by the ~~size~~sales of ~~enterprise~~electricity ~~needed~~at tothe ~~successfully~~Charging ~~carry~~Stations ~~out~~with ~~such~~the aSite ~~business,~~Hosts wein noaccordance ~~longer~~with ~~intend~~the toschedules ~~pursue~~set ~~this business~~forth therein.

OnAs ~~August 1, 2022, the board~~ of ~~directors~~September (the “Board”) of the Company unanimously approved to expand our business in the area of electric vehicle supply equipment (“EVSE”) and will direct the management team to implement our new business plan in such industry. On August 1630, ~~2022~~2023, we ~~formally announced our intention~~ tohad ~~reposition~~two assites ~~EVSE~~under ~~solutions~~construction ~~provider,~~for ~~seeking~~charging tostations ~~grow business in EVSE industry, including building, owning,~~ and ~~operating~~three ~~the~~sites ~~next generation~~under ofplanning ~~electric~~for ~~vehicle~~future ~~charging stations in the U~~construction.S. We ~~intend~~are toactively ~~bring convenient, reliable,~~ negotiating and ~~accessible~~searching ~~charging~~for ~~experience to~~additional ~~electric~~sites ~~vehicle~~for ~~drivers,~~future ~~utilizing frictionless technology and carbon-neutral vehicle-charging infrastructure~~development.

OnAt ~~October~~this 26time, ~~2022,~~ we ~~entered~~reserve ~~into three Charging Station Site Host Agreements (~~the ~~“Agreements”) with two institutions (the “Site Hosts”), respectively, pursuant to which the Site~~ ~~Hosts~~right ~~agree~~ to ~~allow~~further uschange ~~to install~~ our ~~electric~~business ~~vehicle~~plan ~~charging stations~~ at ~~the~~any ~~locations set forth in the Agreements (the “Charging Stations”)~~time. ~~Under the Agreements, we have agreed to share our revenue generated by the sales of electricity at the Charging Stations with the Site Hosts in accordance with the schedules set forth therein.~~

~~At this time, we reserve the right to further change our business plan at any time.~~ 1

1Hukui Investment

In late September 2020, we announced that we and Hukui Biotechnology Corporation (“Hukui”) had entered into a Series C Preferred Shares Subscription ~~Investment~~Agreement dated September 23, 2020 (the “Hukui Agreement”), pursuant to which we have agreed to purchase an aggregate 200,000 shares of Hukui’s Series C Preferred Stock (“Series C Preferred Shares”) at $10.00 per share, for an aggregate investment of $2,000,000.

~~In late~~The ~~September~~Hukui ~~2020,~~Agreement ~~we announced~~ provided that we ~~and~~would ~~Hukui~~purchase ~~Biotechnology~~the ~~Corporation (“Hukui”) had entered into a~~ Series C Preferred Shares ~~Subscription~~in ~~Agreement~~three ~~dated September 23~~tranches, ~~2020~~through ~~(the~~a ~~“Hukui~~date ~~Agreement”),~~on ~~pursuant~~or tobefore ~~which~~June ~~we have agreed to purchase an aggregate 200~~30,~~000~~ ~~shares of Hukui’s Series C Preferred Stock (“Series C Preferred Shares”) at $10.00 per share~~2022, ~~for an~~as ~~aggregate investment of $2,000,000.~~ follows:

● The ~~Hukui~~ ~~Agreement~~first ~~provided~~tranche ~~that~~is we80,000 ~~would purchase the~~ Series C Preferred Shares in ~~three~~the ~~tranches~~amount of $800,000 ~~through~~(the a“First ~~date~~Tranche onInvestment”), orsuch ~~before~~shares ~~June~~having 30been purchased by us on December 15, ~~2022,~~ as2020 ~~follows:~~(the “First Tranche Closing”);

● The ~~first~~second tranche is 8060,000 Series C Preferred Shares in the amount of $~~800~~600,000 (the “~~First~~Second Tranche Investment”), such shares having been purchased by us on ~~December~~June 1525, ~~2020~~2021 (the “~~First~~Second Tranche Closing”); and

● The ~~second~~third tranche is 60,000 Series C Preferred Shares in the amount of $600,000 (the “~~Second~~Third Tranche Investment”), such shares ~~having~~to have been purchased byon usor onbefore June 2530, ~~2021~~2022 (the “~~Second~~Third Tranche Closing”)~~; and~~.

●Following ~~The~~the ~~third~~end ~~tranche~~of isour 602021 fiscal year,~~000~~ ~~Series~~an Cindividual ~~Preferred~~and ~~Shares~~resident inof the ~~amount~~Republic of ~~$600~~China (the “Purchaser”),~~000~~ Hukui and us entered into a Stock Purchase Agreement dated as of November 17, 2021 (the “~~Third~~Stock ~~Tranche~~Purchase ~~Investment~~Agreement”), ~~such~~pursuant ~~shares~~to which we agreed to ~~have~~sell ~~been~~the 140,000 shares of Hukui’s Series C Preferred Stock that we had purchased onin orthe ~~before~~First ~~June~~Tranche ~~30,~~Closing ~~2022~~and (the ~~“Third~~Second Tranche Closing (the “Hukui Shares”) to the Purchaser for $350,000 in cash, or $2.50 per share. The sale of the Hukui Shares closed on November 19, 2021.

~~Following the~~As ~~end~~a result of our ~~2021~~original purchase ~~fiscal~~of ~~year~~the first 80,000 anof ~~individual~~the ~~and~~Hukui ~~resident~~Shares ofon ~~the~~December ~~Republic~~15, of2020, ~~China~~together ~~(the~~with ~~“Purchaser”)~~certain other factors, ~~Hukui~~we ~~and~~may ushave ~~entered~~been deemed to ~~into~~be aan ~~Stock~~investment ~~Purchase~~company ~~Agreement~~under ~~dated~~the asInvestment ofCompany ~~November~~Act 17of 1940, ~~2021~~as amended (the “~~Stock~~Investment ~~Purchase~~Company ~~Agreement~~Act”),. ~~pursuant~~To tothe ~~which~~extent that we ~~agreed to~~may ~~sell~~have ~~the~~been ~~140,000~~deemed ~~shares~~to ofbe ~~Hukui’s~~an ~~Series~~investment Ccompany, ~~Preferred~~we ~~Stock~~have ~~that~~been werelying ~~had~~on ~~purchased~~Rule in3a-2 promulgated under the ~~First~~Investment ~~Tranche~~Company ~~Closing~~Act, allowing ~~and~~us ~~the~~to ~~Second Tranche~~terminate ~~Closing~~our ~~(the~~investment ~~“Hukui~~company ~~Shares”)~~status toon ~~the~~or ~~Purchaser~~before ~~for~~December ~~$350~~15,~~000~~ ~~in cash~~2021, orthe ~~$2.50~~first ~~per~~anniversary ~~share.~~of ~~The~~our ~~sale~~purchase of the first 80,000 of the Hukui Shares ~~closed~~, ~~on November~~without ~~19,~~having ~~2021~~to register and be regulated as an investment company.

~~As a~~Believing ~~result~~that ofit ~~our~~is ~~original~~not ~~purchase of~~ in the ~~first~~best ~~80,000~~interests of the ~~Hukui~~Company ~~Shares~~and onits ~~December~~shareholders ~~15,~~to ~~2020,~~register ~~together~~and ~~with~~be ~~certain~~regulated ~~other~~as ~~factors, we may have been deemed to be~~ an investment company under the Investment Company Act ~~of 1940~~, aswe ~~amended~~explored ~~(the~~different ~~“Investment~~lawful ~~Company Act”).~~means Toby ~~the~~which ~~extent that~~ we ~~may~~could ~~have~~terminate ~~been~~our ~~deemed~~potential ~~to be an~~ investment company, westatus. ~~have~~We ~~been~~determined ~~relying~~that onthe ~~Rule 3a-2 promulgated under~~only ~~the~~viable ~~Investment~~option ~~Company Act, allowing us~~ to terminate our potential investment company status onand orlawfully ~~before~~avoid ~~December~~registration ~~15,~~and ~~2021,~~regulation under the ~~first anniversary~~Investment ofCompany ~~our~~Act ~~purchase~~was ofto ~~the~~sell ~~first 80,000 of~~ the Hukui Shares, ~~without~~on ~~having~~or tobefore ~~register~~the ~~and~~December be15, ~~regulated~~2021, ~~as an investment company~~deadline.

~~Believing that~~After itmaking isdiligent ~~not~~efforts to inseek ~~the~~a ~~best~~purchaser ~~interests~~ of the ~~Company~~Hukui ~~and its shareholders to register and be regulated as an investment company under the Investment Company Act~~Shares, we ~~explored~~received ~~different~~three ~~lawful~~all-cash ~~means~~offers byto ~~which~~purchase wethe ~~could~~Hukui ~~terminate our potential investment company status~~Shares. We ~~determined~~ ~~that~~accepted the ~~only~~offer ~~viable~~of ~~option to terminate our potential investment company status and lawfully avoid registration and regulation~~the ~~under~~Purchaser, ~~the~~which ~~Investment Company Act~~ was ~~to sell~~ the ~~Hukui~~highest ~~Shares~~of onthe orthree ~~before~~all-cash ~~the~~offers ~~December~~that ~~15,~~we ~~2021 deadline~~received.

~~After~~We had purchased the Hukui ~~making~~Shares ~~diligent~~in ~~efforts~~two totranches, ~~seek~~on aDecember ~~purchaser~~15, of2020, and June 30, 2021, pursuant to the Hukui ~~Shares~~Agreement, weat ~~received~~$10.00 ~~three~~per ~~all-cash~~share, ~~offers~~for toan aggregate purchase price of $1,400,000. We sold the Hukui Shares at $2.50 Weper ~~accepted~~share, for a total price of $350,000, resulting in a loss of $1,050,000. ~~the~~We ~~offer~~recognized impairment loss of the ~~Purchaser,~~market ~~which~~value ~~was~~of the ~~highest~~shares of $1,050,000 for the ~~three~~year ~~all-cash~~ended ~~offers~~September ~~that~~30, we2021. ~~received~~See Note 4 to the Consolidated Financial Statements.

~~We had~~On ~~purchased~~December ~~the Hukui Shares in two tranches~~17, ~~on December 15~~2021, ~~2020~~ Hukui and ~~June~~us ~~30,~~entered ~~2021,~~into ~~pursuant~~an toAgreement (the ~~Hukui~~“Termination Agreement”), atpursuant ~~$10.00~~to ~~per share,~~which ~~for~~our anobligation ~~aggregate~~to ~~purchase~~make ~~price of $1,400,000. We sold~~ the ~~Hukui~~Third ~~Shares at $2.50 per share, for a total price of $350,000,~~Tranche ~~resulting~~Investment inwas ~~loss~~terminated ofand ~~$1,050,000. We recognized impairment loss of~~ the ~~market~~Hukui ~~value~~Agreement ofwas ~~the~~terminated. ~~shares~~As ofa $1result,~~050,000~~ ~~for~~we ~~the~~have ~~year~~no ~~ended~~continuing ~~September 30,~~contractual ~~2021.~~obligation ~~See Note 4~~ to ~~the~~make ~~Consolidated~~any investment ~~Financial~~in ~~Statements~~Hukui.

On December 17, 2021, Hukui and us entered into an Agreement (the “Termination Agreement”), pursuant to which our obligation to make the Third Tranche Investment was terminated and the Hukui Agreement was terminated. As a result, we have no continuing contractual obligation to make any investment in Hukui. 2

2With the sale of the Hukui Shares, we believe that we are no longer deemed to be an investment company as defined in the Investment Company Act and, accordingly, we are not required to register and be regulated as an investment company thereunder. Additionally, with the execution of the Termination Agreement, the possibility that we could again become an inadvertent investment company under the Investment Company Act has been removed.

~~With the~~We ~~sale~~have ofdecided ~~the~~to ~~Hukui~~expand our ~~Shares,~~business wein ~~believe~~the ~~that~~area weof ~~are~~electric novehicle ~~longer~~supply ~~deemed~~equipment to(“EVSE”), beand anwe ~~investment~~will ~~company~~need asto ~~defined~~raise incapital ~~the~~to ~~Investment~~pursue ~~Company~~such a ~~Act~~business. ~~and,~~There ~~accordingly,~~are weno ~~are~~commitments ~~not~~in ~~required~~place to ~~register~~fund ~~and~~such bebusiness ~~regulated~~and asno anguarantee ~~investment~~can ~~company~~be ~~thereunder.~~given ~~Additionally,~~that ~~with~~we ~~the~~will ~~execution of~~be ~~the~~able ~~Termination~~to ~~Agreement,~~secure ~~the~~such ~~possibility~~funding on terms that weare ~~could~~favorable ~~again~~to ~~become~~us, anor ~~inadvertent~~at ~~investment~~all ~~company under the Investment Company Act has been removed~~.

We have decided to expand our business in the area of electric vehicle supply equipment (“EVSE”), and we will need to raise capital to pursue such a business. There are no commitments in place to fund such business and no guarantee can be given that we will be able to secure such funding on terms that are favorable to us, or at all .Employees

~~Certain~~As of December 31, 2023, we ~~Regulatory~~had ~~Matters~~2 part time employees and 1 full time employee. Our employees were based in both Taiwan and USA.

~~Blank Check~~ITEM ~~Company~~ 1A. RISK FACTORS

~~Based on~~Not ~~the~~required ~~current~~for ~~and~~smaller ~~proposed business activities described above, the Company is a “blank check” company pursuant to Rule~~reporting 419(a)(2) under the Securities Act. The Securities and Exchange Commission (the “SEC”) defines a blank check company as “any development stage company that is issuing a penny stock, within the meaning of Section 3 (a)(51) of the Exchange Act, and that has no specific business plan or purpose, or has indicated that its business plan is to merge with an unidentified company or companies.”

~~Rule 419~~ITEM requires, among other things, that the proceeds of any public offering of penny stock securities by a blank check company, and all securities issued by a blank check company in such an offering, must be placed in a formal escrow or trust account until certain conditions specified in Rule 419 have been satisfied1B. InUNRESOLVED ~~addition,~~STAFF ~~many states have enacted statutes, rules and regulations limiting the sale of securities of “blank check” companies in their respective jurisdictions.~~ COMMENTS

~~Shell~~Not required for smaller reporting ~~Company~~ companies.

~~Pursuant to~~ITEM ~~Rule 12b-~~2 ~~under the Exchange Act, we are also a “shell company” because we have no or nominal assets (other than cash) and no or nominal operations~~. ~~As such, we are subject to a variety of regulations. As we have also previously disclosed, certain specific rules and regulations of the SEC apply to shell companies, including the following:~~PROPERTIES

●Our ~~Shell~~principal ~~companies~~executive ~~may~~offices are ~~not~~located ~~register~~at ~~securities~~1108 inS. ~~connection~~Baldwin ~~with~~Avenue, anSuite ~~employee~~107, ~~benefit~~Arcadia, ~~plan~~California ~~while~~91007. ~~they~~The ~~are~~arrangement ais ~~shell~~on ~~company~~a ~~and for 60 days after reporting certain current public information~~ month-to-month ~~the~~basis ~~SEC~~at ~~regarding~~a ~~transactions~~cost ~~or events resulting in the termination~~ of $200 ~~shell~~per ~~company status~~month.

●ITEM ~~Stockholders~~3. ofLEGAL shell companies may not rely on the exemption from registration provided by Rule 144, until the following primary requirements have been satisfied: (i) one year has elapsed since the company ceases to be a shell company and certain current information has been timely filed with the SEC regarding the cessation of the company’s status as a shell company; (ii) the company is subject to the reporting requirements under the Exchange Act; and (iii) the company has been current in all of its periodic SEC filings for the 12 months preceding the contemplated sale of stock.PROCEEDINGS

3There are presently no material pending legal proceedings to which we are a party or as to which any of our property is subject, and no such proceedings are known to us to be threatened or contemplated against us.

●ITEM ~~Reporting shell companies are required to disclose transactions and events that result in a shell company ceasing to be a shell company~~4. ~~Such~~MINE ~~disclosure~~SAFETY ~~is typically made on a Current Report on Form 8-K, which requires extensive information about the transactions and events in issue.~~DISCLOSURES

~~GEEC was~~Not ~~incorporated in Nevada on June 21, 2010~~applicable. Our principal place of business is located at 1108 S. Baldwin Avenue, Suite 107, Arcadia, California 91007 and our telephone number is (855) 707-2077. Our website is www.geecenzymes.com. No part of our website is incorporated into this report.

~~Employees~~3

AsPART ~~of November 30, 2022, we had 7 part time employees and 1 full time employee. Our employees were based in both Taiwan and USA.~~II

~~Not required~~Market ~~for smaller reporting companies.~~Information

~~ITEM 1B~~Our common stock (“Common Stock”) is not traded on any stock exchange and is occasionally quoted on the OTC Pink Market. As of December 31, 2023, there were ~~UNRESOLVED~~approximately ~~STAFF~~261 ~~COMMENTS~~record holders of our Common Stock.

~~Not required~~Dividend ~~for smaller reporting companies.~~Policy

~~ITEM 2~~We have not paid any cash dividends to date and do not anticipate or contemplate paying dividends in the foreseeable future. It is the present intention of management ~~PROPERTIES~~to utilize all available funds for the execution of our business model.

~~Our principal~~Securities ~~executive~~Authorized ~~offices~~for ~~are~~Issuance ~~located~~Under ~~at 1108 S. Baldwin Avenue, Suite 107, Arcadia, California 91007. The arrangement is on a month-to-month~~Equity ~~basis~~Compensation atPlans ~~a cost of $200 per month.~~

~~ITEM 3.~~We have not authorized the ~~LEGAL~~issuance ~~PROCEEDINGS~~of, or issued, any securities under a retirement, pension, profit sharing, stock option or other equity compensation plans.

~~There are~~Recent ~~presently~~Sales ~~no material pending legal proceedings to which we are a party or as to which any~~ of ~~our~~Unregistered ~~property is subject, and no such proceedings are known to us to be threatened or contemplated against us.~~Securities

~~ITEM 4~~On February 24, 2023, we sold 375,000,000 shares of our Common Stock at a purchase price of $0.001 per share, for gross and net proceeds of $375,000, before allocating ~~MINE~~certain ~~SAFETY~~expenses ~~DISCLOSURES~~associated with the offering in the amount of $13,000 as adjusted paid-in capital. See Note 6 to the Financial Statements.

~~Not~~On March 31, 2023, we issued ~~applicable~~an aggregate of 134,213,120 share of our Common Stock to certain of our current and former directors, officers, employees, and a consultant, who converted accrued and unpaid compensation in the aggregate amount of $134,213 at a rate of $0.001 per share of our Common Stock.

We offered and issued all of the foregoing securities under the exemption from registration provided by Section 4(a)(2) of the Securities Act, and/or Regulation D or Regulation S promulgated thereunder.

~~PART II~~4

ITEM 5 6. ~~MARKET~~ ~~FOR REGISTRANT’S COMMON EQUITY AND RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES~~ [RESERVED]

~~Market~~Not required for smaller reporting ~~Information~~companies.

~~Our common~~ITEM ~~stock (“Common Stock”) is not traded on any stock exchange and is occasionally quoted on the OTC Pink Market~~7. AsMANAGEMENT’S ~~of November~~DISCUSSION ~~16,~~AND ~~2022,~~ANALYSIS ~~there~~OF ~~were~~FINANCIAL ~~approximately~~CONDITION ~~260~~AND ~~record~~RESULTS ~~holders~~OF ~~of our Common Stock.~~OPERATIONS

~~Dividend~~This discussion should ~~Policy~~be read in conjunction with the Company’s audited consolidated financial statements, including the Notes thereto, for the years ended September 30, 2022 and September 30, 2023, beginning on Page F-1.

We have not paid any cash dividends to date and do not anticipate or contemplate paying dividends in the foreseeable future. It is the present intention of management to utilize all available funds for the execution of our business model.Overview

~~Securities~~On ~~Authorized~~August ~~for~~1, ~~Issuance~~2022, ~~Under~~the ~~Equity~~board ~~Compensation~~of ~~Plans~~directors (the “Board”) of the Company unanimously approved to expand our business in the area of electric vehicle supply equipment (“EVSE”) and will direct the management team to implement its new business plan in such industry. On August 16, 2022, the Company formally announced its intention to reposition as EVSE solutions provider, seeking to grow business in EVSE industry, including building, owning, and operating the next generation of electric vehicle charging stations in the U.S. The Company intends to bring convenient, reliable, and accessible charging experience to electric vehicle drivers, utilizing frictionless technology and carbon-neutral vehicle-charging infrastructure.

WeOn ~~have~~October ~~not~~26, ~~authorized~~2022, ~~the~~we ~~issuance~~entered ~~of,~~into orthree ~~issued,~~Charging ~~any~~Station ~~securities~~Site ~~under~~Host aAgreements ~~retirement~~(the “Agreements”) with two institutions (the “Site Hosts”), ~~pension~~respectively, ~~profit~~pursuant ~~sharing~~to which the Site Hosts agree to allow us to install our electric vehicle charging stations at the locations set forth in the Agreements (the “Charging Stations”). Under the Agreements, ~~stock~~we ~~option~~have oragreed ~~other~~to ~~equity~~share our ~~compensation~~revenue ~~plans~~generated by the sales of electricity at the Charging Stations with the Site Hosts in accordance with the schedules set forth therein.

~~Recent~~As ~~Sales~~of December 31, 2022, the Company has purchased certain electric vehicle charging equipment. Furthermore, the Company is in the process of ~~Unregistered~~obtaining ~~Securities~~permits to construct the Charging Stations at the three confirmed sites. As of December 31, 2022, the Company contracted an architectural firm on providing designing and engineering services for two sites, and working on technical issues for the third site.

InAs ~~order~~of toFebruary ~~fund~~13, 2023, the ~~First~~Company ~~Tranche~~has ~~Investment~~received inthe ~~Hukui~~finalized ~~and~~site ~~for~~plans ~~general~~and ~~working~~electrical ~~capital~~diagrams ~~needs,~~from wethe ~~conducted~~architectural afirm ~~private~~and ~~offering~~electrical engineers offor ~~our~~2 ~~Common Stock~~sites. OnThe ~~December~~Company ~~15,~~has ~~2020,~~also wereceived ~~sold 107,000,000 shares~~permission offrom ~~our~~the ~~Common~~site ~~Stock~~owners to 34proceed ~~individuals~~with atthe acharging ~~purchase~~station ~~price~~construction permit ofapplications ~~$0.01 per share~~with (the ~~“Fall~~local ~~2020~~municipalities. ~~Offering”),~~The ~~for~~Company ~~gross~~expects ~~and~~to ~~net~~install ~~proceeds~~up ofto ~~$1,070,000,~~a ~~before~~total ~~allocating~~of ~~certain~~10 ~~expenses~~charging ~~associated with~~units ~~the~~for ~~offering in~~ the ~~amount~~first ~~of $5~~2 sites,~~852 as~~ ~~adjusted~~and ~~paid-in~~have ~~capital.~~them ~~See~~operational ~~Note~~in 5October toof ~~Consolidated Financial Statements~~2023.

On April 9, 2021, we issued 3,059,836 shares of our Common Stock to repay the outstanding principal and accrued and unpaid interest on a promissory note we issued to evidence a loan made to us by one of our stockholders in the principal amount of $30,000 (the “October 2020 Note”).5

InAs ~~order to fund the Second Tranche Investment in Hukui and for general working capital needs, we conducted a private offering~~ of ~~our~~September ~~Common Stock. On June 15~~30, ~~2021~~2023, wethe ~~sold~~Company ~~63,000,000 shares~~has ofbegan ~~our~~constructions ~~Common~~on ~~Stock~~two tosites 18with ~~individuals,~~total ~~at purchase price~~ of ~~$0.01 per~~10 ~~share (the~~charging ~~“Spring~~units ~~2021 Offering”), for gross~~ and ~~net~~three ~~proceeds~~sites ofwith ~~$630,000,~~signed ~~before allocating certain expenses associated with~~agreement ~~the~~under ~~offering in the amount of $7,230 as adjusted paid-in capital~~planning. ~~See Note 5 to Consolidated Financial Statements.~~

~~Our~~Hukui Board of Directors authorized that all accrued and unpaid amounts of compensation, as of March 31, 2019, and thereafter, may be converted, at the option of our directors, and present and certain former executive officers, into shares of our Common Stock, at a rate of $0.05 per share for compensation earned on or before September 30, 2020 and $0.01 per share for compensation earned on and after October 1, 2020. Our Board of Directors also agreed that all accrued and unpaid amounts of director fees, as of March 31, 2019, and thereafter, may be converted upon the occurrence of certain events, at the option of the director, into shares of our Common Stock, at the same rates.Investment

~~Effective~~Hukui ~~March~~Biotechnology ~~31,~~Corporation ~~2021,~~(“Hukui”) and we ~~issued~~entered aninto ~~aggregate 6,399,965 shares~~a ofSeries ~~our~~C ~~Common~~Preferred ~~Stock~~Shares toSubscription ~~certain~~Agreement ofdated ~~our directors, officers, employees~~September ~~and a consultant~~23, ~~who~~2020 ~~converted accrued and unpaid compensation in~~ (the ~~aggregate~~“Hukui ~~amount of $94,398. Of this amount, (i~~Agreement”) ~~$37~~,~~998 was with~~ ~~respect~~pursuant to ~~amounts~~which ~~accrued~~we ~~during~~agreed ~~fiscal~~to ~~year~~purchase ~~2020~~an ~~and~~aggregate ~~was~~200,000 ~~converted~~shares ~~at a rate~~ of ~~$0.05 per~~Hukui’s ~~share into an aggregate 759,965 shares~~Series ofC ~~our~~Preferred ~~Common~~ Stock; ~~and~~ (~~ii)~~the ~~$56,400 was~~“Series ~~with~~C ~~respect~~Preferred toShares”) ~~amounts accrued during fiscal year 2021 through March 31, 2021 and was converted~~ at ~~a rate of~~ $010.01 00 per share, ~~into~~for an aggregate ~~5,640,000 shares~~ investment of ~~our Common Stock. See Item 11~~$2, ~~“Executive Compensation”~~000,000.

~~Effective~~The ~~September~~Hukui ~~30,~~Agreement ~~2021, we~~provided ~~issued~~that anwe ~~aggregate~~would ~~6,144,000~~purchase ~~shares~~the ofSeries ~~our~~C ~~Common~~Preferred ~~Stock~~Shares toin ~~certain~~three ~~of our current and former directors~~tranches, ~~officers,~~ ~~employees~~through ~~and~~ a ~~consultant,~~date ~~who~~on ~~converted~~or ~~accrued~~before ~~and~~June ~~unpaid compensation in the aggregate amount of $61~~30,~~440 at a rate of $0.01~~ ~~per share of our Common Stock. See Item 11~~2022, ~~“Executive~~as ~~Compensation”.~~follows:

~~We offered~~● ~~and~~The ~~issued~~first ~~all~~tranche ofis ~~the~~80,000 ~~foregoing~~Series ~~securities~~C ~~under~~Preferred Shares in the ~~exemption~~amount ~~from~~of ~~registration~~$800,000 ~~provided~~(the by“First ~~Section~~Tranche ~~4(a~~Investment”)~~(2)~~, ofsuch ~~the~~shares ~~Securities Act,~~having ~~and/or~~been ~~Regulation~~purchased Dby orus ~~Regulation~~on SDecember ~~promulgated~~15, ~~thereunder.~~2020 (the “First Tranche Closing”);

5● The second tranche is 60,000 Series C Preferred Shares in the amount of $600,000 (the “Second Tranche Investment”), such shares having been purchased by us on June 25, 2021 (the “Second Tranche Closing”); and

~~ITEM 6~~● The third tranche is 60,000 Series C Preferred Shares in the amount of $600,000 (the “Third Tranche Investment”), such shares to have been purchased on or before June 30, 2022 (the “Third Tranche Closing”). ~~[RESERVED]~~

~~Not~~An ~~required~~individual and resident of the Republic of China (the “Purchaser”), Hukui and we entered into a Stock Purchase Agreement dated as of November 17, 2021 (the “Stock Purchase Agreement”), pursuant to which we agreed to sell the 140,000 shares of Hukui’s Series C Preferred Stock that we had purchased in the First Tranche Closing and the Second Tranche Closing (the “Hukui Shares”) to the Purchaser for ~~smaller~~$350,000 ~~reporting~~in ~~companies~~cash, or $2.50 per share. The sale of the Hukui Shares closed on November 19, 2021.

~~ITEM 7.~~On ~~MANAGEMENT’S~~December ~~DISCUSSION~~17, ~~AND~~2021, ~~ANALYSIS~~Hukui OFand ~~FINANCIAL~~we ~~CONDITION~~entered ~~AND~~into ~~RESULTS~~an OFAgreement ~~OPERATIONS~~ (the “Termination Agreement”), pursuant to which our obligation to make the Third Tranche Investment was terminated and the Hukui Agreement was terminated. As a result, we have no continuing contractual obligation to make any investment in Hukui.

~~This~~Results ~~discussion~~of ~~should be read in conjunction with the Company’s consolidated financial statements, including the Notes thereto, for the years ended September 30, 2021 and September 30, 2022, beginning on Page F-1.~~Operations

~~Management’s~~Year ~~Discussion~~Ended ~~and~~September ~~Analysis~~30, of2023 ~~Financial~~compared ~~Condition~~to ~~and~~the ~~Results~~Year ofEnded ~~Operations.~~September 30, 2022

~~Overview~~Revenues

~~During~~We ~~our~~did ~~historic~~not ~~period,~~generate weany ~~were~~revenues aduring ~~start-up company whose main focus was to promote, market, distribute and export a range of enzyme products manufactured in~~ the ~~United~~years ~~States~~ended ~~for~~September ~~sale for human and animal consumption in certain Asian markets~~30, ~~including~~2023 ~~ASEAN. Our objective was to commence marketing~~ and distribution of a range of enzyme products for human and animal consumption to sole country distributors, wholesalers, dealers and retailers, as well as to the general public following a Multi-Level Marketing – Franchise Investor Dealer Related (MLM-FIDR) concept, beginning in Taiwan, and then China, Hong Kong, Macau, Thailand, Malaysia, Singapore and Sri Lanka2022.

InOperating 2019 and through the end of fiscal 2021, we explored plans to restart our enzyme products business or develop a new business. In 2019 and through early 2020, we had planned to restart our original enzyme products business, by importing enzyme supplements from the United States for sale in Taiwan. However, due to the COVID-19 pandemic, all non-COVID-19 related matters, including obtaining an import license from Taiwan’s Ministry of Economic Affairs and the Taiwan FDA, were delayed or were taking longer than usual in Taiwan beginning in late-January 2020. For various reasons, including the fact that, without a reasonably foreseeable end of the pandemic and Taiwan government resources being shifted to dealing with the pandemic, we decided to abandon the plan to restart our enzyme products business.Expenses

~~During~~We ~~fiscal~~incurred ~~year~~total ~~2020,~~operating weexpenses ~~announced~~of ~~that~~$432,296 weand ~~were~~$348,845 infor the ~~preliminary~~years ~~stage~~ended ofSeptember ~~developing~~30, a2023 ~~new~~and 2022, respectively. Our operating expenses consist of business ~~plan~~development toexpenses, ~~sell~~legal ~~and~~fees, ~~distribute~~other ~~physiological sea~~professional ~~water~~fees, ~~and~~payroll ~~nasal~~expenses, ~~spray~~stock-based incompensation, ~~Taiwan~~rent, bank charges, and ~~the~~transfer ~~United~~agent ~~States~~fees. ~~However,~~The ~~after~~increase ~~exploring~~in ~~this~~operating ~~possible~~expenses ~~business~~for asthe ayear ~~result~~ended ofSeptember ~~several factors~~30, ~~including~~ ~~but~~2023 ~~not~~compared ~~limited~~ to ~~difficulties~~the same period ended in ~~commencing~~2022 awas ~~new~~primarily ~~business~~due ~~during~~to ~~the~~increase ~~ongoing~~in ~~COVID-19~~payroll ~~pandemic~~expenses, westock-based ~~decided~~compensation ~~not~~as towell ~~pursue~~as business development expenses related to the ~~nasal~~installation ~~spray~~of ~~business~~charging stations.

InOther September 2020, we announced that we were exploring business opportunities for medical mask, medical-grade gloves and possibly other PPE. During fiscal 2021, due to lack of sufficient funding, we decided not to pursue the PPE business. We continued to explore other products with high demand since the advent of the COVID-19 pandemic, specifically rapid test kits. However, due to lack of funding and other factors, including the size of enterprise needed to successfully carry out such a business, we no longer intend to pursue this business.expense

OnDuring the ~~August~~year 1ended September 30, ~~2022~~2023, ~~the~~we ~~board~~incurred of$195,406 ~~directors~~other ~~(the~~expenses ~~“Board”) of~~mainly ~~the~~due ~~Company unanimously approved~~ to ~~expand~~interest ~~our~~incurred ~~business~~for inunpaid ~~the~~penalty ~~area~~from ofIRS ~~electric vehicle supply equipment (“EVSE”)~~ and ~~will~~ ~~direct~~ the ~~management~~loss ~~team~~on todisposal ~~implement~~of our ~~new~~Singapore ~~business~~subsidiary ~~plan~~of in$192,365. ~~such~~During ~~industry.~~the Onyear ~~August~~ended 16September 30, 2022, we ~~formally~~incurred ~~announced our intention to reposition as EVSE solutions provider~~$3,823 ~~seeking~~other ~~to grow business in EVSE industry, including building, owning, and operating the next~~expenses ~~generation~~mainly ofdue ~~electric vehicle charging stations in the U.S. We intend~~ to ~~bring~~interest ~~convenient,~~incurred ~~reliable,~~for ~~and~~unpaid ~~accessible~~penalty ~~charging~~from ~~experience to electric vehicle drivers, utilizing frictionless technology and carbon-neutral vehicle-charging infrastructure~~IRS.

OnNet October 26, 2022, we entered into three Charging Station Site Host Agreements (the “Agreements”) with two institutions (the “Site Hosts”), respectively, pursuant to which the Site Hosts agree to allow us to install our electric vehicle charging stations at the locations set forth in the Agreements (the “Charging Stations”). Under the Agreements, we agree to share our revenue generated by the sales of electricity at the Charging Stations with the Site Hosts in accordance with the schedules set forth therein.Loss

AtAs ~~this~~a ~~time~~result of the above, weour ~~reserve~~net loss increased from $352,668 in the ~~right~~year toended ~~further~~September ~~change~~30, ~~our~~2022 ~~business~~to ~~plan~~$627,702 atin ~~any~~the ~~time~~same period ended in 2023.

6Effect of the COVID-19 Pandemic on our Business

~~Hukui~~While ~~Investment~~our liquidity and capital resources are severely limited and present serious obstacles to starting a business, these limitations are unrelated to the COVID-19 pandemic and resulting global economic crisis.

InOur ~~late~~personnel ~~September~~are ~~2020~~in Taiwan, wewhich ~~announced~~has ~~that~~been ~~Hukui~~relatively ~~and~~less weaffected ~~had~~by ~~entered into~~ the ~~Hukui~~pandemic ~~Agreement,~~compared ~~pursuant~~ to ~~which~~many weother ~~agreed~~countries toin ~~purchase an aggregate 200~~Asia,~~000~~ ~~shares~~Europe ofand the ~~Hukui’s~~United ~~Series C Preferred Shares at $10~~States.~~00 per share, for an aggregate investment of $2,000,000.~~

~~The~~Depending ~~Hukui~~upon ~~Agreement~~the ~~provided~~extent ~~that~~and weduration ~~would~~of ~~purchase~~ the ~~Series~~pandemic Cand ~~Preferred~~the ~~Shares~~resulting inglobal ~~three~~economic ~~tranches~~crisis, ~~through~~these aconditions ~~date~~may onhave oran ~~before~~adverse ~~June~~impact ~~30,~~on ~~2022,~~our asability ~~follows:~~to raise capital and commence any business we may pursue.

●Liquidity and ~~The~~Capital ~~First Tranche Investment is 80,000 Series C Preferred Shares in the amount of $800,000, such shares having been purchased by us on December 15, 2020 in the First Tranche Closing;~~Resources

~~● The Second Tranche Investment is 60,000 Series C Preferred Shares in the amount of $600,000, such shares having been purchased by us on June 25, 2021 in the Second Tranche Closing; and~~Working Capital

● The Third Tranche Investment is 60,000 Series C Preferred Shares in the amount of $600,000, such shares to have been purchased on or before June 30, 2022 in the Third Tranche Closing.

	September 30,		September 30,
	2023		2022
Current Assets	$	134,111	$	150,893
Current Liabilities		115,616		205,016
Working Capital (Deficit)	$	18,495	$	(54,123	)

~~Following~~As ~~the end~~ of ~~our~~September ~~2021 fiscal year~~30, ~~the Purchaser~~2023, ~~Hukui and~~ we ~~entered~~had ~~into~~current ~~the~~assets ~~Stock~~of ~~Purchase Agreement~~$134,111 ~~pursuant~~and toa ~~which~~working wecapital ~~agreed~~surplus ~~to sell~~of ~~the~~$18,495. ~~140~~In comparison,~~000~~ ~~Hukui~~as ~~Shares~~of ~~that~~September 30, 2022, we had ~~purchased~~current inassets ~~the~~of ~~First Tranche Closing and the Second Tranche Closing to the Purchaser for~~ $~~350~~150,~~000~~893 inand ~~cash,~~a orworking ~~$2.50~~capital ~~per~~deficit ~~share. The sale~~ of ~~the Hukui Shares closed on November 19~~$54, ~~2021~~123.

We had ~~purchased~~$115,616 ~~the Hukui Shares~~ in ~~two~~total ~~tranches,~~current onliabilities ~~December~~as ~~15,~~of ~~2020~~September ~~and June~~ 30, ~~2021~~2023, ~~pursuant~~consisting toof ~~the Hukui Agreement~~$100,849 atin ~~$10.00~~accounts ~~per share~~payable, ~~for~~$37 anin ~~aggregate~~accrued ~~purchase~~expenses, and ~~price of~~ $114,~~400,000. We~~730 ~~sold~~due ~~the~~to ~~Hukui~~related ~~Shares at $2~~parties.50 ~~per~~This ~~share,~~is ~~for~~compared ato total ~~price~~current liabilities of $~~350~~205,~~000, resulting~~016 in ~~loss~~total current liabilities as of $1September 30,~~050~~ 2022,~~000.~~ Weconsisting ~~recognized~~of ~~impairment~~$102,185 ~~loss~~in ofaccounts ~~the~~payable ~~market~~and ~~value~~$102,831 ofdue ~~the~~to ~~shares~~related ofparties. ~~$1,050,000~~The ~~for~~decrease ~~the~~in ~~year~~due ~~ended~~to ~~September~~related parties was ~~30,~~primarily ~~2021.~~due ~~See~~to ~~Note~~unpaid 4compensation to ~~Notes~~officers toand ~~Consolidated~~directors ~~Financial~~repaid ~~Statements~~by shares.

OnWe ~~December~~had ~~17,~~total ~~2021,~~stockholders’ ~~Hukui~~equity ~~and~~of we$53,720 ~~entered~~and ~~into~~an ~~the~~accumulated ~~Termination~~deficit ~~Agreement~~of $10,503,191 ~~pursuant~~as toof ~~which~~September ~~our~~30, ~~obligation~~2023. toIn ~~make~~comparison, ~~the Third Tranche Investment~~we ~~was~~had ~~terminated~~a ~~and~~total ~~the~~stockholders’ ~~Hukui~~deficit ~~Agreement~~of ~~was terminated. As a result~~$83,349 weand ~~have~~an noaccumulated ~~continuing~~deficit ~~contractual~~of ~~obligation~~$9,875,489 toas ~~make~~of ~~any~~September ~~investment in~~30, ~~Hukui~~2022.

As we are currently pursuing business in the area of electric vehicle supply equipment (“EVSE”), we will need to raise capital to pursue such a business. There are no commitments in place to fund any such business and no guarantee can be given that we will be able to secure such funding on terms that are favorable to us, or at all. 7

~~For~~Cash the fiscal year ended September 30, 2020, Jui Pin (John) Lin, our former President and Chief Executive Officer, periodically provided the capital we needed to operate in the form of loans in the aggregate principal amount of $120,410, the principal and accrued and unpaid interest of which are convertible, at his option, into shares of our Common Stock at $0.05 per share. On December 28, 2020, we repaid Mr. Lin $65,410 of the principal amount of loans due and payable plus accrued interest in the amount of $1,162, for a total of $66,572. On January 5, 2021, we repaid Mr. Lin $20,000 of the principal amount of another such loan due and payable plus accrued interest in the amount of $403, for a total of $20,403.Flows

On August 26, 2020, Jui Pin (John) Lin loaned us $35,000 at 4% interest rate and six months’ maturity. The loan was repaid on February 26, 2021 in the principal amount of $35,000, together with interest in the amount of of $706, for a total of $35,706.

	Year ended September 30, 2023			Year ended September 30, 2022
Cash flows used in operating activities	$	(305,025	)	$	(222,828	)
Cash flows provided by (used in) investing activities		(67,451	)		350,000
Cash flows provided by financing activities		362,000			-
Effect of exchange rate changes on cash		-			(43	)
Net increase in cash during period	$	(10,476	)	$	127,129

OnDuring ~~October~~the 9,year ~~2020,~~ended ~~another~~September ~~stockholder~~30, ~~loaned~~2023, uswe used $30305,~~000~~025 ~~(the~~of ~~“October~~cash ~~2020~~in ~~Loan”),~~operating onactivities ~~substantially~~which ~~the~~was ~~same~~attributable ~~terms~~primarily asto ~~the~~our net loss ~~terms~~of $627,702 offset by loss on disposal of ~~the~~subsidiary, ~~loans~~stock-based ~~from~~compensation, ~~Mr.~~and ~~Lin.~~change Onin ~~April~~operating 9assets and liabilities of $322,677. In ~~2021~~comparison, during the ~~lender~~year ~~converted~~ended ~~the~~September ~~outstanding~~30, ~~principal~~2022, ~~together~~we ~~with~~used ~~accrued~~$222,828 ~~and~~of ~~unpaid~~cash ~~interest~~ in ~~the~~operating ~~amount~~activities which was attributable primarily to our net loss of $~~598~~352,668 ~~into 3,059,836 shares~~offset ofby ~~the~~stock-based ~~Company’s~~compensation ~~Common~~and ~~Stock,~~change atin aoperating ~~rate~~assets and liabilities of $0129,840.~~01 per share.~~

During the ~~fiscal~~ year ended September 30, ~~2021~~2023, we ~~raised~~used ~~an aggregate~~ $~~1.8~~67,451 ~~million~~of incash ~~two~~investing ~~private~~activity ~~offerings,~~in ~~the~~purchase ~~Fall~~of ~~2020~~equipment. ~~Offering~~We ~~and~~received ~~the Spring 2021 Offering~~$350,000 toin ~~raise~~payment for the ~~capital~~sale ~~needed~~of to140,000 ~~fund~~Hukui ~~our~~Shares ~~operations~~during ~~and make~~ the ~~First~~year ~~Tranche~~ended ~~Investment~~September ~~and~~30, ~~Second Tranche Investment in Hukui~~2022.

WeDuring ~~may~~the ~~also~~year ~~raise~~ended ~~equity~~September 30, ~~debt~~2023, ~~convertible~~we ~~debt~~received or$362,000, anet ~~combination~~ of ~~any~~directly ofassociated ~~the~~legal ~~foregoing,~~fees from ~~other~~private ~~parties~~offering ~~for the capital we may need for any~~ of ~~the~~our ~~purposes~~Common ~~specified in this report~~Stock. During ~~There is no agreement in place between~~ the ~~Company~~year ~~and~~ended ~~anyone~~September ~~for~~30, ~~such capital to continue to be made available to us as needed~~2022, ~~and~~ we ~~cannot~~did ~~guarantee~~not ~~that~~have any ~~such~~financing ~~capital will continue to be available to us on favorable terms, or at all, in the future~~activity.

7There is substantial doubt that we can continue as an ongoing business for the next twelve months unless we obtain additional capital to pay our expenses as they become due. We do not anticipate any significant additional revenue until and unless we begin to execute our plan of operations involving the start of our new electric vehicle charging station business. There is no assurance that we will ever reach that stage. The consolidated financial statements presented herein do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classification of liabilities that might be necessary in the event that we cannot continue as a going concern.

~~Results~~Our ability to continue as a going concern is dependent upon our ability to successfully execute our business plan and generate profitable operations in the future, and, until and unless we achieve that, to obtain the necessary financing to meet our obligations and repay our liabilities arising from normal business operation as and when they become due. To date, our capital requirements have primarily been funded by shareholders through the purchase of ~~Operations~~our Common Stock in private offerings and short-term borrowings from a former officer and another shareholder.

~~Year~~The ~~Ended~~Company ~~September~~sold 30140,000 ~~2022~~Hukui ~~compared~~Shares tofor $350,000 cash on November 19, 2021 and received $362,000 from private placement during the ~~Year~~nine months ~~Ended~~ended ~~September~~June 30, ~~2021~~2023. The proceeds have been used for operation expenses.

~~Revenues~~Contractual Obligations

We ~~did~~do not ~~generate~~have ~~any~~material ~~revenues~~contractual ~~during~~obligations ~~the~~and ~~years~~commitments. ~~ended~~We ~~September~~only ~~30,~~have ~~2022~~one ~~and~~lease ~~2021~~that is renewed on a month-to-month basis.

~~Operating~~Off-Balance ~~Expenses~~Sheet Arrangements

WeAs ~~incurred~~of ~~total~~September ~~operating~~30, ~~expenses~~2023, ofwe ~~$396,311~~had ~~and~~not ~~$363,637~~entered ~~for~~into any other financial guarantees or other commitments to guarantee the ~~years~~payment ~~ended~~obligations of any third parties. As of September 30, ~~2022~~2023, ~~and~~we ~~2021,~~had ~~respectively.~~not ~~Our~~entered ~~operating~~into any derivative contracts that are indexed to our shares and classified ~~expenses~~as ~~consist~~shareholder’s ofequity ~~legal~~or ~~fees,~~that ~~other~~are ~~professional~~not ~~fees,~~reflected ~~payroll~~in ~~expenses~~our condensed consolidated financial statements. Furthermore, ~~stock-based~~as ~~compensation~~of September 30, ~~rent~~2023, ~~bank~~we ~~charges,~~had ~~and~~not ~~transfer agent~~had ~~fees.~~any ~~The~~retained ~~increase~~or contingent interest in ~~operating~~assets ~~expenses~~transferred ~~for~~to ~~the~~an ~~year~~unconsolidated ~~ended~~entity that serves as credit, liquidity or market risk support to such entity. As of September 30, ~~2022~~2023, ~~compared~~we tohad ~~the~~not ~~same~~had ~~period~~any ~~ended~~variable interest in ~~2021~~any ~~was primarily~~unconsolidated ~~due~~entity that provides financing, liquidity, market risk or credit support to ~~the~~us ~~increase~~or engages in ~~payroll~~leasing, ~~expenses~~hedging or research and ~~stock-based~~development services ~~compensation~~with us.

~~Other expense~~8

~~During the year ended September 30, 2022, we incurred $3,823 other~~Critical ~~expenses~~accounting ~~mainly~~policies ~~due~~and to interest incurred for unpaid penalty from IRS. During the year ended September 30, 2021, we had a net other income of $52,250, which included incurred $78,476 of other income due to liabilities written off, partially offset by a $25,000 penalty plus interest of $1,226 from the IRS for failing to file Form 5472 timely. During the year ended September 30, 2021 we incurred $1,050,000 impairment loss of investment. We invested $1,400,000 in Hukui’s Series C Preferred stock, which was sold on November 17, 2021 for $350,000, resulting in loss of $1,050,000. We wrote down the investment on September 30, 2021 to reflect fair market value of the investment.estimates

~~Net~~Our ~~Loss~~discussion and analysis of our financial condition and results of operations are based upon our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of these consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. We continually evaluate our estimates, including those related to income taxes, and the valuation of equity transactions. We base our estimates on historical experience and on various other assumptions that we believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Any future changes to these estimates and assumptions could cause a material change to our reported amounts of revenues, expenses, assets and liabilities. Actual results may differ from these estimates under different assumptions or conditions. For the years ended September 30, 2023, and 2022, no significant estimates and assumptions have been made in the consolidated financial statements. The following are some of the critical accounting policies in relation to the preparation of the consolidated financial statements. For a full summary of our critical accounting policies, please refer to Note 2 to the Consolidated Financial Statements.

AsStock-Based ~~a result of the above, our net loss decreased from $1,364,432 in the year ended September 30, 2021 to $400,134 in the same period ended in 2022.~~Compensation

~~Effect~~We ofaccount ~~the~~for ~~COVID~~stock-19based ~~Pandemic~~compensation in which we obtain employee services in share-based payment transactions under FASB ASC Topic 718, Compensation – Stock Compensation, which requires us to expense the cost of employee services received in exchange for an award of equity instruments based on ~~our~~the ~~Business~~grant date fair value of such instruments over the vesting period.

~~While~~Recent ~~our~~accounting liquidity and capital resources are severely limited and present serious obstacles to starting a business, these limitations are unrelated to the COVID-19 pandemic and resulting global economic crisis.pronouncements

~~Our~~We ~~personnel~~do ~~are~~not inexpect ~~Taiwan,~~that ~~which~~the ~~has~~adoption ~~been~~of ~~relatively~~recently ~~less~~issued ~~affected~~accounting bypronouncements ~~the~~will ~~pandemic~~have ~~compared~~a tomaterial ~~many~~impact ~~other~~on ~~countries~~our infinancial ~~Asia~~position, ~~Europe and~~results ~~the~~of ~~United States. However~~operations, ~~even~~or ~~before~~cash anflows. ~~increase~~For ina ~~the~~full ~~number~~summary of ~~cases~~recent ofaccounting ~~COVID-19 in Taiwan~~pronouncements, weplease ~~experienced~~refer ~~delays~~to inNote ~~obtaining business~~2 licenses and permits, and any other governmental approvals that might have been required for businesses that we previously considered commencing, since government offices have been working with reduced staff during the pandemic. We expect this situation to ~~continue and possibly become more challenging depending upon~~ the ~~duration~~Consolidated ~~of the pandemic~~Financial Statements.

Depending upon the extent and duration of the pandemic and the resulting global economic crisis, these conditions may have an adverse impact on our ability to raise capital and commence any business we may pursue.9

~~Liquidity~~ITEM ~~and~~7A. ~~Capital~~QUANTITATIVE ~~Resources~~AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

~~Working~~Not ~~Capital~~required for smaller reporting companies.

	September 30,			September 30,
	2022			2021
Current Assets	$	150,893		$	35,044
Current Liabilities		205,016			105,346
Working Capital Deficit	$	(54,123	)	$	(70,302	)

ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

8The full text of our audited consolidated financial statements begins on page F-1 of this annual report.

AsITEM ~~of September 30, 2022, we had current assets of $150,893 and a working deficit of $54,123~~9. InCHANGES ~~comparison,~~IN asAND ofDISAGREEMENTS ~~September~~WITH ~~30,~~ACCOUNTANTS ~~2021,~~ON ~~we had~~ACCOUNTING ~~current~~AND ~~assets~~FINANCIAL ~~of $35,044 and a working capital deficit of $70,302.~~DISCLOSURE

AsOn February ~~of September 30~~23, 2022, ~~we had~~(i) ~~total~~DYH ~~assets~~& ofCompany ~~$150,893,~~(“DYH”) ~~compared~~resigned ~~with~~as ~~total~~the ~~assets~~independent ofregistered ~~$385,044~~public ataccounting ~~September~~firm ~~30,~~of ~~2021.~~the ~~The~~Company; and ~~decrease~~(ii) inthe ~~total~~Board ~~assets~~of ~~was~~Directors ~~primarily due~~of to the ~~sale~~Company, ofwhich ~~investment~~acts ~~and~~as ~~cash~~the ~~spent~~audit incommittee, ~~operating~~engaged ~~expenses~~KCCW ~~after~~Accountancy ~~selling~~Corp. (“KCCW”) as the ~~140,000~~Company’s ~~Hukui~~new ~~Shares~~independent ~~for~~registered ~~cash~~public accounting firm.

WeThe ~~had~~reports ~~$205,016~~of inDYH ~~total~~on ~~current~~the ~~liabilities~~consolidated asfinancial statements of ~~September~~the ~~30,~~Company ~~2022,~~as ~~consisting~~ of ~~$102,185 in accounts payable~~ and ~~$102,831~~for ~~due~~the toyears ~~related parties.~~ended ~~This is compared to total current liabilities of $105,346 in total current liabilities as of~~ September 30, ~~2021~~2020, ~~consisting of~~and ~~$100,746~~2021 indid not ~~accounts~~contain ~~payable,~~an ~~$1,590~~adverse inopinion ~~accrued~~or ~~expenses,~~disclaimer ~~and~~of $3opinion,~~010~~ ~~due~~nor towere ~~related~~they ~~parties.~~qualified ~~The~~or ~~increase~~modified inas ~~due~~ to ~~related~~uncertainty, ~~parties was~~audit ~~primarily~~scope ~~due~~or ~~to unpaid compensation to officers and directors~~accounting principle.

WeDuring ~~had~~the ~~total~~years ~~stockholders’~~ended ~~deficit~~September ~~of $83~~30,~~349~~ 2020 and an2021 ~~accumulated~~and ~~deficit~~through ofFebruary $923,~~922~~ 2022,~~955~~ asthere were no disagreements with DYH on any matter of ~~September~~accounting principles 30or practices, ~~2022.~~financial Instatement ~~comparison~~disclosure, ~~we had~~or aauditing ~~total~~scope ~~stockholders’~~or ~~equity~~procedure, ofwhich ~~$253~~disagreements,~~472~~ ~~and~~if annot ~~accumulated~~resolved ~~deficit~~to the satisfaction of $9DYH,~~522,821~~ aswould have caused DYH to make reference to the subject matter of ~~September~~the ~~30,~~disagreement ~~2021~~in its reports on the Company’s consolidated financial statements for such years.

OnThe ~~December~~Company ~~15,~~has ~~2020,~~provided weDYH ~~completed~~with a ~~private~~copy ~~offering~~ of ~~our~~the ~~Common~~disclosures ~~Stock.~~it Weis ~~sold~~making ~~107,000,000~~herein ~~shares~~and ofhas ~~our~~requested ~~Common~~that ~~Stock~~DYH tofurnish 34it ~~individuals at~~with a ~~purchase~~letter ~~price~~addressed to ofthe ~~$0.01~~Securities ~~per~~and ~~share,~~Exchange ~~for~~Commission ~~gross~~stating ~~proceeds~~whether ofor ~~$1,070,000~~not ~~before~~DYH ~~allocating~~agrees ~~certain expenses associated~~ with the ~~offering in~~above ~~the~~statements. ~~amount~~A copy of ~~$5,852~~such asletter ~~adjusted~~is ~~paid-in~~provided herewith ~~capital~~as Exhibit 16.1.

~~Effective~~No consultations ~~March~~occurred ~~31,~~between ~~2021,~~the weCompany ~~issued~~and anKCCW ~~aggregate~~during ~~6,399,965~~the ~~shares~~years ~~of our~~ended ~~Common~~September ~~Stock~~30, to2020 ~~some~~and of2021 ~~our~~and ~~directors~~through February 23, ~~officers~~2022, regarding ~~employees~~either ~~and~~(i) ~~independent~~the ~~consultants,~~application ~~who~~of ~~converted~~accounting ~~accrued~~principles ~~and~~to ~~unpaid~~a ~~compensation in~~specific ~~the~~completed ~~aggregate~~or ~~amount~~proposed transaction, the type of ~~$94,398.~~audit Ofopinion that ~~this~~might ~~amount,~~be ~~(i)~~rendered ~~$37,998~~on ~~was~~the ~~with~~Company’s ~~respect~~financial tostatements, ~~amounts~~or ~~accrued~~other ~~during~~written ~~fiscal~~or ~~year~~oral ~~2020~~information ~~and~~provided that was ~~converted~~an important atfactor aconsidered ~~rate~~by ofthe ~~$0.05~~Company ~~per~~in ~~share~~reaching ~~into~~a decision as to an ~~aggregate~~accounting, ~~759~~auditing,~~965~~ ~~shares~~or offinancial ~~our~~reporting ~~Common Stock~~issue; ~~and~~or (ii) ~~$56,400~~any matter that was ~~with~~either ~~respect~~the tosubject ~~amount~~of ~~accrued during~~a ~~fiscal~~disagreement, ~~year~~as ~~2021~~that ~~through~~term ~~March~~is ~~31,~~defined ~~2021~~in Item 304(a)(1)(iv) of Regulation S-K and ~~was~~the ~~converted~~related atinstructions to aItem ~~rate~~304 of ~~$0.01~~Regulation ~~per~~S-K, ~~share~~or ~~into~~a an“reportable ~~aggregate 5~~event,~~640,000~~” ~~shares~~as that term is defined in Item 304(a)(1)(v) of ~~our Common~~Regulation ~~Stock~~S-K.

OnITEM ~~April~~9A. 9,CONTROLS ~~2021,~~AND wePROCEDURES ~~issued 3,059,836 shares of our Common Stock to repay the principal and interest accrued upon the maturity of the October 2020 Note.~~

OnEvaluation ~~June~~of ~~15,~~Disclosure ~~2021,~~Controls ~~we sold~~ and ~~issued~~Procedures 63,000,000 shares of our Common Stock to 18 individuals at purchase price of $0.01 per share in the Spring 2021 Offering. Gross proceeds were $630,000, before allocating certain expenses associated with the offering in the amount of $7,230 as adjusted paid-in capital.

OnOur ~~July~~disclosure ~~15,~~controls ~~2021,~~and ~~the~~procedures ~~Company~~are ~~completed~~designed to ensure that the ~~Spring~~information ~~2021~~relating ~~Offering~~to ofour ~~its~~Company, ~~Common~~including ~~Stock~~our consolidated subsidiaries, required onto ~~which~~be ~~date~~disclosed itin ~~sold~~our ~~and~~SEC ~~issued additional~~reports 10is recorded,~~000~~ processed,~~000 shares~~ summarized and reported within the time periods specified in SEC ofrules ~~its~~and ~~Common~~forms, ~~Stock~~and is accumulated and communicated to ~~five~~our ~~individuals~~management, atincluding aour ~~purchase~~chief ~~price~~executive ofofficer ~~$0.01 per~~and ~~share~~chief financial officer, as appropriate to allow for ~~gross~~timely ~~proceeds~~decisions regarding required disclosure. We conducted an evaluation, under the supervision and with the participation of ~~$100~~management,~~000~~ including our chief executive officer and chief financial officer, ~~before~~of ~~allocating~~the effectiveness of the design ~~certain~~and ~~expenses~~operation ~~associated~~of ~~with~~our ~~the~~disclosure ~~offering~~controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the ~~amount~~Securities Exchange Act of ~~$959~~1934, as ~~adjusted~~amended) ~~paid-~~as of the end of the period covered by this annual report. Based on this evaluation, our chief executive officer and chief financial officer concluded that, as of the evaluation date, our disclosure controls and procedures were not effective due to material weaknesses in~~-capital~~ our internal control over financial reporting, as described below.

During the year ended September 30, 2021, one of our shareholders made a loan to us in the principal amount of $30,000 (the “October 2020 Loan”), primarily to pay our expenses. The October 2020 Loan bore simple interest at a rate of 4% per annum and was payable as to both principal and interest on the maturity date of April 9, 2021. On the maturity date, the holder of the note evidencing the October 2020 Loan converted the outstanding principal, together with accrued and unpaid interest of $598, into 3,059,836 shares of our Common Stock, at the rate of $0.01 per share.10

9Management’s Report on Internal Control Over Financial Reporting

~~Cash~~Our ~~Flows~~management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Exchange Act Rules 13a-15(f) and 15d-15(f). Under the supervision and with the participation of management, including our chief executive officer and chief financial officer, we conducted an evaluation of the design and operating effectiveness of our internal controls over financial reporting based on the framework in “Internal Control-Integrated Framework (2013)” issued by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”).

	Year Ended September 30, 2022			Year Ended September 30, 2021
Cash flows used in operating activities	$	(222,828	)	$	(304,588	)
Cash flows provided by (used in) investing activities		350,000			(1,400,000	)
Cash flows provided by financing activities		-			1,695,549
Effect of exchange rate changes on cash		(43	)		218
Net increase (decrease) in cash during period	$	127,129		$	(8,821	)

Our internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of consolidated financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures are being made only in accordance with authorizations of management and directors; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of our assets that could have a material effect on the consolidated financial statements.

~~During~~Management assessed the ~~year~~effectiveness ~~ended September 30, 2022, we used $222,828~~ of ~~cash~~the inCompany’s ~~operating~~internal ~~activities~~control ~~which~~over ~~was~~financial ~~attributable~~reporting ~~primarily~~as ~~to our net loss~~ of ~~$400,134~~evaluation ~~offset~~date ~~by change in issuance of stock option~~ and ~~operating~~identified ~~assets and liabilities of $177,306. In comparison, during~~ the ~~year~~following ~~ended~~material September 30, 2021, we used $304,588 of cash in operating activities which was attributable primarily to our net loss of $1,364,432 offset by impairment of $1,050,000 to investment and change in operating assets and liabilities of $9,844.weaknesses:

~~With~~Inadequate ~~respect~~Segregation toof ~~our~~Duties: ~~investing~~We ~~activities,~~have wean ~~received~~inadequate ~~$350,000~~number ~~in payment for the sale~~ of ~~the~~personnel ~~140,000~~to ~~Hukui~~properly ~~Shares~~implement ~~during~~control ~~the year ended September 30, 2022~~procedures. ~~During the year ended September 30, 2021, we used $1,400,000 for investment in Hukui.~~

~~During~~Comingling ~~the~~of ~~year~~funds: ~~ended~~We ~~September~~do ~~30, 2022, we did~~ not have ~~any~~adequate ~~financing~~control ~~activity.~~of ~~During~~our ~~the~~petty ~~year ended September 30, 2021, we had total~~ cash ~~inflow of $1~~,~~695,549~~ ~~from~~resulting ~~financing~~in ~~activities. We received $30,000 from~~ the ~~October~~comingling ~~2020 Loan. We repaid $120,410 to the notes from related party, who was our then President and Chief Executive Officer, Jui Pin Lin. We received $1,785,959, net~~ of ~~directly associated expenses, including legal, transfer agent, and printing and delivery expenses, from two private offerings of~~ our ~~Common~~petty ~~Stock,~~cash ~~which were~~with ~~completed in December 2020 and July 2021, respectively. For accounting purpose, we recorded~~ the ~~net~~nominal ~~proceeds from private offering~~account ~~instead~~holder’s ofpersonal ~~the gross amount of $1,800,000~~funds.

~~There~~Lack isof ~~substantial~~Adequate ~~doubt~~Staffing: ~~that we can continue as an ongoing business for the next twelve months unless we obtain additional capital to pay our expenses as they become due.~~ We do not ~~anticipate~~have ~~any~~adequate ~~significant~~in-house ~~additional~~accounting ~~revenue~~personnel ~~until~~ and ~~unless~~expertise wein ~~begin~~key topositions, ~~execute~~resulted onin ~~our plan~~overly ~~of operations involving the start of our new electric vehicle charging station business. There is no assurance that we will ever~~relying ~~reach~~on ~~that~~outside ~~stage.~~consultants ~~The~~in ~~consolidated~~preparing financial statements ~~presented herein do not include any adjustments relating to the recoverability~~ and ~~classification~~other ofrequired ~~recorded~~disclosures ~~assets,~~by or the ~~amounts~~Securities and ~~classification~~Exchange ~~of liabilities that might be necessary in the event that we cannot continue as a going concern~~Commission.

~~Our~~Ineffective ~~ability~~oversight: toWe ~~continue~~do asnot aexercise ~~going~~effective ~~concern~~oversight ~~is dependent upon our ability to successfully execute our business plan~~ and ~~generate~~monitoring ~~profitable operations~~procedures indesigned ~~the future,~~ and, ~~until~~implemented ~~and unless we achieve that,~~ to ~~obtain~~certain ~~the~~control ~~necessary financing to meet our obligations and repay our liabilities arising from normal business operation as and when they become due~~activities. To date, our capital requirements have primarily been funded by shareholders through the purchase of our Common Stock in private offerings and short-term borrowings from a former officer and another shareholder.

~~The~~Overly ~~Company~~relied ~~sold the~~on ~~140,000 Hukui~~outside ~~Shares~~professionals: ~~for~~We ~~$350,000 cash~~are onunable ~~November~~to ~~19,~~prepare ~~2021.~~internally ~~The~~financial ~~proceeds~~statements ~~have~~and ~~been~~relied ~~used~~on ~~for~~outside ~~operation~~professional consultants ~~expenses~~to prepare financial statements and adequate disclosures.

10A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the Company’s annual or interim financial statements will not be prevented or detected on a timely basis. As a result of the material weaknesses in internal control over financial reporting identified above, management concluded that the Company’s internal control over financial reporting was not effective as of September 30, 2022 based on the criteria set forth in “Internal Control-Integrated Framework” issued by COSO.

~~Contractual~~Due ~~Obligations~~to the nature of the material weaknesses, there is a more than remote likelihood that misstatements which could be material to the annual or interim financial statements could occur that would not be prevented or detected. The material weaknesses identified above either individually or in aggregation did not result in any identified misstatements or errors in the Company’s consolidated financial statements at and for the year ended September 30, 2023.

~~We do not have material contractual obligations and commitments. We only have one lease that is renewed on a month-to-month basis.~~11

~~Off-Balance~~Management’s ~~Sheet~~Plan ~~Arrangements~~for Remediation

~~As of September 30, 2022, we had not entered into any other financial~~Management ~~guarantees~~has ordiscussed ~~other commitments to guarantee~~ the ~~payment~~material ~~obligations~~weaknesses ofnoted ~~any~~above ~~third~~with ~~parties. As of September 30, 2022, we had not entered into any derivative contracts that are indexed to~~ our ~~shares~~independent ~~and~~registered ~~classified~~public asaccounting ~~shareholder’s equity or that are not reflected in our consolidated financial statements~~firm. ~~Furthermore,~~Management asis ofcommitted ~~September 30, 2022, we had not had any retained or contingent interest in assets transferred~~ to ~~an unconsolidated entity that serves as credit, liquidity or market risk support to such entity. As of September 30, 2022,~~ weimproving ~~had~~its ~~not~~internal ~~had~~controls ~~any variable interest in any unconsolidated entity that provides financing~~and, ~~liquidity,~~subject ~~market risk or credit support~~ to us orhaving ~~engages~~adequate infinancial ~~leasing~~resources, ~~hedging~~intends ~~or research and development services with us.~~to:

~~Critical accounting~~● ~~policies~~increase the frequency of independent reconciliations of significant accounts which will mitigate the lack of segregation of duties to monitor and ~~estimates~~review until there are sufficient personnel to segregate duties;

~~Our discussion~~● ~~and~~consider ~~analysis~~providing ofprofessional ~~our~~courses financial condition and results of operations are based upon our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of these consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. We continually evaluate our estimates, including those related to income taxes, and the valuation of equity transactions. We base our estimates on historical experience and on various other assumptions that we believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Any future changes to these estimates and assumptions could cause a material change to our ~~reported~~key ~~amounts~~position of revenues, expenses, assets and liabilities. Actual results may differ from these estimates under different assumptions or conditions. For the years ended September 30, 2022 and 2021, no significant estimates and assumptions have been made in the consolidated financial statements. The following are some of the critical accounting policies in relation to the preparation of the consolidated financial statements. For a full summary of our critical accounting policies, please refer to Note 2 to the Consolidated Financial Statements.personnel;

~~Foreign currency~~● ~~translation~~hire additional employees to realize segregation of duties; and

~~The financial~~● ~~statements~~strengthen ofmanagement ~~our~~monitoring ~~subsidiary~~control ~~denominated~~over inaccounting currencies other than the USD are translated into USD using the closing rate method. The balance sheet items are translated into USD using the exchange rates at the respective balance sheet dates. The capital and ~~various reserves~~financial ~~are~~statements ~~translated~~preparation ~~at historical exchange rates prevailing at the time of the transactions while income and expenses items are translated at the average exchange rate for the period~~processing. ~~All exchange differences are recorded in stockholders’ equity.~~

~~Stock-Based~~However, ~~Compensation~~due to limitation of funds and personnel, we have so far been unable to begin to implement the plan to remediate the material weaknesses noted above.

WeInherent ~~account~~Limitations for stock-based compensation in which we obtain employee services in share-based payment transactions under FASB ASC Topic 718, Compensation – Stock Compensation, which requires us to expense the cost of employee services received in exchange for an award of equity instruments based on ~~the~~Effectiveness ~~grant date fair value~~ of ~~such~~Controls ~~instruments over the vesting period.~~

~~Recent~~A ~~accounting~~control ~~pronouncements~~system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system’s objectives will be met. Because of its inherent limitations, internal control over financial reporting may not prevent or detect all control issues or misstatements. Accordingly, our controls and procedures are designed to provide reasonable, not absolute, assurance that the objectives of our control system are met. Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become adequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

WeChanges doin ~~not~~Internal ~~expect~~Control that the adoption of recently issued accounting pronouncements will have a material impact on our financial position, results of operations, or cash flows. For a full summary of recent accounting pronouncements, please refer to Note 2 to the Consolidated Financial Statements.

~~Currency~~There ~~exchange~~have ~~rates~~been no changes in our internal control over financial reporting that occurred during the year ended September 30, 2023 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

~~Our~~ITEM ~~functional currency is the USD, and the functional currency of our operations is the TWD~~9B. ItOTHER is anticipated that all of our sales will be denominated in TWD. As a result, changes in the relative values of USD and TWD affect our reported amounts of revenues and profit (or loss) as the results of our operations are translated into USD for reporting purposes. In particular, fluctuations in currency exchange rates could have a significant impact on our financial stability. Fluctuations in exchange rates between the USD and the TWD would also affect our gross and net profit margins and could result in foreign exchange and operating losses.INFORMATION

11None.

~~Our~~ITEM ~~exposure to foreign exchange risk primarily relates to currency gains or losses resulting from timing differences between the signing of sales contracts and the settling of these contracts~~9C. ~~Furthermore,~~DISCLOSURE weREGARDING ~~translate~~FOREIGN ~~monetary~~JURISDICTIONS ~~assets~~THAT ~~and~~PREVENT liabilities denominated in other currencies into TWD, the functional currency of our operations. Our results of operations and cash flow are translated at average exchange rates during the period, and assets and liabilities are translated at the unified exchange rate at the end of the period. Translation adjustments resulting from this process are included in accumulated other comprehensive income in our statement of shareholders’ equity. We have not used any forward contracts, currency options or borrowings to hedge our exposure to foreign currency exchange risk. We cannot predict the impact of future exchange rate fluctuations on our results of operations and may incur net foreign currency losses in the future.INSPECTIONS

To the extent that we hold assets denominated in USD, any appreciation of the TWD against the USD could result in a charge in our statement of operations and a reduction in the value of our USD-denominated assetsNone. ~~On the other hand, a decline in the value of the TWD against the USD could reduce the USD equivalent amounts of our financial results.~~

For financial reporting purposes, the financial statements of the Company’s Singapore subsidiary, which are prepared using the SGD, are translated into the Company’s reporting currency, USD. Assets and liabilities are translated using the exchange rate on the balance sheet date, which was 0.6970 and 0.7368 as of September 30, 2022 and 2021, respectively. Revenue and expenses are translated using average exchange rates prevailing during each reporting period. The 0.7293 and 0.7458 average exchange rates were used to translate revenues and expenses for the years ended September 30, 2022 and 2021, respectively. Stockholders’ equity is translated at historical exchange rates. Adjustments resulting from the translation are recorded as a separate component of accumulated other comprehensive loss in stockholders’ deficit.12

~~ITEM~~PART ~~7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK~~ III

~~Not~~ITEM ~~required~~10. ~~for~~DIRECTORS, ~~smaller~~EXECUTIVE ~~reporting~~OFFICERS ~~companies.~~AND CORPORATE GOVERNANCE

~~ITEM~~As 8.of ~~FINANCIAL~~the ~~STATEMENTS~~date ~~AND~~of ~~SUPPLEMENTARY~~the ~~DATA~~filing of this Annual Report, our current directors and executive officers and additional information concerning them are as follows:

See pages F-1 through F-15.

Name	Age	Position

David Tang	45	Chief Executive Officer

Jui Pin (John) Lin	68	Chairman of the Board, President, and Director

Kuang Ming (James) Tsai	73	Director, Chief Financial Officer

Wen-Piao (Jack) Lai	71	Director

Hsin-Ta (Darren) Su	46	Director

Hui-Chuan (Sandra) Lin	39	Director and Secretary

~~ITEM~~David 9Tang has served as our Chief Executive Officer since July 15, 2022. ~~CHANGES~~Prior INto ~~AND~~joining ~~DISAGREEMENTS~~us, ~~WITH~~Mr. ~~ACCOUNTANTS~~Tang ONwas ~~ACCOUNTING~~a ~~AND~~Relationship ~~FINANCIAL~~Manager ~~DISCLOSURE~~of Venture Lending Emerging Technologies division at East West Bank in California from 2019 to 2022. Prior to that, Mr. Tang was an advisor to many startups in Hong Kong, including Maxvoice and Maxisense from 2016 to 2019. Mr. Tang was the founder and the Chief Executive Officer of Fontainebleau Partners, a technology startup in Hong Kong from 2012 to 2016. In 2011, Mr. Tang was an Equity Research Analyst at BNP Paribas Securities in Hong Kong and Taipei. In 2009, Mr. Tang was an MBA Consultant for Swire Coca-Cola HK Limited. From 2005 to 2008, Mr. Tang was a Relationship Manager at Manufacturing Bank in California, a Sumitomo Mitsui Banking Corporation subsidiary. From 2004 to 2005, Mr. Tang was a Client Financial Analyst at Citibank in California. Mr. Tang has a bachelor degree in History from University of California, Irvine and a Master of Business Administration degree in Finance from Hong Kong University of Science & Technology. Mr. Tang is currently a mentor at KidsX Accelerator, a network of pediatric experts and innovators founded and administered by Children’s Hospital Los Angeles.

OnJui Pin ~~February~~(John) 23Lin has served as our President since July 14, 2022, ~~(i)~~and ~~DYH~~Mr. &Lin ~~Company~~has ~~(“DYH”)~~served ~~resigned~~as a director since June 17, 2021. He also served as our President from March 4, 2020 to August 1, 2021 and as our Chief Executive Officer from March 18, 2020 to August 1, 2021. Mr. Lin previously served as our President, Chief Executive Officer, Chief Financial Officer, Secretary and Treasurer, and as a director, from April 18, 2017 to August 4, 2017. From November 1983 to the ~~independent~~present, ~~registered~~Mr. ~~public~~Lin ~~accounting~~has ~~firm~~served as the President of Risesun Electrical & Industry Co. Ltd. located in Taiwan. From March 1994 to the ~~Company;~~present, ~~and~~he has served as President of Risesun Electric & Industry (iiKunshan) Co. ~~the~~Ltd. ~~Board~~located ofin ~~Directors~~China. ofFrom May 1998 to the ~~Company~~present, ~~which~~Mr. ~~acts~~Lin has served as the Chairman and Director of Yogo Textile Co. Ltd. located ~~audit~~in ~~committee~~Bangladesh. From September 2015 to the present, ~~engaged~~he ~~KCCW~~has ~~Accountancy~~served as the President of First Empire Corp. ~~(“KCCW”)~~located in Seychelles. From November 2018 to the present, Mr. Lin has served as the ~~Company’s~~President ~~new~~of ~~independent~~Rekun ~~registered~~Electronic ~~public~~Technology ~~accounting~~(Kunshan) Corp. located in China. Mr. Lin received ~~firm~~a bachelor degree from the Oriental Institute of Technology in Taipei, Taiwan in 1977, where he majored in Textile Engineering.

The reports of DYH on the consolidated financial statements of the Company as of and for the years ended September 30, 2020 and 2021 did not contain an adverse opinion or disclaimer of opinion, nor were they qualified or modified as to uncertainty, audit scope or accounting principle.13

~~During~~Kuang ~~the~~Ming ~~years~~(James) ~~ended~~Tsai ~~September~~has 30served as our Chief Financial Officer since July 22, ~~2020~~2023, ~~and~~our ~~2021~~Chief ~~and~~Operating ~~through~~Officer ~~February~~since 23July 14, 2022, and ~~there~~has ~~were~~served noas ~~disagreements~~a ~~with~~director ~~DYH~~since onJune ~~any~~11, ~~matter~~2018. ofMr. ~~accounting~~Tsai served as our President from June 29, 2018 to March 4, 2020, our Chief Executive ~~principles~~Officer orfrom ~~practices~~June 29, ~~financial~~2018 ~~statement~~to ~~disclosure~~March 18, or2020 ~~auditing~~and ~~scope~~our orChief ~~procedure~~Financial Officer from September 12, ~~which~~2018 ~~disagreements~~to March 18, if2020. ~~not~~From ~~resolved~~July 2017 to June 2018, Mr. Tsai served as the ~~satisfaction~~ President of ~~DYH~~YAMA KAWA Bilingual Club, ~~would~~part ~~have~~of ~~caused~~District ~~DYH~~67 toToastmasters ~~make~~International. ~~reference~~From 2010 to ~~the~~2017, ~~subject~~Mr. ~~matter~~Tsai was retired, during which period he was an investor of ~~the~~securities. ~~disagreement~~From in2006 ~~its~~to ~~reports~~2010, onhe served as the ~~Company’s~~President of ~~consolidated~~Blanfield ~~financial~~Pty ~~statements~~Ltd., ~~for~~an ~~such~~import ~~years~~company. Mr. Tsai received a Bachelor of Arts Degree from National Taiwan University in 1973, majoring in Economics.

~~The~~Wen-Piao ~~Company~~(Jack) Lai has ~~provided~~served ~~DYH~~as ~~with~~ a ~~copy~~director ofsince ~~the~~June ~~disclosures~~17, it2021. isMr. ~~making~~Lai ~~herein~~founded Kuan Dar Textile Co., Ltd., located in Taoyuan City, Taiwan, in 1987 and has ~~requested~~served ~~that~~as ~~DYH~~its ~~furnish~~President itsince ~~with~~that atime. ~~letter~~From ~~addressed~~ January 2016 to December 2017, Mr. Lai served as President of the ~~Securities~~Alumni Association ~~and~~of ~~Exchange~~Sha-Lu ~~Commission~~Industrial ~~stating~~Vocational ~~whether~~Senior orHigh ~~not~~School, ~~DYH~~from ~~agrees~~which ~~with~~he ~~the~~graduated ~~above~~in ~~statements~~1967. AMr. ~~copy~~Lai has extensive experience in business operations and management through more than 30 years of ~~such~~business ~~letter~~management isexperiences ~~provided~~in the company he founded. He also has ~~herewith~~participated aswith ~~Exhibit~~volunteer 16firefighting with Taoyuan City Bade Fire Station Squadron in Taoyuan City, Taiwan since 1999.1.

NoHsin-Ta ~~consultations~~(Darren) ~~occurred~~Su ~~between~~has ~~the~~served ~~Company~~as ~~and~~a ~~KCCW~~director ~~during~~since ~~the~~October ~~years ended September 30~~29, ~~2020 and~~ 2021 and ~~through~~as ~~February~~our ~~23,~~IT ~~2022, regarding~~manager ~~either~~since ~~(i)~~March ~~the~~2020. ~~application~~From ofApril ~~accounting~~2020 ~~principles~~ to aOctober ~~specific completed or proposed transaction~~2021, ~~the type of audit opinion~~ ~~that~~he ~~might~~was bea ~~rendered~~software ondeveloper ~~the~~for ~~Company’s~~JC ~~financial~~Healthcare ~~statements~~Technology Co., orLtd. ~~other~~In ~~written~~Taiwan. orFrom ~~oral~~May ~~information~~2016 ~~provided that was an important factor considered by the Company in reaching a decision as~~ to anMarch ~~accounting~~2020, ~~auditing,~~he orwas ~~financial~~a ~~reporting~~software ~~issue; or (ii) any matter~~developer ~~that~~Evolve ~~was~~Development ~~either~~Co., ~~the subject of a disagreement~~Ltd., ~~as that term is defined~~ in ~~Item~~Taiwan. ~~304(a)(1)(iv)~~Mr. ofSu ~~Regulation~~received ~~S-K~~an ~~and~~associate ~~the~~degree ~~related instructions to Item 304~~ of ~~Regulation~~computer ~~S-K,~~engineering orin a1998 ~~“reportable~~from ~~event,”~~Kuang asWu ~~that~~Junior ~~term is defined~~ College in ~~Item 304(a)(1)(v) of Regulation S-K~~Taiwan.

~~ITEM 9A~~Hui-Chuan (Sandra) Lin has served as Secretary since July 15, 2022. Ms Lin was previously a Sales Representative of Tai-Wan Motor Parts Co., ~~CONTROLS~~Ltd ~~AND~~since ~~PROCEDURES~~2017. Ms. Lin received a Master of Business Administration from the University of Glasgow in 2012. Ms. Lin also received her bachelor’s degree in civil engineering from Chung Yuan Christian University in 2007.

~~Evaluation~~None of ~~Disclosure~~our ~~Controls~~directors presently serves as a director of any other public companies. We have not entered into indemnification agreements with our directors, although they have indemnification protection under the laws of the State of Nevada, in which we are incorporated. We do not currently maintain director and ~~Procedures~~officer liability insurance.

~~Our~~We ~~disclosure~~believe ~~controls and procedures are designed to ensure~~ that ~~the~~what ~~information~~qualifies ~~relating~~each toof our ~~Company,~~directors ~~including our consolidated subsidiaries, required~~ to beserve ~~disclosed~~as insuch ~~our SEC reports~~ is ~~recorded,~~that ~~processed,~~each ~~summarized~~of ~~and~~our ~~reported~~directors ~~within~~has ~~the~~a ~~time~~good ~~periods~~working ~~specified~~relationship ~~in SEC~~with ~~rules and forms, and is accumulated and communicated to~~ our ~~management,~~shareholders ~~including our chief executive officer and chief financial officer~~generally, as ~~appropriate~~has tobeen ~~allow~~engaged ~~for~~in ~~timely~~private ~~decisions~~raises ~~regarding required disclosure. We conducted an evaluation, under the supervision and with the participation~~ of ~~management~~capital, ~~including~~which ~~our~~we ~~chief~~will ~~executive officer and chief financial officer~~require, ~~of the effectiveness of the design~~ and ~~operation~~has ofa ~~our~~broad ~~disclosure~~background ~~controls and procedures (as defined~~ in ~~Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934~~business, ~~as amended) as of the end of the period covered by this annual report. Based on this evaluation, our chief executive officer~~ ~~and~~all ~~chief financial officer concluded that, as~~ of ~~the~~which ~~evaluation~~qualities ~~date, our disclosure controls~~ and ~~procedures~~attributes ~~were~~could ~~not~~help ~~effective~~us ~~due to material weaknesses~~ in ~~our~~the ~~internal control over financial reporting, as described below~~future.

12Term of Office

~~Management’s~~Directors ~~Report~~hold onoffice ~~Internal~~until ~~Control~~the ~~Over~~next ~~Financial~~annual ~~Reporting~~meeting of our shareholders and until their successors have been duly elected and qualified. Our Bylaws provide that our Board of Directors will consist of no less than one nor more than nine members, as may be set from time to time by our shareholders. Our officers are appointed by, and serve at the discretion of, the Board of Directors.

~~Our~~Director management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Exchange Act Rules 13a-15(f) and 15d-15(f). Under the supervision and with the participation of management, including our chief executive officer and chief financial officer, we conducted an evaluation of the design and operating effectiveness of our internal controls over financial reporting based on the framework in “Internal Control—Integrated Framework (2013)” issued by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”).Independence

Our ~~internal~~Board ~~control~~of ~~over~~Directors ~~financial~~is ~~reporting~~currently ~~includes~~composed ~~those~~of ~~policies~~5 ~~and~~members, ~~procedures~~neither ~~that~~of ~~(i) pertain~~whom toqualifies ~~the~~as ~~maintenance~~an ofindependent ~~records that,~~director in ~~reasonable~~accordance ~~detail,~~with ~~accurately and fairly reflect~~ the ~~transactions~~published listing ~~and~~requirements ~~dispositions~~ of the ~~assets;~~Nasdaq ~~(ii) provide~~Stock ~~reasonable assurance~~Market. ~~that~~The ~~transactions~~Nasdaq ~~are~~independence ~~recorded~~definition asincludes ~~necessary~~a toseries ~~permit preparation~~ of ~~consolidated~~objective ~~financial~~tests, ~~statements~~such inas ~~accordance with generally~~that ~~accepted~~the ~~accounting~~director ~~principles~~is not, and ~~that~~has ~~receipts~~not ~~and~~been ~~expenditures~~for ~~are~~at ~~being~~least ~~made~~three ~~only~~years, inone ~~accordance with authorizations~~ of ~~management and~~our ~~directors;~~employees and ~~(iii) provide~~that ~~reasonable~~neither ~~assurance~~the ~~regarding~~director, ~~prevention~~nor orany ~~timely detection~~ of ~~unauthorized~~his ~~acquisition, use,~~ or her ~~disposition~~family ofmembers ~~our~~has ~~assets~~engaged ~~that~~in ~~could~~various ~~have~~types aof ~~material~~business ~~effect~~dealings onwith ~~the consolidated financial statements~~us.

~~Management assessed the effectiveness of the Company’s internal control over financial reporting as of evaluation date and identified the following material weaknesses:~~14

~~Inadequate~~In ~~Segregation~~addition, our Board of ~~Duties:~~Directors Wehas ~~have~~not anmade ~~inadequate~~a ~~number~~subjective determination as to any of ~~personnel~~our directors that no relationships exist which, in the opinion of our Board of Directors, would interfere with the exercise of independent judgment in carrying out the responsibilities of a director, although such subjective determination is required by Nasdaq requirements. Had our Board of Directors made these determinations, our Board of Directors would have reviewed and discussed information provided by our directors and us with regard to ~~properly~~each ~~implement~~director’s business ~~control~~and ~~procedures~~personal activities and relationships as they may relate to us and our management.

~~Comingling~~Involvement ~~of funds: We do not have adequate control of our petty cash, resulting~~ in ~~the~~Certain ~~comingling~~Legal ~~of our petty cash with the nominal account holder’s personal funds.~~Proceedings

~~Lack~~During ofthe ~~Adequate~~past ~~Staffing: We~~ten doyears, ~~not~~there have ~~adequate~~been ~~in-house~~no ~~accounting~~events ~~personnel~~under any bankruptcy act, no criminal proceedings and ~~expertise~~no injudgments, ~~key~~injunctions, ~~positions~~orders or decrees material to the evaluation of the ability and integrity of any director, ~~resulted~~executive inofficer, ~~overly~~promoter or control person of ~~relying~~the onCompany, ~~outside~~including ~~consultants~~any inallegations ~~preparing~~(not ~~financial~~subsequently ~~statements~~reversed, ~~and~~suspended or vacated), permanent or temporary injunction, or any other order ~~required~~of ~~disclosures~~any byfederal or state authority or self-regulatory organization, relating to activities in any phase of the ~~Securities~~securities, commodities, banking, savings and ~~Exchange~~loan, ~~Commission~~or insurance businesses in connection with the purchase or sale of any security or commodity, or involving mail or wire fraud in any business.

~~Ineffective~~Corporate ~~oversight:~~Governance, WeCommittee doStructure ~~not exercise effective oversight~~ and ~~monitoring~~Conflicts ~~procedures~~of ~~designed and implemented to certain control activities.~~Interest

~~Overly~~We ~~relied~~do onnot ~~outside~~have ~~professionals:~~standing audit, compensation and nominating/corporate governance committee, or committees performing similar functions. We have ~~are~~not ~~unable~~adopted toa ~~prepare~~code ~~internally~~of ~~financial~~ethics. ~~statements~~We ~~and~~anticipate ~~relied~~that onas ~~outside~~we ~~professional~~become ~~consultants~~more familiar with the obligations of U.S. public companies, we will implement appropriate corporate governance structures to ~~prepare~~comply ~~financial~~with ~~statements~~SEC and/or ~~adequate~~stock ~~disclosures~~exchange requirements. We intend to comply with all corporate governance requirements applicable to us at this time.

ASince ~~material~~our ~~weakness~~Board isof aDirectors ~~deficiency~~does not have standing audit, compensation or anominating/corporate ~~combination~~governance ofcommittees, ~~deficiencies~~or any other committees, the infunctions ~~internal~~that ~~control~~would ~~over~~have ~~financial~~been ~~reporting,~~performed by such ~~that~~committees ~~there~~are is performed by our Board of Directors as a ~~reasonable~~whole. ~~possibility~~We ~~that~~do not currently have a ~~material~~director ~~misstatement~~who ofwould satisfy the ~~Company’s~~requirements ~~annual~~of orbeing ~~interim~~an audit committee financial ~~statements~~expert. ~~will~~Our ~~not~~Board beof ~~prevented~~Directors has determined orthat ~~detected~~such oncommittees aare ~~timely~~not ~~basis.~~necessary Asat athis ~~result~~time, ofsince the ~~material~~Company ~~weaknesses~~is in ~~internal~~the ~~control~~early ~~over~~stages ~~financial~~of ~~reporting~~its ~~identified~~plan ~~above~~of operations, and there is ~~management~~no ~~concluded~~active trading of our Common Stock. It should be noted that ~~the~~since, ~~Company’s~~at ~~internal~~most, ~~control~~only ~~over~~one ~~financial~~of ~~reporting~~our ~~was~~directors ~~not~~is ~~effective~~independent, asthere is a risk of ~~September~~conflicts 30of interest arising from time to time. During the next fiscal year, ~~2022~~our ~~based~~Board of Directors will monitor whether and when onit would be appropriate to diversify the ~~criteria~~Board ~~set~~of ~~forth~~Directors into ~~“Internal~~include ~~Control—Integrated~~independent ~~Framework”~~directors ~~issued~~and/or byestablish ~~COSO~~Audit, Compensation and/or Nominating/Corporate Governance Committees.

~~Due~~Shareholder Communications towith the ~~nature~~Board of ~~the~~Directors material weaknesses, there is a more than remote likelihood that misstatements which could be material to the annual or interim financial statements could occur that would not be prevented or detected. The material weaknesses identified above either individually or in aggregation did not result in any identified misstatements or errors in the Company’s consolidated financial statements at and for the year ended September 30, 2022.

13We have not implemented a formal policy or procedure by which our stockholders can communicate directly with our Board of Directors. Nevertheless, our directors welcome the views of our shareholders. During the next fiscal year, our Board of Directors will continue to monitor whether and when it would be appropriate to adopt such a process.

~~Management’s~~ITEM ~~Plan~~11. ~~for~~EXECUTIVE ~~Remediation~~ COMPENSATION

~~Management~~The ~~has~~Summary ~~discussed~~Compensation ~~the~~Table ~~material~~shows ~~weaknesses~~certain ~~noted~~compensation ~~above~~information ~~with~~for ~~our~~services ~~independent~~rendered ~~registered~~in ~~public~~all ~~accounting~~capacities ~~firm.~~for ~~Management~~the isfiscal ~~committed~~years toended ~~improving~~September ~~its~~30, ~~internal~~2023 ~~controls~~and 2022. Other than as set forth herein, no executive officer’s salary and bonus exceeded $100,000 ~~subject~~in toany ~~having~~of the ~~adequate~~applicable ~~financial~~years. ~~resources~~The following information includes the dollar value of base salaries, ~~intends~~bonus ~~to:~~awards, the number of stock options granted and certain other compensation, if any, whether paid or deferred.

● increase the frequency of independent reconciliations of significant accounts which will mitigate the lack of segregation of duties to monitor and review until there are sufficient personnel to segregate duties;15

●Summary Compensation ~~consider providing professional courses for our key position personnel;~~Table

● hire additional employees to realize segregation of duties; and

Name and Principal Position	Fiscal Year		Salary ($)		Bonus ($)		Stock Awards ($)		Option Awards ($)		All other compensation ($)		Total ($)
David Tang		2022		31,250		-		-		15,822		-		47,072
Chief Executive Officer		2023		150,000		-		-		75,000		-		225,000

Wen-Piao (Jack) Lai⁽¹⁾		2022		22,210		-		-		-		-		22,210
Director, Former CEO		2023		1,800		-		-		-		-		1,800

Shao-Cheng (Will) Wang⁽²⁾		2022		27,600										27,600
		2023		0										0

Jin Pin (John) Lin⁽³⁾		2022		8,048		-		-		-		-		8,048
President		2023		9,000		-		-		-		-		9,000

Kuang-Ming (James) Tsai⁽⁴⁾		2022		20,755		-		-		-		-		20,755
Chief Financial Officer		2023		5,400		-		-		-		-		5,400

Hsin-Ta (Darren) Su(5)		2022		17,189		-		-		-		-		17,189
Treasurer		2023		15,300		-		-		-		-		15,300

Hui-Chuan (Sandra) Lin⁽⁶⁾		2022		4,529		-		-		-		-		4,529
Secretary		2023		5,400		-		-		-		-		5,400

●1 ~~strengthen~~From ~~management~~September ~~monitoring~~30, ~~control~~2021, ~~over~~through ~~accounting~~September 30, 2022, Mr. Lai was entitled to receive his compensation in the amount of $2,500 per month. Of the total amount of the $22,210 earned by Mr. Lai through September 30, 2022, as executive compensation, $0 was paid and ~~financial~~$22,210 ~~statements~~was ~~preparation~~accrued. ~~processing~~Mr. Lai converted his accrued amount into 24,010,000 shares of common stock on March 24, 2023.

~~However~~2 34, ~~due~~500,000 shares of Mr. Wang’s accrued and unpaid compensation has been converted to ~~limitation~~shares of ~~funds~~our ~~and~~Common ~~personnel~~Stock on March 24, we2023. ~~have~~From soSeptember ~~far~~30, ~~been~~2021, ~~unable~~through toSeptember ~~begin~~30, 2022, Mr. Wang was entitled to ~~implement~~receive his compensation in the ~~plan~~amount toof ~~remediate~~$2,300 per month. Of the ~~material~~total ~~weaknesses noted~~amount ~~above~~of the $27,600 earned by Mr. Wang through September 30, 2022, as the former CFO $0 was paid and $27,600 was accrued. Additionally, Mr. Wang has resigned from the Chief Financial Officer position on July 22, 2023.

~~Inherent Limitations~~3 Mr. Lin served as our President from March 4, 2020, until August 1, 2021 and as our Chief Executive Officer from March 18, 2020 until August 1, 2021. From September 30, 2021, through September 30, 2022, Mr. Lin was entitled to receive his compensation in the amount of $3,000 per month,which was owed to him and being accrued by the Company in the total amount of $17,048. Then, on ~~Effectiveness~~March 24, 2023, he converted the amount due to him in 17,048,000 shares of ~~Controls~~the Company’s common stock. Of the total amount of the $8,048 earned by Mr. Lin through September 30, 2022, as executive compensation, $0 was paid and $8,048 was accrued. Additionally, Mr. Lin served as our President and Chief Executive Officer from August 1, 2021, until October 29, 2021. From August 1, 2021, through September 30, 2021, Mr. Lin received compensation of $2,500 a month. All accrued and unpaid compensation has been converted to shares of our Common Stock.

~~A control~~4 ~~system,~~From noSeptember ~~matter~~30, ~~how~~2021 ~~well~~to ~~designed~~September ~~and~~30, ~~operated~~2022, ~~can~~Mr. ~~provide~~Tsai ~~only~~was ~~reasonable,~~entitled ~~not~~to ~~absolute,~~receive ~~assurance~~his ~~that~~compensation in the ~~control~~amount ~~system’s objectives~~of ~~will~~$1,800 beper ~~met~~month. ~~Because~~Of ofthe ~~its~~total ~~inherent~~amount ~~limitations,~~of ~~internal~~the ~~control~~$20,755 ~~over~~earned ~~financial~~by ~~reporting~~Mr. ~~may~~Tsai ~~not~~through ~~prevent~~September or30, ~~detect~~2022, ~~all control~~as ~~issues~~executive ~~or misstatements. Accordingly~~compensation, ~~our~~$0 ~~controls~~was paid and ~~procedures~~$20,755 ~~are~~was ~~designed~~accrued. toOn ~~provide~~March ~~reasonable~~24, ~~not absolute~~2023, ~~assurance that~~Mr. ~~the~~Tsai ~~objectives~~converted ofthe ~~our~~accrued ~~control~~amount ~~system~~of ~~are~~his ~~met.~~compensation ~~Projections~~into of26,155,000 ~~any~~shares ~~evaluation~~ of ~~effectiveness to future periods are subject to~~ the ~~risk~~ ~~that~~Company ~~controls~~Common ~~may~~Stock. ~~become~~From ~~adequate~~July ~~because~~22, ~~of changes in conditions~~2023, orMr. ~~that~~Tsai ~~the~~was ~~degree~~appointed ofas ~~compliance~~Chief ~~with~~Financial ~~the policies or procedures may deteriorate~~Officer.

~~Changes~~ 5 From September 30, 2021, through September 30, 2022, Mr. Su was entitled to receive his compensation in ~~Internal~~the ~~Control~~amount of $1,800 per month as the treasurer. Of the total amount of the $17,188.94 earned by Mr. Su through September 30, 2022, $2,200 was paid and $14,988.94 was accrued. Mr. Su has accrued $18,271.12 and converted 18,271,120 into the Company’s Common Stock.

~~There have~~6 ~~been~~From noSeptember ~~changes~~30, 2021, through September 30, 2022, Ms. Lin was entitled to receive her compensation in ~~our~~the ~~internal~~amount ~~control~~of ~~over~~$1,800 ~~financial~~per ~~reporting~~month ~~that~~as ~~occurred~~the ~~during~~secretary. Of the ~~year~~total ~~ended~~amount of the $4,529 earned by Ms. Lin through September 30, 2022, ~~that~~$0 ~~have materially~~was ~~affected~~paid and $4,529 orwas ~~are~~accrued. ~~reasonably~~Ms. ~~likely~~Lin tohas ~~materially~~accrued ~~affect~~$9,929 ~~our~~of ~~internal~~unpaid ~~control~~compensation ~~over~~, ~~financial~~which ~~reporting~~was converted into 9,929,000 shares of the Company’s Common Stock. Additionally, in fiscal year 2023, Ms. Lin accrued $5,400 in compensation, which was then converted into 9,929,000 shares of the Company’s Common Stock.

~~ITEM 9B. OTHER INFORMATION~~16

~~None.~~Employment Agreements

~~ITEM~~We have not entered into employment ~~9C.~~agreements ~~DISCLOSURE~~with ~~REGARDING~~any ~~FOREIGN~~of ~~JURISDICTIONS~~our ~~THAT~~named ~~PREVENT~~executive ~~INSPECTIONS~~officers except for David Tang, CEO and Kuang Ming (James) Tsai, CFO.

~~None.~~ Employment Contract - David Tang

14On July 29, 2022, the Company and David Tang (the “Executive”) executed an employment agreement (the “Employment Agreement”) dated July 29, 2022. Pursuant to the Employment Agreement, the Executive’s full time employment with the Company as the Chief Executive Officer began on July 15, 2022, and the Executive’s responsibilities include executing development of electric vehicle supply equipment (“EVSE”) or commonly known as charging stations and coordinating global strategy and marketing. Additionally, under the Employment Agreement, the Executive shall receive an annual base salary of $150,000 and be eligible for annual bonus subject to certain millstones as mutually agreed by the Executive and the board of directors (the “Board”) of the Company. In accordance with the Employment Agreement, the Executive is also eligible for other benefits, such as medical/dental insurance and telecommunication/commuting reimbursements and paid vacation days.

~~PART~~In connection with the Employment ~~III~~Agreement, on July 29, 2022, the Company and the Executive entered into a stock option agreement (the “Stock Option Agreement”), pursuant to which the Company granted the Executive the stock option (the “Stock Option”) as of July 15, 2022 (the “Date of Grant”) to purchase 15,000,000 shares of the Company’s common stock with the first twenty-five percent (25%) of the Stock Option to be vested on July 15, 2023; the second twenty-five percent (25%) of the Stock Option to be vested on July 15, 2024; the third twenty-five percent (25%) of the Stock Option to be vested on July 15, 2025; and the fourth twenty-five percent (25%) of the Stock Option to be vested on July 15, 2026. Unless terminated earlier pursuant to the Stock Option Agreement, the Stock Option shall expire on July 15, 2032 (the “Expiration Date”).

~~ITEM 10. DIRECTORS,~~Employment ~~EXECUTIVE~~Contract ~~OFFICERS~~– ~~AND~~Kuang ~~CORPORATE~~Ming ~~GOVERNANCE~~ (James) Tsai

AsOn July 22, 2023, the Company ofand Kuang Ming (James) Tsai (the ~~date~~“CFO”) ofexecuted an employment agreement (the ~~filing~~“CFO ofEmployment ~~this~~Agreement”). ~~Annual~~Pursuant to ~~Report~~the CFO Employment Agreement, ~~our~~Mr. ~~current~~Tsai ~~directors~~will be responsible for duties pertaining to the Chief Financial Officer, including financial reporting and ~~executive~~fund ~~officers~~raising. The Company and ~~additional~~Mr. ~~information~~Tsai ~~concerning~~hereby ~~them~~agree that the Company will pay Mr. Tsai a special one-time bonus upon successful ~~are~~fund raise of the Company as ~~follows:~~a result of Mr. Tsai’s efforts or relationships, payable upon receipt of such investment. The special one-time bonus will be four percent (4%) of the total proceeds for any new funding up to $250,000.00, and five percent (5%) of the total proceeds for any new funding over $250,000.00.

Name	Age	Position
David Tang	44	Chief Executive Officer
Jui Pin (John) Lin	67	Chairman of the Board, President, and Director
Shao-Cheng (Will) Wang	64	Chief Financial Officer
Kuang Ming (James) Tsai	73	Director, Chief Operating Officer
Wen-Piao (Jack) Lai	70	Director
Hsin-Ta (Darren) Su	45	Director
Hui-Chuan (Sandra) Lin	38	Director and Secretary

Additionally, as Mr. Tsai is a significant shareholder in the Company, he will forgo any monthly cash compensation, and pursuant to the agreement, the compensation arrangement will be reviewed quarterly, subject to adjustment as needed. Further, Mr. Tsai no longer receives the consultancy compensation as of the start date of the CFO Employment Agreement.

~~David Tang~~Compensation ~~has~~Conversion ~~served as our Chief Executive Officer since July 15, 2022. Prior~~ to ~~joining~~Common us, Mr. Tang was a Relationship Manager of Venture Lending Emerging Technologies division at East West Bank in California from 2019 to 2022. Prior to that, Mr. Tang was an advisor to many startups in Hong Kong, including Maxvoice and Maxisense from 2016 to 2019. Mr. Tang was the founder and the Chief Executive Officer of Fontainebleau Partners, a technology startup in Hong Kong from 2012 to 2016. In 2011, Mr. Tang was an Equity Research Analyst at BNP Paribas Securities in Hong Kong and Taipei. In 2009, Mr. Tang was an MBA Consultant for Swire Coca-Cola HK Limited. From 2005 to 2008, Mr. Tang was a Relationship Manager at Manufacturing Bank in California, a Sumitomo Mitsui Banking Corporation subsidiary. From 2004 to 2005, Mr. Tang was a Client Financial Analyst at Citibank in California. Mr. Tang has a bachelor degree in History from University of California, Irvine and a Master of Business Administration degree in Finance from Hong Kong University of Science & Technology. Mr. Tang is currently a mentor at KidsX Accelerator, a network of pediatric experts and innovators founded and administered by Children’s Hospital Los Angeles.Stock

~~Jui Pin~~On ~~(John)~~December ~~Lin has served as our President since July 14~~11, 2022, ~~and Mr. Lin has served as a director since June 17, 2021. He also~~our ~~served~~Board asof ~~our~~Directors ~~President~~authorized ~~from~~that ~~March~~all 4,accrued ~~2020 to August 1, 2021~~ and asunpaid ~~our~~amounts ~~Chief~~of ~~Executive Officer from March 18~~compensation, ~~2020 to August 1, 2021. Mr. Lin previously served~~ as ~~our~~of ~~President,~~December ~~Chief Executive Officer~~31, ~~Chief Financial Officer~~2022, ~~Secretary~~may ~~and~~be ~~Treasurer~~converted, ~~and~~at ~~as a director, from April 18, 2017 to August 4, 2017. From November 1983 to~~ the ~~present, Mr. Lin has served as the President~~ option of ~~Risesun~~our ~~Electrical & Industry Co. Ltd. located in Taiwan. From March 1994 to the present~~directors, heand ~~has served as President of Risesun Electric & Industry (Kunshan) Co. Ltd. located in China. From May 1998 to the~~ present, ~~Mr. Lin has served as the Chairman~~ and ~~Director~~certain offormer ~~Yogo~~executive ~~Textile Co. Ltd. located in Bangladesh. From September 2015 to the present~~officers, heinto ~~has~~shares ~~served as the President~~ of ~~First~~our ~~Empire~~Common ~~Corp~~Stock. ~~located~~No infurther ~~Seychelles.~~action ~~From November 2018 to the present, Mr. Lin~~ has ~~served~~taken ~~as the President of Rekun Electronic Technology (Kunshan) Corp~~place. ~~located in China. Mr. Lin received a bachelor degree from the Oriental Institute of Technology in Taipei, Taiwan in 1977, where he majored in Textile Engineering.~~

~~Shao-Cheng (Will)~~Outstanding ~~Wang~~Equity ~~has~~Awards ~~served~~at asFiscal our Chief Financial Officer, Treasurer and Secretary since March 18, 2020. From June 17, 2021 to October 29, 2021 he also served as a director. In August 2020, Mr. Wang became the president of Yuhan Trading Company in Taichung, Taiwan. From January 1994 to the present, Mr. Wang has served as an information technology consultant for Hsinlan Chemical, Co, Ltd. located in Taichung City, Taiwan. From May 2018 to the present, he has served as the General Secretary for Chinese Taipei Wushu Confederation of the Koushu/Wushu Federation of the Republic of China (Taiwan). From August 1986 to July 2015, he was a teacher and Director of Academic Affairs for Taichung ShaYear-Lu Industrial Senior High School in Taichung, Taiwan. Mr. Wang received a bachelor’s degree from the Division of Industrial Technics Education of the National Taiwan Normal University and a master’s degree from the Graduate Institute of Statistics of Chung Hua University in Hsinchu City, Taiwan.End

15There are no outstanding equity awards to any of our named executive officers other than the stock option issued to David Tang.

~~Kuang Ming~~No ~~(James) Tsai has served as our Chief Operating Officer since July 14~~retirement, ~~2022~~pension, ~~and has served as a director since June 11, 2018.~~profit ~~Mr. Tsai served as our President from June 29~~sharing, ~~2018~~stock tooption ~~March~~or 4,insurance ~~2020,~~programs ~~our~~or ~~Chief~~other ~~Executive~~similar ~~Officer~~programs ~~from~~have ~~June~~been ~~29,~~adopted ~~2018~~by ~~to March 18, 2020 and our Chief Financial Officer from September 12, 2018 to March 18, 2020. From July 2017 to June 2018, Mr. Tsai served as~~ the ~~President of YAMA KAWA Bilingual Club, part of District 67 Toastmasters International~~Company. ~~From~~We ~~2010~~have tono ~~2017,~~present ~~Mr.~~intention ~~Tsai was retired, during which period he was an investor~~ of ~~securities. From 2006 to 2010, he served as the President of Blanfield Pty Ltd., an import company. Mr. Tsai received~~ aadopting ~~Bachelor~~any ofsuch ~~Arts~~plans ~~Degree from National Taiwan University~~ in ~~1973,~~the ~~majoring~~foreseeable ~~in Economics~~future.

~~Wen-Piao (Jack) Lai has served as a director since June~~ 17, 2021. Mr. Lai founded Kuan Dar Textile Co., Ltd., located in Taoyuan City, Taiwan, in 1987 and has served as its President since that time. From January 2016 to December 2017, Mr. Lai served as President of the Alumni Association of Sha-Lu Industrial Vocational Senior High School, from which he graduated in 1967. Mr. Lai has extensive experience in business operations and management through more than 30 years of business management experiences in the company he founded. He also has participated with volunteer firefighting with Taoyuan City Bade Fire Station Squadron in Taoyuan City, Taiwan since 1999.

~~Hsin-Ta (Darren)~~ITEM ~~Su has served as a director since October 29, 2021 and as our IT manager since March 2020~~12. ~~From~~SECURITY ~~April~~OWNERSHIP ~~2020~~OF toCERTAIN ~~October~~BENEFICIAL ~~2021, he~~OWNERS ~~was~~AND aMANAGEMENT ~~software~~AND ~~developer~~RELATED ~~for~~STOCKHOLDER JC Healthcare Technology Co., Ltd. In Taiwan. From May 2016 to March 2020, he was a software developer Evolve Development Co., Ltd., in Taiwan. Mr. Su received an associate degree of computer engineering in 1998 from Kuang Wu Junior College in Taiwan.MATTERS

~~Hui-Chuan (Sandra)~~The ~~Lin~~following ~~has~~table ~~served~~sets forth, as ~~Secretary~~of ~~since~~December ~~July~~31, 152023, ~~2022.~~the Msnumber ~~Lin~~of ~~was~~shares ~~previously~~of aour ~~Sales~~Common ~~Representative~~Stock owned of ~~Tai-Wan~~record ~~Motor~~and ~~Parts~~beneficially ~~Co.~~by all directors, executive officers ~~Ltd~~and ~~since~~persons ~~2017.~~who ~~Ms.~~beneficially ~~Lin~~own ~~received~~more athan ~~Master~~5% of ~~Business~~the ~~Administration~~outstanding ~~from~~shares ~~the~~of ~~University~~Common Stock of ~~Glasgow~~the Company. We have determined beneficial ownership in ~~2012.~~accordance Mswith the rules of the SEC. ~~Lin~~Except ~~also~~as ~~received~~indicated ~~her~~by the footnotes below, we believe, based on the information furnished ~~bachelor’s~~to ~~degree~~us, that the persons and entities named in ~~civil~~the ~~engineering~~table ~~from~~below ~~Chung~~have ~~Yuan~~sole ~~Christian~~voting ~~University~~and ininvestment ~~2007~~power with respect to all shares of Common Stock that they beneficially own.

None of our directors presently serves as a director of any other public companies. We have not entered into indemnification agreements with our directors, although they have indemnification protection under the laws of the State of Nevada, in which we are incorporated. We do not currently maintain director and officer liability insurance.

Name and Address	Amount and Nature of Beneficial Ownership			Percentage of Class⁽¹⁾
5% or more Stockholders:
Shao-cheng Wang No. 11, Ln. 120, Yongshun St., Dajia Dist., Taichung City 437 Taiwan 402 (R.O.C)		87,155,889			10.77	%

Directors and Executive Officers:
David Tang 1108 S. Baldwin Avenue, Suite 107 Arcadia, California 91007		0			0	%
Jui Pin (John) Lin 1108 S. Baldwin Avenue, Suite 107 Arcadia, California 91007		80,468,000	(2)		9.95	%
Wen-Piao (Jack) Lai 1108 S. Baldwin Avenue, Suite 107 Arcadia, California 91007		72,070,500			8.91	%
Kuang Ming (James) Tsai 1108 S. Baldwin Avenue, Suite 107 Arcadia, California 91007		31,555,000			3.90	%
Hui-Chuan (Sandra) Lin⁽²⁾ 1108 S. Baldwin Avenue, Suite 107 Arcadia, California 91007		14,433,400	(2)		1.76	%
Hsin-Ta (Darren) Su 1108 S. Baldwin Avenue, Suite 107 Arcadia, California 91007		32,077,196			3.97	%
All Directors and Executive Officers as a group (5 persons)		230,395,696			39.2	%

~~We believe~~(1) ~~that~~Percentages ~~what~~are ~~qualifies~~calculated ~~each~~on ofthe ~~our~~basis ~~directors to serve as such is that each~~ of ~~our directors has a good working relationship with our shareholders generally~~808,900,041 ~~has~~shares ~~been~~of ~~engaged~~Common inStock ~~private~~outstanding ~~raises~~as of ~~capital,~~December ~~which we will require~~28, ~~and has a broad background in business, all of which qualities and attributes could help us in the future~~2023.

~~Term of~~(2) ~~Office~~Hui-Chuan (Sandra) Lin is Jui Pin (John) Lin’s daughter.

Directors hold office until the next annual meeting of our shareholders and until their successors have been duly elected and qualified. Our Bylaws provide that our Board of Directors will consist of no less than one nor more than nine members, as may be set from time to time by our shareholders. Our officers are appointed by, and serve at the discretion of, the Board of Directors.18

~~Our Board~~Related of Directors is currently composed of 5 members, neither of whom qualifies as an independent director in accordance with the published listing requirements of the Nasdaq Stock Market. The Nasdaq independence definition includes a series of objective tests, such as that the director is not, and has not been for at least three years, one of our employees and that neither the director, nor any of his or her family members has engaged in various types of business dealings with us.Parties

16Name of related parties Relationship with the Company Yi Lung (Oliver) Lin Principal shareholder Jui Pin (John) Lin Principal shareholder, Director, Former President and Chief Executive Officer Jia Tian (Jeffery) Lin Former Chief Executive Officer Wen-Piao (Jack) Lai Director, Former Chief Executive Officer Kuang Ming (James) Tsai Director, Chief Financial Officer Hsin-Ta (Darren) Su Director, Treasurer Hui-Chuan (Sandra) Lin Director, daughter of Jui Pin (John) Lin David Tang Chief Executive Officer

~~In addition,~~Due ~~our Board of Directors has not made a subjective determination as~~ to ~~any~~Related of our directors that no relationships exist which, in the opinion of our Board of Directors, would interfere with the exercise of independent judgment in carrying out the responsibilities of a director, although such subjective determination is required by Nasdaq requirements. Had our Board of Directors made these determinations, our Board of Directors would have reviewed and discussed information provided by our directors and us with regard to each director’s business and personal activities and relationships as they may relate to us and our management.Parties

~~Involvement in~~The ~~Certain~~Company’s ~~Legal~~due ~~Proceedings~~to related parties balances are as follows:

During the past ten years, there have been no events under any bankruptcy act, no criminal proceedings and no judgments, injunctions, orders or decrees material to the evaluation of the ability and integrity of any director, executive officer, promoter or control person of the Company, including any allegations (not subsequently reversed, suspended or vacated), permanent or temporary injunction, or any other order of any federal or state authority or self-regulatory organization, relating to activities in any phase of the securities, commodities, banking, savings and loan, or insurance businesses in connection with the purchase or sale of any security or commodity, or involving mail or wire fraud in any business.

	September 30, 2023		September 30, 2022
Kuang Ming (James) Tsai	$		$	20,755
David Tang		14,023
Jui Pin (John) Lin				8,048
Jia Tian (Jeffery) Lin				2,500
Wen-Piao (Jack) Lai				22,210
Hsin-Ta (Darren) Su		707		17,189
Hui-Chuan (Sandra) Lin				4,529
Total	$	14,730	$	102,831

~~Corporate Governance,~~The ~~Committee~~related ~~Structure~~party ~~and~~balances ~~Conflicts~~are ofunsecured, ~~Interest~~interest-free and due on demand.

~~We do~~ITEM ~~not have standing audit, compensation and nominating/corporate governance committees, or committees performing similar functions~~14. We ~~have~~PRINCIPAL ~~not~~ACCOUNTING ~~adopted~~FEES aAND code of ethics. We anticipate that as we become more familiar with the obligations of U.S. public companies, we will implement appropriate corporate governance structures to comply with SEC and/or stock exchange requirements. We intend to comply with all corporate governance requirements applicable to us at this time. SERVICES

~~Since our~~The ~~Board~~following oftable ~~Directors does not have standing audit, compensation or nominating/corporate governance committees, or any other committees,~~summarizes the ~~functions~~fees ~~that~~charged ~~would have been performed~~ by ~~such~~KCCW ~~committees~~Accounting ~~are performed by our Board of Directors as a whole~~Corp. We(“KCCW”) dofor ~~not currently have a director who would satisfy~~ the ~~requirements~~services ofrendered ~~being~~to ~~an audit committee financial expert. Our Board of Directors has determined that such committees are not necessary at this time, since~~ the ~~Company~~company isand ~~in the early stages of~~ its ~~plan~~subsidiaries ofin operations, and there is no active trading of our Common Stock. It should be noted that since, at most, only one of our directors is independent, there is a risk of conflicts of interest arising from time to time. During the next fiscal ~~year, our Board of Directors will monitor whether and when~~ ityears ~~would be appropriate to diversify the Board~~ of ~~Directors~~2023 ~~to include independent directors~~ and~~/or~~ ~~establish Audit, Compensation and/or Nominating/Corporate Governance Committees.~~ 2022:

Shareholder Communications with the Board of Directors

	Amount Billed and Paid
Type of Fee	Fiscal Year 2022		Fiscal Year 2023
Audit (1)	$	37,767	$	34,365
Audit related (2)		-		-
Total	$	37,767	$	34,365

~~We have~~(1) ~~not~~Represents ~~implemented~~aggregate afees ~~formal~~charged ~~policy~~by orKCCW ~~procedure~~for byaudits ~~which~~of ~~our~~consolidated ~~stockholders~~financial ~~can~~statements ~~communicate~~for ~~directly~~fiscal ~~with~~years ~~our~~ended ~~Board~~September of30, ~~Directors. Nevertheless~~2022, ~~our~~ ~~directors~~and ~~welcome~~2023, ~~the~~and ~~views~~quarterly ofreviews ~~our~~during ~~shareholders. During the next~~ fiscal year, ~~our~~2022 ~~Board of Directors will continue to monitor whether~~ and ~~when~~2023, ~~it would be appropriate to adopt such a process~~respectively.

~~ITEM 11. EXECUTIVE COMPENSATION~~ 19

~~The Summary~~PART Compensation Table shows certain compensation information for services rendered in all capacities for the fiscal years ended 2022 and 2021. Other than as set forth herein, no executive officer’s salary and bonus exceeded $100,000 in any of the applicable years. The following information includes the dollar value of base salaries, bonus awards, the number of stock options granted and certain other compensation, if any, whether paid or deferred .IV

17ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES

~~Summary~~(a) Documents filed as ~~Compensation~~part ~~Table~~of this report:

Name and Principal Position	Fiscal Year	Salary ($)		Bonus ($)		Stock Awards ($)		Option Awards ($)		All other compensation ($)		Total ($)
David Tang1	2021		-		-		-		-		-		-
Chief Executive Officer	2022		31,250		-		-		63,288		-		94,538
Wen-Piao (Jack) Lai2	2021		-		-		-		-		-		-
Director, Former CEO	2022		22,210		-		-		-		-		22,210
Shao-Cheng (will) Wang3	2021		24,540		-		-		-		-		24,540
Chief Financial Officer	2022		27,600		-		-		-		-		27,600
Jin Pin (John) Lin4	2021		30,000		-		-		-		-		30,000
President	2022		8,048		-		-		-		-		8,048
Kuang-Ming (James) Tsai5	2021		28,200		-		-		-		1,000		29,200
Chief Operating Officer	2022		20,755		-		-		-		-		20,755
Hsin-Ta (Darren) Su6	2021		-		-		-		-		-		-
Treasurer	2022		17,189		-		-		-		-		17,189
Hui-Chuan (Sandra) Lin7	2021		-		-		-		-		-		-
Secretary	2022		4,529		-		-		-		-		4,529

1. Financial Statements

1The ~~Mr.~~consolidated ~~Tang~~financial statements ~~was~~contained ~~hired~~herein inare ~~July~~as ~~2022~~listed ~~and~~on ~~has since received compensation in~~ the ~~amount~~“Index ofto ~~$12,500~~Consolidated ~~per~~Financial ~~month.~~Statements” Ofon ~~the~~page ~~total~~F-1 ~~amount~~ of ~~$31,250~~this ~~earned by Mr~~report. ~~Tang through September 30, 2022 as executive compensation, $31,250 has been paid in cash.~~

2 ~~From September 30, 2021 through September 30, 2022, Mr~~. ~~Lai~~Financial ~~received~~Statement compensation in the amount of $2,500 per month. Of the total amount of the $22,210 earned by Mr. Lai through September 30, 2022 as executive compensation, $0 was paid and $22,210 was accrued. Mr. Lai has not yet converted his accrued amount into share of our Common Stock.Schedule

3The ~~From~~consolidated ~~April~~financial statement 1,schedule ~~2020~~contained ~~through~~herein ~~June~~is ~~30,~~as ~~2020,~~listed ~~Mr.~~on ~~Wang received compensation in~~ the ~~amount~~“Index ~~of $2,500. Effective July 1, 2020, this amount was reduced~~ to ~~$2,000~~Consolidated ~~per~~Financial ~~month.~~Statements” Ofon ~~the~~page ~~total~~F-1 ~~amount~~ of ~~$13,500~~this ~~earned by Mr~~report. ~~Wang through September 30, 2020 as executive compensation, $2,121 has been paid and $11,379 was accrued. His compensation was increased to $2,300 per month on August 6, 2021.~~ All ~~accrued~~other ~~and~~schedules ~~unpaid~~have ~~compensation has~~ been ~~converted~~omitted tobecause ~~shares~~they ofare ~~our~~not ~~Common Stock. From September 30~~applicable, ~~2021~~not ~~through September 30~~required, ~~2022,~~or ~~Mr.~~the ~~Wang~~information ~~received~~is ~~compensation~~included in the ~~amount~~consolidated financial ofstatements ~~$2,300~~or ~~per~~notes ~~month~~thereto. Of the total amount of the $27,600 earned by Mr. Wang through September 30, 2022 as executive compensation, $0 was paid and $27,600 was accrued. Mr. Wang has not yet converted his accrued amount into share of our Common Stock.

4 Mr. Lin served as our President from March 4, 2020 until August 1, 2021 and as our Chief Executive Officer from March 18, 2020 until August 1, 2021. From April 1, 2020 through June 30, 2020, Mr. Lin received compensation in the amount of $4,000 per month. Effective July 1, 2020, this amount was reduced to $3~~,000 per month~~. Of the total amount of $21,000 and $30,000 earned by Mr. Lin through July 31, 2021 as executive compensation, $0 has been paid and all earnings have been converted to shares of our Common Stock. In September 2021, after he ceased serving as our President and Chief Executive Officer, Mr. Lin earned $500 for attending a meeting of the Board of Directors. From September 30, 2021 through September 30, 2022, Mr. Lin received compensation in the amount of $3,000 per month. Of the total amount of the $8,048 earned by Mr. Lin through September 30, 2022 as executive compensation, $0 was paid and $8,048 was accrued. Mr. Lin has not yet converted his accrued amount into share of our Common Stock.Exhibits

5See ~~From~~Exhibit ~~October 1, 2020 to August 6, 2021, Mr~~Index. Tsai received compensation of $2,500 per month, and $1,500 from August 6, 2021 until September 30, 2021. Except for $1,000 for attending a meeting of the Board of Directors in September 2021, all other accrued and unpaid balance has been converted to shares of our Common Stock. From September 30, 2021 through September 30, 2022, Mr. Tsai received compensation in the amount of $1,800 per month. Of the total amount of the $20,755 earned by Mr. Tsai through September 30, 2022 as executive compensation, $0 was paid and $20,755 was accrued. Mr. Tsai has not yet converted his accrued amount into share of our Common Stock.

6(b) From September 30, 2021 through September 30, 2022, Mr. Su received compensation in the amount of $1,800 per month. Of the total amount of the $17,188.94 earned by Mr. Su through September 30, 2022 as executive compensation, $2,200 was paid and $14,988.94 was accrued. Mr. Su has not yet converted his accrued amount into share of our Common Stock.Exhibits:

7 From September 30, 2021 through September 30, 2022, Ms. Lin received compensation in the amount of $1,800 per month. Of the total amount of the $4,529 earned by Ms. Lin through September 30, 2022 as executive compensation, $0 was paid and $4,529 was accrued. Ms. Lin has not yet converted his accrued amount into share of our Common Stock.20

18The following exhibits are attached hereto and incorporated herein by reference.

Employment Agreements

Exhibit No.		Description
3.1(1)		Articles of Incorporation of Genufood Energy Enzymes Corp. dated June 21, 2010
3.2(1)		Certificate of Amendment dated December 10, 2010 to Articles of Incorporation of Genufood Energy Enzymes Corp.
3.3(1)		Certificate of Amendment dated August 1, 2014 to Articles of Incorporation of Genufood Energy Enzymes Corp.
3.4(1)		Certificate of Amendment dated February 24, 2015 to Articles of Incorporation of Genufood Energy Enzymes Corp.
3.5(2)		Certificate of Change Pursuant to Nevada Revised Statutes Section 78.209, as filed by Genufood Energy Enzymes Corp. with the Secretary of State of the State of Nevada on June 24, 2020.
3.6(3)		Bylaws of Genufood Energy Enzymes Corp.
4.1(4)		Description of Securities
10.1(5)		Stock Purchase Agreement made and entered into as of November 17, 2021, by and among Genufood Energy Enzymes Corp.; Yu-Lin Chen; and Hukui Biotechnology Corporation
10.2(6)		Agreement dated as of December 17, 2021 by and between Genufood Energy Enzymes Corp. and Hukui Biotechnology Corporation
10.3(7)		Employment Agreement between David Tang and Genufood Energy Enzymes Corp. dated July 29, 2022
10.4(7)		Stock Option Agreement between David Tang and Genufood Energy Enzymes Corp. dated July 29, 2022
10.5(8)		Employment Agreement between Kuang Ming (James) Tsai and Genufood Enzymes Corp. dated July 22, 2023
16.1(9)		Letter from DYH & Company to the Securities and Exchange Commission.
21(4)		List of subsidiaries
23.1*		Consent of Independent Registered Public Accounting Firm KCCW Accountancy Corp.
24.1*		Power of Attorney (included after signatures hereto)
31.1*		Certification by the Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 and Rules 13a-14 and 15d-14 under the Securities Exchange Act of 1934
31.2*		Certification by the Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 and Rules 13a-14 and 15d-14 under the Securities Exchange Act of 1934
32.1*		Certification of Periodic Financial Report by the Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
32.2*		Certification of Periodic Financial Report by the Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS		Inline XBRL Instance Document.
101.SCH		Inline XBRL Taxonomy Extension Schema Document.
101.CAL		Inline XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF		Inline XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB		Inline XBRL Taxonomy Extension Label Linkbase Document.
101.PRE		Inline XBRL Taxonomy Extension Presentation Linkbase Document.
104		Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

~~We have~~* ~~not~~Filed ~~entered into employment agreements with any of our named executive officers except for David Tang, CEO~~herewith.

Employment Contract – David Tang

(1)	Incorporated by reference from our registration statement on Form 10, filed with the Securities and Exchange Commission on October 25, 2019.
(2)	Incorporated by reference from our Current Report on Form 8-K dated June 23, 2020.
(3)	Incorporated by reference from our Current Report on Form 8-K dated July 7, 2021.
(4)	Incorporated by reference from our Annual Report on Form 10-K dated January 13, 2022
(5)	Incorporated by reference from our Current Report on Form 8-K dated November 19, 2021.
(6)	Incorporated by reference from our Current Report on Form 8-K dated December 20, 2021.
(7)	Incorporated by reference from our Current Report on Form 8-K dated August 4, 2022
(8)	Incorporated by reference from our Current Report on Form 8-K dated July 27, 2023
(9)	Incorporated by reference from our Current Report on Form 8-K dated February 28, 2022

~~On July 29, 2022, the Company and David Tang~~ (~~the “Executive”~~c) ~~executed~~Financial ~~an employment agreement (the “Employment Agreement”) dated July 29,~~Statement 2022. Pursuant to the Employment Agreement, the Executive’s full time employment with the Company as the Chief Executive Officer began on July 15, 2022, and the Executive’s responsibilities include executing development of electric vehicle supply equipment (“EVSE”) or commonly known as charging stations and coordinating global strategy and marketing. Additionally, under the Employment Agreement, the Executive shall receive an annual base salary of $150,000 and be eligible for annual bonus subject to certain millstones as mutually agreed by the Executive and the board of directors (the “Board”) of the Company. In accordance with the Employment Agreement, the Executive is also eligible for other benefits, such as medical/dental insurance and telecommunication/commuting reimbursements and paid vacation days.Schedules:

InNot connection with the Employment Agreement, on July 29, 2022, the Company and the Executive entered into a stock option agreement (the “Stock Option Agreement”), pursuant to which the Company granted the Executive the stock option (the “Stock Option”) as of July 15, 2022 (the “Date of Grant”) to purchase 15,000,000 shares of the Company’s common stock with the first twenty-five percent (25%) of the Stock Option to be vested on July 15, 2023; the second twenty-five percent (25%) of the Stock Option to be vested on July 15, 2024; the third twenty-five percent (25%) of the Stock Option to be vested on July 15, 2025; and the fourth twenty-five percent (25%) of the Stock Option to be vested on July 15, 2026. Unless terminated earlier pursuant to the Stock Option Agreement, the Stock Option shall expire on July 15, 2032 (the “Expiration Date”).applicable

~~Compensation~~ITEM ~~Conversion~~16. toFORM ~~Common~~10-K ~~Stock~~SUMMARY

On December 11, 2022, our Board of Directors authorized that all accrued and unpaid amounts of compensation, as of December 31, 2022, may be converted, at the option of our directors, and present and certain former executive officers, into shares of our Common StockNone. ~~No further action has taken place.~~

~~Compensation Modification~~ 21

~~Effective April 1, 2021, our Board of Directors further modified compensation levels for our officers, directors and consultants, as follows:~~SIGNATURES

●Pursuant ~~The~~to ~~monthly~~the ~~salary~~requirements of Section 13 or 15(d) of the ~~President/Chief~~Securities ~~Executive~~Exchange ~~Officer~~Act ~~remains~~of at1934, $4the registrant has duly caused this report to be signed on its behalf by the undersigned,~~000~~ thereunto duly authorized.

● The monthly salary of the Treasurer/Chief Financial Officer/Secretary remains at $2,500.

	GENUFOOD ENERGY ENZYMES CORP.

Date: January 12, 2024	By:	/s/ David Tang
		David Tang
		Chief Executive Officer

● The monthly consultancy fee paid to Kuang Ming Tsai is $2,500.

Signature	Title	Date

/s/ David Tang	Chief Executive Officer	January 12, 2024
David Tang	(principal executive officer)

/s/ Jui Pin (John) Lin	Chairman of the Board	January 12, 2024
Jui Pin (John) Lin

/s/ Kuang Ming (James) Tsai	Director and Chief Financial Officer (principal financial officer)	January 12, 2024
Kuang Ming (James) Tsai
/s/ Wen-Piao (Jack) Lai	Director	January 12, 2024
Wen-Piao (Jack) Lai
/s/ Hsin-Ta (Darren) Su	Director	January 12, 2024
Hsin-Ta (Darren) Su
/s/ Hui-Chuan (Sandra) Lin	Director	January 12, 2024
Hui-Chuan (Sandra) Lin

~~Effective August 6, 2021, our Board of Directors further modified compensation levels for its officers, directors and consultants, as follows:~~22

●GENUFOOD ~~The~~ENERGY ~~monthly~~ENZYMES ~~salary of the President/Chief Executive Officer is $2,500.~~CORPORATION

●INDEX ~~The~~TO ~~monthly~~CONSOLIDATED ~~salary~~FINANCIAL ~~of the Treasurer/Chief Financial Officer/Secretary is $2,300.~~STATEMENTS

● The monthly consultancy fee paid to Kuang Ming Tsai is $1,500.

Statement		Page

Consolidated Financial Statements for the Years Ended September 30, 2023 and 2022

Index to Consolidated Financial Statements		F-1

Report of Independent Registered Public Accounting Firm (PCAOB ID 2851)		F-2

Consolidated Balance Sheets as of September 30, 2023 and 2022		F-3

Consolidated Statements of Operations and Comprehensive Loss for the Years Ended September 30, 2023 and 2022		F-4

Consolidated Statements of Changes in Stockholders’ Equity (Deficit) for the Years Ended September 30, 2023 and 2022		F-5

Consolidated Statements of Cash Flows for the Years Ended September 30, 2023 and 2022		F-6

Notes to Consolidated Financial Statements		F-7

~~● The fee paid to the Chairman of the Board for attending meetings of the Board of Directors is $~~F-1~~,000 per meeting.~~

●REPORT ~~The~~OF ~~fee~~INDEPENDENT REGISTERED ~~paid~~PUBLIC toACCOUNTING all other non-employee directors for attending meetings of the Board of Directors is $500 per meeting; employee directors will not be paid a fee for attending Board meetings beyond their officer salary.FIRM

~~Effective July~~To ~~15,~~the ~~2022, our~~ Board of Directors ~~further modified compensation levels for its officers, directors~~ and ~~consultants, as follows:~~Stockholders of

●Genufood ~~The~~Energy ~~monthly~~Enzymes ~~salary of the Chief Executive Officer is $12,500.~~Corporation

	●	The monthly salary of the President is $3,000.
	●	The monthly salary paid to Kuang Ming Tsai as Chief Operating Officer is $1,800.

Opinion on the Consolidated Financial Statements

~~Outstanding~~We have audited the accompanying ~~Equity~~consolidated ~~Awards~~balance atsheets ~~Fiscal~~of Genufood ~~Year-End~~Energy Enzymes Corporation (the “Company”) as of September 30, 2023, and 2022, and the related consolidated statements of operations and comprehensive loss, changes in stockholders’ equity (deficit), and cash flows for the years then ended and the related notes (collectively referred to as “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of September 30, 2023 and 2022 and the results of its operations and its cash flows for the years ended September 30, 2023 and 2022, in conformity with accounting principles generally accepted in the United States of America.

~~There are~~Going ~~no outstanding equity awards to any of our named executive officers.~~Concern

NoThe accompanying consolidated ~~retirement~~financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 3 to the consolidated financial statements, ~~pension~~as of September 30, ~~profit~~2023, ~~sharing~~the Company had recurring losses from operations, ~~stock~~an ~~option~~accumulated ordeficit, ~~insurance~~and ~~programs~~a ornegative cash ~~other~~flows ~~similar~~from ~~programs~~operating ~~have~~activities. ~~been~~As ~~adopted~~such bythere ~~the~~is ~~Company~~substantial doubt about its ability to continue as a going concern. WeManagement’s ~~have~~plans noin ~~present~~regard ~~intention~~to ofthese ~~adopting~~matters ~~any~~are ~~such~~also ~~plans~~described in Note 3. The consolidated financial statements do not include any adjustments that might result from the ~~foreseeable~~outcome ~~future~~of this uncertainty.

19Basis for Opinion

~~ITEM 12~~These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on these consolidated ~~SECURITY~~financial ~~OWNERSHIP~~statements OFbased ~~CERTAIN~~on ~~BENEFICIAL~~our ~~OWNERS~~audits. ~~AND~~We ~~MANAGEMENT~~are ~~AND~~a ~~RELATED~~public ~~STOCKHOLDER~~accounting ~~MATTERS~~firm registered with the Public Company Accounting Oversight Board (United States) (“PCAOB”) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

~~The~~We ~~following~~conducted ~~table~~our ~~sets~~audits in ~~forth,~~accordance aswith ofthe ~~January~~standards ~~11,~~of ~~2023,~~ the ~~number of~~PCAOB. ~~shares~~Those ofstandards ~~our~~require ~~Common~~that ~~Stock~~we ~~owned~~plan ~~of record~~ and ~~beneficially~~perform bythe ~~all~~audit ~~directors,~~to ~~executive~~obtain ~~officers~~reasonable ~~and~~assurance about ~~persons~~whether ~~who~~the ~~beneficially~~financial ~~own~~statements ~~more than~~are 5%free of ~~the~~material ~~outstanding~~misstatement, ~~shares~~whether ofdue ~~Common~~to ~~Stock~~error ofor ~~the~~fraud. The Company. Weis not required to have, ~~determined~~nor ~~beneficial~~were ~~ownership~~we inengaged ~~accordance~~to ~~with~~perform, ~~the~~an ~~rules~~ audit of ~~the~~its ~~SEC.~~internal ~~Except~~control asover ~~indicated~~financial byreporting. ~~the~~As ~~footnotes~~part ~~below~~of our audit, we ~~believe,~~are ~~based~~required to onobtain ~~the~~an ~~information~~understanding ~~furnished~~of tointernal ~~us,~~control ~~that~~over ~~the~~financial ~~persons~~reporting ~~and~~but ~~entities named~~not infor the ~~table~~purpose ~~below~~of ~~have~~expressing ~~sole~~an ~~voting~~opinion ~~and~~on ~~investment~~the ~~power~~effectiveness of ~~with~~the ~~respect~~entity’s tointernal ~~all~~control ~~shares~~over offinancial ~~Common~~reporting. ~~Stock~~Accordingly, ~~that~~we ~~they~~express ~~beneficially~~no ~~own~~such opinion.

Name and Address	Amount and Nature of Beneficial Ownership			Percentage of Class(1)
5% Stockholders
Hsu, Yu-Pin 4F, No.4, Alley 5, Lane 251, Chung Hsiao E.R.D., Sec. 3 Taipei Taiwan (R.O.C.)		24,000,000			8.0	%
Yi Lung (Oliver) Lin No. 175-1, 4th Floor-1, Nanher Rd. South Dist.,Taichung City Taiwan 402 (R.O.C)		20,752,542	(2)		6.9	%
Huei Ling Wang No. 175-1, 4th Floor-1, Nanher Rd. South Dist.,Taichung City Taiwan 402 (R.O.C)		20,752,542	(2)		6.9	%
Directors and Executive Officers:
Jui Pin (John) Lin 1108 S. Baldwin Avenue, Suite 107 Arcadia, California 91007		63,470,000	(3)		21.2	%
Wen-Piao (Jack) Lai 1108 S. Baldwin Avenue, Suite 107 Arcadia, California 91007		18,110,500	(4)		6.0	%
Shao-Cheng (Will) Wang 1108 S. Baldwin Avenue, Suite 107 Arcadia, California 91007		12,655,889			4.2	%
Nan-Yao (Jake) Chan 1108 S. Baldwin Avenue, Suite 107 Arcadia, California 91007		9,000,000	(5)		3.0	%
Hsin-Ta (Darren) Su 1108 S. Baldwin Avenue, Suite 107 Arcadia, California 91007		8,806,076			2.9	%
Kuang Ming (James) Tsai 1108 S. Baldwin Avenue, Suite 107 Arcadia, California 91007		5,566,055	(6)		1.9	%
All Directors and Executive Officers as a group (6 persons)		117,608,520			39.2	%

Our audit included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audit provides a reasonable basis for our opinion.

~~(1)~~Critical ~~Percentages~~Audit ~~are calculated on the basis of 299,686,921 shares of Common Stock outstanding as of January 8, 2023.~~Matters

~~(2)~~Critical ~~Consists~~audit ofmatters are ~~(i)~~matters ~~8,714,688~~arising ~~shares~~from ~~held~~the bycurrent ~~Access~~period ~~Finance~~audit ~~and~~of ~~Securities~~the ~~(NZ)~~financial ~~Limited,~~statements ~~which~~that wewere ~~believe~~communicated isor ~~controlled~~required byto Oliver Lin; (ii) 1,729,765 shares held by Access Management and Consulting, which we believe is controlled by Oliver Lin; (iii) 21,528 shares held by Lin Yi Lung Foundation Charitable Trust, which we believe may be ~~controlled~~communicated ~~by Oliver Lin; (iv) 9,386,531 shares held by Huei Ling Wang,~~ to the ~~wife~~audit ofcommittee ~~Oliver~~and ~~Lin;~~that: (v1) ~~900,000~~relate ~~shares~~to ~~held~~accounts ~~by Beckenburg Boon Kee Lim, a son of Oliver Lin, whom we believe may reside with his parents~~ or ~~act~~disclosures inthat ~~concert~~are ~~with~~material ~~respect~~ to the ~~ownership~~financial ofstatements ~~his shares;~~ and (vi2) 30involved ~~shares~~our especially ~~held by Benedict Lim Boon Cheong~~challenging, ~~a son of Oliver Lin~~subjective, ~~whom we believe may reside with his parents~~ or ~~act~~complex injudgments. ~~concert~~We ~~with~~determined ~~respect~~that tothere ~~the~~are ~~ownership~~no ofcritical ~~his~~audit ~~shares~~matters.

~~(3)~~/s/ KCCW ~~Consists of (i) 63,420,000 held by Mr~~Accountancy Corp. Lin; and (ii) 50,000 shares issuable in the event of the conversion of accrued and unpaid director fees in the amount of $500 through September 30, 2021. Mr. Lin served as President of the Company until August 1, 2021.

~~(4)~~We ~~Consists~~have ofserved ~~(i)~~as ~~18,060,500 held by Mr. Lai; and (ii) 50,000 shares issuable in~~ the Company’s ~~event~~auditor ofsince ~~the conversion of accrued and unpaid director fees in the amount of $500 through September 30, 2021~~2022.

~~(5)~~Diamond ~~Consists of 9~~Bar,~~000,000 shares owned by the wife of Mr. Chan.~~ California

~~(6)~~January ~~Consists of (i) 5~~11,~~466,055~~ ~~held by Mr. Tsai; and (ii) 100,000 shares issuable in the event of the conversion of accrued and unpaid director fees in the amount of $1,000 through September 30, 2021.~~2024

20F-2

~~ITEM 13. CERTAIN~~GENUFOOD ~~RELATIONSHIPS~~ENERGY ~~AND~~ENZYMES ~~RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE~~CORPORATION

~~Related~~CONSOLIDATED ~~Parties~~BALANCE SHEETS

Name of related parties Relationship with the Company Yi Lung (Oliver) Lin Principal shareholder Jui Pin (John) Lin Principal shareholder, Director, Former President and Chief Executive Officer Jia Tian (Jeffery) Lin Former Chief Executive Officer Wen-Piao (Jack) Lai Director, Chief Executive Officer Shao-Cheng (Will) Wang Chief Financial Officer Kuang Ming (James) Tsai Director Nan-Yao (Jake) Chan Former Director Hsin-Ta (Darren) Su Director, Treasurer Hui-Chuan (Sandra) Lin Employee, daughter of Jui Pin (John) Lin

	September 30,			September 30,
	2023			2022
				(Restated)
Assets
Current assets
Cash and cash equivalents	$	125,924		$	136,400
Prepayment		8,187			14,493
Total Current Assets		134,111			150,893

Equipment		67,451			-

Total Assets	$	201,562		$	150,893

Liabilities and Stockholders’ Equity
Current liabilities
Accounts payable	$	100,849		$	102,185
Accrued expenses		37			-
Due to related parties		14,730			102,831
Total Current Liabilities		115,616			205,016

Commitment and contingencies (Note 9)		32,226			29,226

Stockholders’ Equity (Deficit)
Common stock; $0.001 par value; 10,000,000,000 shares authorized; 808,900,041 and 299,686,921 shares issued and outstanding as of September 30, 2023 and September 30, 2022, respectively		808,900			299,687
Additional paid-in capital		16,989,592			16,927,592
Discount on common stock		(7,241,581	)		(7,241,581	)
Accumulated deficit		(10,503,191	)		(9,875,489	)
Accumulated other comprehensive loss		-			(193,558	)
Total Stockholders’ Equity (Deficit)		53,720			(83,349	)

Total Liabilities and Stockholders’ Equity	$	201,562		$	150,893

~~Due~~The accompanying notes are toan ~~Related~~integral ~~Parties~~part of these consolidated financial statements.

~~The Company’s due to related parties balances are as follows:~~F-3

	September 30, 2022		September 30, 2021
Kuang Ming (James) Tsai	$	20,755	$	1,000
Jui Pin (John) Lin		8,048		1,510
Jia Tian (Jeffery) Lin		2,500		-
Shao-Cheng (Will) Wang		27,600		-
Wen-Piao (Jack) Lai		22,210		500
Hsin-Ta (Darren) Su		17,189		-
Hui-Chuan (Sandra) Lin		4,529		-
Total	$	102,831	$	3,010

GENUFOOD ENERGY ENZYMES CORPORATION

~~The~~CONSOLIDATED ~~related~~STATEMENTS ~~party~~OF ~~balances~~OPERATIONS ~~are unsecured,~~AND ~~interest-free and due on demand.~~COMPREHENSIVE LOSS

ITEM 14. PRINCIPAL ACCOUNTING FEES AND SERVICES

	For the Year Ended September 30,
	2023			2022
				(Restated)
Revenue	$	-		$	-

Operating expenses
General and administrative expenses		432,296			348,845
Total operating expenses		432,296			348,845

Loss from operations		(432,296	)		(348,845	)

Other income (expense)
Interest income (expense)		2			6
Loss on disposal of subsidiary		(192,365	)		-
Foreign currency income (loss)		(43	)		6
Other non-operating income (expenses), net		(3,000	)		(3,835	)
Total other expense, net		(195,406	)		(3,823	)

Loss before income taxes		(627,702	)		(352,668	)

Provision for income taxes		-			-

Net loss		(627,702	)		(352,668	)

Other comprehensive income (loss)
Foreign currency transaction adjustments		193,558			25

Comprehensive loss	$	(434,144	)	$	(352,643	)

Loss per share of common stock - basic and diluted		*			*

Weighted average shares outstanding - basic and diluted		526,044,946			299,686,921

~~The~~* ~~following~~Less ~~table~~than ~~summarizes the fees charged by KCCW Accounting Corp~~$0.01 ~~(“KCCW”)~~per ~~and DYH & Company (“DYH”) for the services rendered to the company and its subsidiaries in fiscal years of 2022 and 2021:~~share

	Amount Billed and Paid
Type of Fee	Fiscal Year 2021		Fiscal Year 2022
Audit (1)	$	32,842	$	37,767
Audit related (2)		87		-
Total	$	32,929	$	37,767

The accompanying notes are an integral part of these consolidated financial statements.

(1) Represents aggregate fees charged by DYH and KCCW for audits of consolidated financial statements for fiscal years ended September 30, 2021, and 2022, and quarterly reviews during fiscal year 2021 and 2022, respectively.F-4

~~(2)~~GENUFOOD ENERGY ~~Represents~~ENZYMES ~~aggregate audits related direct out-of-pock expenses charged by DYH.~~CORPORATION

21CONSOILDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (DEFICIT)

PART IV

														Accumulated			Total
	Common Stock				Additional			Discount on						Other			Stockholder’s
	Number of Shares		Amount		Paid-in- Capital			common stock			Accumulated Deficit			Comprehensive Income (loss)			Equity (Deficit)
Balance at September 30, 2021		299,686,921	$	299,687	$	16,911,770		$	(7,241,581	)	$	(9,522,821	)	$	(193,583	)	$	253,472
Stock-based compensation (restated)		-		-		15,822			-			-			-			15,822
Net loss (restated)		-		-		-			-			(352,668	)		-			(352,668	)
Foreign currency translation		-		-		-			-			-			25			25
Balance at September 30, 2022 (restated)		299,686,921		299,687		16,927,592			(7,241,581	)		(9,875,489	)		(193,558	)		(83,349	)
Stock-based compensation		-		-		75,000			-			-			-			75,000
Common stock issued		375,000,000		375,000		(13,000	)		-			-			-			362,000
Issuance of common stock for debt conversion		134,213,120		134,213		-			-			-			-			134,213
Disposal of subsidiary		-		-		-			-			-			193,643			193,643
Net loss		-		-		-			-			(627,702	)		-			(627,702	)
Foreign currency translation		-		-		-			-			-			(85	)		(85	)
Balance at September 30, 2023		808,900,041	$	808,900	$	16,989,592		$	(7,241,581	)	$	(10,503,191	)	$	-		$	53,720

~~ITEM 15.~~The accompanying notes ~~EXHIBITS~~are ~~AND~~an ~~FINANCIAL~~integral ~~STATEMENT~~part ~~SCHEDULES~~of these consolidated financial statements.

~~(a) Documents filed as part of this report:~~F-5

~~1. Financial~~GENUFOOD ~~Statements~~ENERGY ENZYMES CORPORATION

~~The consolidated~~CONSOLIDATED ~~financial~~STATEMENTS ~~statements~~OF ~~contained~~CASH ~~herein are as listed on the “Index to Consolidated Financial Statements” on page F-1 of this report.~~FLOWS

2. Financial Statement Schedule

	For the Year Ended September 30,
	2023			2022
				(Restated)
Cash Flows from Operating Activities
Net loss	$	(627,702	)	$	(352,668	)
Adjustments to reconcile net loss to net cash used in operating activities
Stock-based compensation		75,000			15,822
Loss on disposal of subsidiary		192,365			-
Change in operating assets and liabilities
Prepayment		6,306			11,280
Accounts payable		(143	)		1,507
Accrued expenses		37			(1,590	)
Due to related parties		46,112			99,821
Commitment and contingencies		3,000			3,000
Net cash used in operating activities		(305,025	)		(222,828	)

Cash Flows from Investing Activities
Purchase of equipment		(67,451	)		-
Proceeds from sale of Hukui investment		-			350,000
Net cash (used in) provided by investing activities		(67,451	)		350,000

Cash Flows from Financing Activities
Proceeds from issuance of common stock, net of offering costs		362,000			-
Net cash provided by financing activities		362,000			-

Effect of exchange rate changes on cash and cash equivalents		-			(43	)

Net (decrease) increase in cash and cash equivalents		(10,476	)		127,129

Cash and cash equivalents, beginning of period		136,400			9,271
Cash and cash equivalents, end of period	$	125,924		$	136,400

Supplemental Disclosures
Cash paid for interest	$	-		$	-
Cash paid for income taxes	$	-		$	-

Supplemental Non-Cash Investing and Financing Activities
Issuance of common stock for debt conversion	$	134,213		$	-

The ~~consolidated~~ ~~financial~~accompanying ~~statement~~notes ~~schedule contained herein is as listed on the “Index to Consolidated Financial Statements”~~are onan ~~page~~integral ~~F-1~~part of ~~this~~these ~~report. All other schedules have been omitted because they are not applicable, not required, or the information is included in the~~ consolidated financial statements ~~or notes thereto~~.

~~3. Exhibits~~F-6

~~See Exhibit~~GENUFOOD ~~Index.~~ENERGY ENZYMES CORP

~~(b)~~NOTES TO CONSOLIDATED ~~Exhibits:~~FINANCIAL STATEMENTS

~~The following~~NOTE ~~exhibits~~1 ~~are~~– ~~attached~~GENERAL ~~hereto~~ORGANIZATION AND ~~and incorporated herein by reference.~~BUSINESS

Exhibit No.		Description
3.1(1)		Articles of Incorporation of Genufood Energy Enzymes Corp. dated June 21, 2010
3.2(1)		Certificate of Amendment dated December 10, 2010 to Articles of Incorporation of Genufood Energy Enzymes Corp.
3.3(1)		Certificate of Amendment dated August 1, 2014 to Articles of Incorporation of Genufood Energy Enzymes Corp.
3.4(1)		Certificate of Amendment dated February 24, 2015 to Articles of Incorporation of Genufood Energy Enzymes Corp.
3.5(2)		Certificate of Change Pursuant to Nevada Revised Statutes Section 78.209, as filed by Genufood Energy Enzymes Corp. with the Secretary of State of the State of Nevada on June 24, 2020.
3.6(3)		Bylaws of Genufood Energy Enzymes Corp.
4.1(4)		Description of Securities
10.1(5)		Stock Purchase Agreement made and entered into as of November 17, 2021, by and among Genufood Energy Enzymes Corp.; Yu-Lin Chen; and Hukui Biotechnology Corporation
10.2(6)		Agreement dated as of December 17, 2021 by and between Genufood Energy Enzymes Corp. and Hukui Biotechnology Corporation
10.3(7)		Employment Agreement between David Tang and Genufood Energy Enzymes Corp. dated July 29, 2022
10.4(7)		Stock Option Agreement between David Tang and Genufood Energy Enzymes Corp. dated July 29, 2022
16.1(8)		Letter from DYH & Company to the Securities and Exchange Commission.
21(4)		List of subsidiaries
23.1*		Consent of Independent Registered Public Accounting Firm DYH & Company
23.2*		Consent of Independent Registered Public Accounting Firm KCCW Accountancy Corp.
24.1*		Power of Attorney (included after signatures hereto)
31.1*		Certification by the Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 and Rules 13a-14 and 15d-14 under the Securities Exchange Act of 1934
31.2*		Certification by the Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 and Rules 13a-14 and 15d-14 under the Securities Exchange Act of 1934
32.1*		Certification of Periodic Financial Report by the Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
32.2*		Certification of Periodic Financial Report by the Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS		Inline XBRL Instance Document.
101.SCH		Inline XBRL Taxonomy Extension Schema Document.
101.CAL		Inline XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF		Inline XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB		Inline XBRL Taxonomy Extension Label Linkbase Document.
101.PRE		Inline XBRL Taxonomy Extension Presentation Linkbase Document.
104		Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

Genufood Energy Enzymes Corp., USA (the “Company” or “GEEC”) was incorporated under the laws of the State of Nevada on June 21, 2010. On February 13, 2012, GEEC incorporated a wholly-owned subsidiary, Genufood Enzymes (S) Pte Ltd (“GESPL”) in Singapore, which was dissolved on January 9, 2023.

*Since ~~Filed~~its inception, ~~herewith~~the Company has always been in the development stage and never generated significant revenues. The Company is currently developing business in Electric Vehicle Charge station. The Company has engaged in business agreements and development with various parties. During the year ended September 30, 2023, the Company has initiated its electric vehicle charging station business.

(1)	Incorporated by reference from our registration statement on Form 10, filed with the Securities and Exchange Commission on October 25, 2019.
(2)	Incorporated by reference from our Current Report on Form 8-K dated June 23, 2020.
(3)	Incorporated by reference from our Current Report on Form 8-K dated July 7, 2021.
(4)	Incorporated by reference from our Annual Report on Form 10-K dated January 13, 2022
(5)	Incorporated by reference from our Current Report on Form 8-K dated November 19, 2021.
(6)	Incorporated by reference from our Current Report on Form 8-K dated December 20, 2021.
(7)	Incorporated by reference from our Current Report on Form 8-K dated August 4, 2022
(8)	Incorporated by reference from our Current Report on Form 8-K dated February 28, 2022

The Company made two investments in Hukui Biotechnology Corporation (“Hukui”) by purchasing 80,000 shares of Hukui’s Series C Preferred Stock for $800,000 on December 15, 2020; and purchasing 60,000 shares of Hukui’s Series C Preferred Stock for $600,000 on June 25, 2021. The Company, an individual and resident of the Republic of China (the “Purchaser”), and Hukui, entered into a Stock Purchase Agreement dated as of November 17, 2021, pursuant to which the Company agreed to sell these 140,000 shares of Hukui’s Series C Preferred Stock (the “Hukui Shares”) to the Purchaser for $350,000 in cash, or $2.50 per share. The sale of the Hukui Shares closed on November 19, 2021.

On August 1, 2022, the board of directors (cthe “Board”) of the Company unanimously approved to expand our business in the area of electric ~~Financial~~vehicle ~~Statement~~supply ~~Schedules:~~equipment (“EVSE”) and will direct the management team to implement its new business plan in such industry. On August 16, 2022, the Company formally announced its intention to reposition as EVSE solutions provider, seeking to grow business in EVSE industry, including building, owning, and operating the next generation of electric vehicle charging stations in the U.S. The Company intends to bring convenient, reliable, and accessible charging experience to electric vehicle drivers, utilizing frictionless technology and carbon-neutral vehicle-charging infrastructure.

~~Not~~On October ~~applicable~~26, 2022, the Company entered into three Charging Station Site Host Agreements (the “Agreements”) with two institutions (the “Site Hosts”), respectively, pursuant to which the Site Hosts agree to allow the Company to install its electric vehicle charging stations at the locations set forth in the Agreements (the “Charging Stations”). Under the Agreements, the Company has agreed to share the revenue generated by the sales of electricity at the Charging Stations with the Site Hosts.

~~ITEM 16.~~As of September ~~FORM~~30, ~~10-K~~2023, ~~SUMMARY~~the Company has two sites under construction for charging stations and three sites under planning.

~~None.~~NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

22Basis of Presentation

~~SIGNATURES~~The Company’s consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“US GAAP”) and pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”).

~~Pursuant to~~Principle ~~the requirements~~ of ~~Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.~~Consolidation

~~GENUFOOD~~The ~~ENERGY~~consolidated financial ~~ENZYMES~~statements ~~CORP~~include the accounts of GEEC and its wholly-owned subsidiary GESPL. ~~By:~~All ~~/s/~~significant ~~David~~inter-company ~~Tang~~accounts ~~David~~and ~~Tang~~transactions have ~~Chief~~been ~~Executive~~eliminated ~~Officer~~in consolidation. The wholly-owned subsidiary of the Company did not have business activities prior to its dissolution.

~~Date:~~Use ~~January 13, 2023~~of Estimates

~~POWER~~The preparation OFof ~~ATTORNEY~~the consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

~~KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints, jointly and severally, Wen~~F-Piao Lai and Kuang Ming Tsai, and each of them, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.7

~~Pursuant~~Concentrations ~~to the requirements~~ of ~~the~~Credit ~~Securities Exchange Act of 1934 this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.~~Risk

Signature	Title	Date
/s/ David Tang	Chief Executive Officer	January 13, 2023
David Tang	(principal executive officer)
/s/	Chairman of the Board, President, and Director	January 13, 2023
Jui Pin (John) Lin
/s/ Shao-Cheng (Will) Wang	Chief Financial Officer (principal accounting officer)	January 13, 2023
Shao-Cheng (Will) Wang
/s/ Kuang Ming (James) Tsai	Director, Chief Operating Officer	January 13, 2023
Kuang Ming (James) Tsai
/s/ Wen-Piao (Jack) Lai	Director	January 13, 2023
Wen-Piao (Jack) Lai
/s/ Hsin-Ta (Darren) Su	Director	January 13, 2023
Hsin-Ta (Darren) Su
/s/	Director and Secretary	January 13, 2023
Hui-Chuan (Sandra) Lin

Financial instruments that potentially subject the Company to significant concentrations of credit risk consisted primarily of cash, to the extent balances exceeded limits that were insured by the Federal Deposit Insurance Corporation. The Company does not require collateral and maintains reserves for potential credit losses. Such losses have historically been immaterial and have been within management’s expectations.

23Cash and Cash Equivalents

~~GENUFOOD~~The Company ~~ENERGY~~considers ~~ENZYMES~~all ~~CORPORATION~~highly liquid instruments with original maturities of three months or less when acquired to be cash equivalents. As of September 30, 2023, and 2022, the Company did not have cash equivalents.

~~INDEX~~Fair TOValue ~~CONSOLIDATED~~of ~~FINANCIAL~~Financial ~~STATEMENTS~~ Instruments

Statement		Page
Consolidated Financial Statements for the Years Ended September 30, 2022 and 2021
Index to Consolidated Financial Statements		F-1
Report of Independent Registered Public Accounting Firm (PCAOB ID 2851)		F-2
Report of Independent Registered Public Accounting Firm		F-3
Consolidated Balance Sheets as of September 30, 2022 and 2021		F-5
Consolidated Statements of Operations and Comprehensive Loss for the Years Ended September 30, 2022 and 2021		F-6
Consolidated Statements of Changes in Stockholders’ Equity (Deficit) for the Years Ended September 30, 2022 and 2021		F-7
Consolidated Statements of Cash Flows for the Years Ended September 30, 2022 and 2021		F-8
Notes to Consolidated Financial Statements		F-9

The Company follows the guidance of the ASC Topic 820-10, “Fair Value Measurements and Disclosures” (“ASC 820-10”), with respect to financial assets and liabilities that are measured at fair value. ASC 820-10 establishes a three-tier fair value hierarchy that prioritizes the inputs used in measuring fair value as follows:

F-● Level 1 inputs are quoted prices available for identical assets and liabilities in active markets. ● Level 2 inputs are observable for the asset or liability, either directly or indirectly, including quoted prices for similar assets and liabilities in active markets or other inputs that are observable or can be corroborated by observable market data. ● Level 3 inputs are less observable and reflect our own assumptions.

~~REPORT~~The Company’s OFfinancial ~~INDEPENDENT~~instruments ~~REGISTERED~~consist ~~PUBLIC~~principally ~~ACCOUNTING~~of ~~FIRM~~cash and cash equivalents, accounts payable and accrued expenses and due to related parties. The carrying amounts of such financial instruments in the accompanying consolidated balance sheets approximate their fair values due to their relatively short-term nature. It is management’s opinion that the Company is not exposed to any significant currency or credit risks arising from these financial instruments.

ToForeign ~~the~~Currency ~~Board~~Translation ~~of Directors~~ and ~~Stockholders of~~Transactions

~~Genufood~~The reporting ~~Energy~~and ~~Enzymes~~functional ~~Corporation~~currency ~~and~~of GEEC is the USD. The functional currency of GESPL, a wholly owned subsidiary of GEEC, is the Singapore Dollar (“SGD”).

~~Opinion~~For financial reporting purposes, the financial statements of the Company’s Singapore subsidiary, which are prepared using the SGD, are translated into the Company’s reporting currency, USD. Assets and liabilities are translated using the exchange rate on the ~~Consolidated~~balance ~~Financial~~sheet ~~Statements~~date, which was 0.6970 as of September 30, 2022. Revenue and expenses are translated using average exchange rates prevailing during each reporting period. The 0.7293 average exchange rates were used to translate revenues and expenses for the year ended September 30, 2022. Stockholders’ equity is translated at historical exchange rates. Adjustments resulting from the translation are recorded as a separate component of accumulated other comprehensive loss in stockholders’ deficit.

WeTransactions ~~have~~denominated ~~audited~~in ~~the~~currencies ~~accompanying~~other ~~consolidated~~than ~~balance~~the ~~sheet~~functional ofcurrency ~~Genufood~~are ~~Energy~~translated ~~Enzymes~~into ~~Corporation (~~the ~~“Company”)~~functional ascurrency ofat ~~September 30, 2022, and~~ the ~~related~~exchange ~~consolidated~~rates ~~statements of operations and comprehensive~~prevailing ~~loss,~~at ~~changes in stockholders’ equity (deficit), and cash flows for~~ the ~~year~~dates ~~then~~of ~~ended and~~ the ~~related notes (collectively referred to as “consolidated financial statements”)~~transactions. InThe ~~our~~resulting ~~opinion,~~exchange ~~the consolidated financial statements present fairly~~difference, inpresented ~~all material respects, the financial position of the Company~~ as offoreign ~~September~~currency ~~30,~~transaction ~~2022 and the results of its operations and its cash flows for the year ended September 30~~loss, ~~2022,~~is inincluded ~~conformity with accounting principles generally accepted~~ in the accompanying ~~United~~consolidated ~~States~~statements of ~~America~~operations.

~~Going~~Business ~~Concern~~ Segments

The ~~accompanying~~ ~~consolidated financial statements have been prepared assuming that the~~ Company ~~will continue as a going concern. As discussed~~ inoperates Note 3 to the consolidated financial statements, as of September 30, 2022, the Company had recurring losses from operations, an accumulated deficit, and a negative cash flows from operating activities. As such there is substantial doubt about its ability to continue as a going concern. Management's plans in ~~regard~~only toone ~~these matters are also described in Note 3~~segment. ~~The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.~~

~~Basis for~~Net ~~Opinion~~Income (Loss) Per Share

~~These~~The Company ~~consolidated~~calculates ~~financial~~net ~~statements~~loss ~~are~~per ~~the~~share ~~responsibility~~in ofaccordance ~~the~~with ~~Company’s~~ASC ~~management~~Topic 260, “Earnings per Share.” ~~Our~~Basic ~~responsibility~~loss isper toshare ~~express~~is ancomputed ~~opinion~~by ondividing ~~these~~the ~~consolidated~~net ~~financial~~loss ~~statements~~by ~~based~~the onweighted-average ~~our~~number ~~audits.~~of Wecommon ~~are~~shares aoutstanding ~~public~~during ~~accounting~~the ~~firm~~period. ~~registered~~Diluted ~~with~~income ~~the~~(loss) ~~Public~~per ~~Company~~share ~~Accounting~~is ~~Oversight~~computed ~~Board~~similar ~~(United~~to ~~States)~~basic income (~~“PCAOB”~~loss) ~~and~~per ~~are~~share ~~required~~except tothat bethe ~~independent~~denominator ~~with~~is ~~respect~~increased to include the ~~Company~~number inof ~~accordance~~additional ~~with~~common shares that would have been outstanding if the ~~U.S.~~potential ~~federal~~common ~~securities~~stock ~~laws~~equivalents had been issued and if the ~~applicable~~additional ~~rules~~common ~~and~~shares were ~~regulations~~dilutive. ofThere ~~the~~were ~~Securities~~no ~~and~~potential ~~Exchange~~dilutive ~~Commission~~debt or equity instruments issued and outstanding at any time during the ~~PCAOB~~years ended September 30, 2023 and 2022.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audit, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the entity’s internal control over financial reporting. Accordingly, we express no such opinion.F-8

~~Our~~Discounts audit included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on aCommon test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audit provides a reasonable basis for our opinion.Stock

~~Critical~~Common stock ~~Audit~~issued ~~Matters~~lower than the Company’s par value is treated as common stock issued under discounts. The portion of the discount is shown separately as a deduction from the Company’s account of common stock on the Company’s consolidated financial statements.

~~The critical~~Stock-Based audit matters communicated below are matters arising from the current period audit of the consolidated financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the consolidated financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.Compensation

~~Recognition~~The Company ofaccounts ~~Stock~~for its stock-~~Based~~based compensation in which the Company obtains employee services in share-based payment transactions under FASB ASC Topic 718, Compensation ~~Cost~~– Stock Compensation, which requires the Company to expense the cost of employee services received in exchange for ~~Stock~~an ~~Options~~award ~~Issued~~of equity instruments based on the grant date fair value of such instruments over the vesting period.

AsIncome described in Note 5 to the consolidated financial statements, the Company granted stock options to its Chief Executive Officer and estimated total stock compensation cost related to the issuance of stock options. The stock compensation cost was valued at the grant date, and management evaluated the fair value of these stock options at the grant date and recognized based on the vesting schedule.Taxes

WeIncome taxes ~~identified~~are accounted for under the ~~recognition~~asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of ~~stock~~existing ~~options~~assets asand aliabilities ~~critical~~and ~~audit~~their ~~matter~~respective ~~due~~tax bases and operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the ~~significant~~years ~~judgments~~in ~~made~~which bythose ~~management~~temporary ~~when~~differences ~~developing~~are expected to be recovered or settled. The effect on deferred ~~underlying~~tax ~~assumptions~~assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is recorded to reduce the Company’s deferred tax assets to the amount that is more likely than not to be realized.

The Company ~~following~~considers ~~are~~positive ~~the~~and ~~primary~~negative ~~procedures~~evidence wewhen ~~performed~~determining towhether ~~address~~a ~~this~~portion ~~critical~~or ~~audit~~all ~~matter~~of its deferred tax assets will more likely than not be realized. WeThis ~~obtained~~assessment anconsiders, ~~understanding~~among other matters, the nature, frequency and ~~evaluated~~severity ~~management’s~~of current and cumulative losses, forecasts ~~process~~of ~~relating~~future profitability, the duration of statutory carry-forward periods, its experience with tax attributes expiring unused, and its tax planning strategies. The ultimate realization of deferred tax assets is dependent upon its ability to ~~significant~~generate ~~judgments~~sufficient future taxable income within the carry-forward periods provided for in the tax law and ~~assumptions~~during ~~developed~~the byperiods ~~management~~in which the temporary differences become deductible. When Weassessing ~~evaluated~~the ~~and~~realization ~~tested~~of deferred tax assets, the Company has considered possible sources of ~~data~~taxable ~~and~~income ~~assumptions~~including (i) future ~~used~~reversals byof ~~management.~~existing Intaxable ~~addition~~temporary differences, we(ii) ~~tested~~future ~~the~~taxable ~~completeness~~income exclusive of reversing temporary differences and ~~accuracy~~carry-forwards, (iii) future taxable income arising from implementing tax planning strategies, and (iv) specific known trend of ~~the~~profits ~~underlying~~expected ~~assumptions~~to ~~used~~be reflected bywithin ~~management~~the industry.

/The Company recognizes a tax benefit associated with an uncertain tax position when, in its judgment, it is more likely than not that the position will be sustained upon examination by a taxing authority. For a tax position that meets the more-likely-than-not recognition threshold, the Company initially and subsequently measures the tax benefit as the largest amount that the Company judges to have a greater than 50% likelihood of being realized upon ultimate settlement with a taxing authority. The Company’s~~/ KCCW~~ liability associated with unrecognized ~~Accountancy~~tax ~~Corp~~benefits is adjusted periodically due to changing circumstances, such as the progress of tax audits, case law developments and new or emerging legislation. Such adjustments are recognized entirely in the period in which they are identified. The Company’s effective tax rate includes the net impact of changes in the liability for unrecognized tax benefits and subsequent adjustments as considered appropriate by management. The Company classifies interest and penalties recognized on the liability for unrecognized tax benefits as income tax expense.

WeThere were ~~have~~no ~~served~~current asand deferred income tax provision recorded for the ~~Company’s~~years ~~auditor~~ended ~~since~~September 30, 2023 and 2022 since the Company has recurring losses.

~~Diamond~~Recent ~~Bar,~~Accounting ~~California~~Pronouncements

~~January~~The Company ~~13,~~considers ~~2023~~the applicability and impact of all Accounting Standards Updates (“ASUs” or “ASU”) on the Company’s consolidated financial statements. Updates not listed below were assessed and determined to be either not applicable or are expected to have minimal impact on the Company’s consolidated financial position or results of operations. Recently issued ASUs that the Company feels may be applicable to the Company are as follows:

FIn August 2020, the FASB issued Accounting Standards Update No. 2020-06, Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40). The subtitle is Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity. This ASU addresses complex financial instruments that have characteristics of both debt and equity. The application of this ASU would reduce the number of accounting models for convertible debt instruments and convertible preferred stock. Limiting the accounting models would result in fewer embedded conversion features being separately recognized from the host contract as compared with current GAAP. Convertible instruments that continue to be subject to separation models are (1) those with embedded conversion features that are not clearly and closely related to the host contract, that meet the definition of a derivative, and that do not qualify for a scope exception from derivative accounting and (2) convertible debt instruments issued with substantial premiums for which the premiums are recorded as paid-in capital. To date, no such bifurcation has been necessary. Management is evaluating the potential impact. This ASU becomes effective for fiscal years beginning after December 15, 2023.

~~REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM~~F-9

~~To the Board of Directors and~~NOTE ~~Stockholders~~3 of– ~~Genufood~~GOING ~~Energy Enzymes Corporation and subsidiary~~CONCERN

~~Opinion~~As of September 30, 2023, and 2022, the Company had an accumulated deficit of $10,503,191 and $9,875,489, respectively. To date, the Company’s cash flow requirements have been primarily met through proceeds received from sales of its common stock and investment. These and other factors raise substantial doubt about the Company’s ability to continue as a going concern. These consolidated financial statements do not include any adjustments to reflect the possible future effects on the ~~Consolidated~~recoverability ~~Financial~~and ~~Statements~~classification of assets and liabilities that may result in the Company not being able to continue as a going concern.

WeThe ~~have audited the accompanying consolidated~~Company ~~balance~~sold ~~sheets of Genufood Energy Enzymes Corporation (~~the ~~“Company”) as of September 30~~140,000 ~~2021~~Hukui ~~and~~Shares ~~2020,~~for ~~and the related consolidated statements of operations~~$350,000 ~~comprehensive~~in ~~loss, stockholders’ equity (deficiency), and~~ cash ~~flows~~on ~~for~~November ~~each of the years in the two year periods ended September 30~~19, 2021, and ~~the~~received ~~related notes (collectively the “consolidated financial statements”). In our opinion~~$362,000 ~~the~~from ~~consolidated~~private ~~financial~~placement ~~statements~~during ~~present fairly, in all material respects,~~ the ~~consolidated financial position of the Company~~year asended of September 30, ~~2021~~2023. ~~and~~The ~~2020,~~proceeds ~~and~~have ~~the~~been ~~results~~used ~~of its consolidated operations and cash flows~~ for ~~each~~operation ofexpenses. ~~the~~Management ~~years~~is incurrently ~~the~~seeking ~~two-year period~~additional ~~ended~~funds ~~September~~for ~~30, 2021, in conformity with accounting principles generally accepted in the United States of America~~future operation.

~~Going~~NOTE 4 ~~Concern~~– EQUIPMENT

~~The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern.~~ As ~~discussed~~of ~~in Note 3 to the consolidated financial statements,~~September ~~the Company has experienced recurring losses~~30, ~~negative cash flows from operations~~2023, ~~has limited capital resources,~~ and ~~recognized~~2022 ~~a significant loss for~~ the ~~year. These matters raise substantial doubt about the~~ Company’s ~~ability~~had toequipment ~~continue~~of as$67,451 aand ~~going~~$0, ~~concern.~~respectively, ~~Management’s plans~~consisting inof ~~regard~~equipment to ~~these~~be ~~matters~~installed ~~are~~at ~~also~~its ~~described in Note 3. The consolidated financial statements do not include any adjustments that~~electric ~~might~~vehicle ~~result~~charging ~~from~~stations ~~the~~and ~~outcome~~related ofinstallation ~~this uncertainty~~costs.

~~Basis~~NOTE 5 ~~for~~– ~~Opinion~~INVESTMENT

~~These~~Pursuant to ~~consolidated~~that ~~financial~~certain ~~statements~~Series ~~are~~C ~~the responsibility~~Preferred ofShares Subscription Agreement dated September 23, 2020 between the Company’s ~~management.~~and ~~Our~~Hukui ~~responsibility~~(the is“Hukui Agreement”), the Company agreed to ~~express~~purchase an ~~opinion~~aggregate on200,000 ~~the~~Series ~~Company’s~~C ~~consolidated~~Preferred ~~financial statements~~Shares, ~~based~~at on$10.00 ~~our~~per ~~audits.~~share, Wefor ~~are~~an aggregate investment of $2,000,000, in a ~~public~~series ~~accounting~~of ~~firm~~three ~~registered~~closings ~~with~~from ~~the~~December ~~Public~~15, ~~Company~~2020 ~~Accounting~~through ~~Oversight~~June ~~Board~~30, ~~(United~~2022. On December 15, 2020, the Company ~~States)~~purchased ~~(PCAOB)~~80,000 ~~and~~shares ~~are~~of ~~required~~Series toC bePreferred ~~independent~~Stock ~~with~~at ~~respect~~$10.00 toper share, for a total purchase price of $800,000; and on June 25, 2021, the Company inpurchased ~~accordance~~an ~~with~~additional ~~the~~60,000 Ushares of Series C Preferred Stock at $10.S.00 ~~federal~~per ~~securities~~share, ~~laws~~for ~~and~~a total purchase price of $600,000. ~~the~~The ~~applicable~~total ~~rules~~$1,400,000 ~~and~~investment ~~regulations~~consists of ~~the~~less ~~Securities~~than ~~and~~20% ~~Exchange~~of ~~Commission~~Hukui’s ~~and~~total ~~the~~equity ~~PCAOB~~with no significant control over or influence on Hukui. The investment was recorded at cost.

WeOn ~~conducted our audits in accordance with the~~November ~~standards~~17, of2021, the ~~PCAOB.~~Company ~~Those~~entered ~~standards~~into ~~require~~a ~~that~~stock wepurchase ~~plan~~agreement ~~and~~to ~~perform~~sell ~~the~~all ~~audit~~140,000 toHukui ~~obtain~~Shares ~~reasonable~~at ~~assurance~~$2.50 ~~about~~per ~~whether~~share ~~the~~for ~~consolidated financial~~a ~~statements~~total ~~are free~~ of ~~material misstatement~~$350, ~~whether due to error or fraud.~~ 000, The ~~Company~~sale iswas ~~not~~completed ~~required~~on toNovember ~~have~~19, ~~nor were we engaged to perform~~2021, anresulting ~~audit~~in ofloss ~~its internal control over financial reporting. As part~~ of ~~our audits~~$1,050,000. weThe ~~are~~Company ~~required~~recognized toimpairment ~~obtain~~loss ~~an understanding~~ of ~~internal control over financial reporting, but not for~~ the ~~purpose~~market value of ~~expressing an opinion on~~ the ~~effectiveness~~shares of ~~the~~$1,050,000 ~~Company’s internal~~for ~~control~~the ~~over~~year ~~financial~~ended ~~reporting.~~September ~~Accordingly~~30, ~~we express no such opinion~~2021.

~~Our audits included performing procedures to assess~~NOTE ~~the~~6 ~~risks~~– ofSTOCKHOLDERS’ ~~material~~EQUITY misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.(DEFICIT)

~~F-3~~The Company is authorized under its articles of incorporation, as amended, to issue 10,000,000,000 shares of Common Stock, par value $0.001 per share.

~~Critical~~On ~~Audit~~February 24, ~~Matters~~2023, the Company conducted a private placement offering and sold 375,000,000 shares of common stock at $0.001 per share, for gross proceeds of $375,000, and incurred offering costs of $13,000.

~~The~~On ~~critical audit matters communicated below~~March ~~are~~24, ~~matters~~2023, ~~arising from~~ the ~~current~~Company ~~period~~issued ~~audit~~134,213,120 shares of ~~the~~common ~~consolidated~~stock ~~financial statements that were communicated or required~~ to beits ~~communicated to~~board ~~the audit committee or the Board~~ of ~~Directors~~directors, officers, and ~~that:~~former ~~(1)~~officers ~~relate~~ to ~~accounts~~repay ~~or disclosures that are material to~~ the ~~financial statements~~ ~~and~~compensation ~~(2)~~due ~~involved~~to ~~our~~them ~~especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter~~ in ~~any way our opinion on~~ the ~~financial~~aggregate ~~statements,~~amount ~~taken~~of ~~as a whole~~$134,213 ~~and~~at ~~we are not, by communicating~~ the ~~critical~~conversion ~~audit~~rate ~~matters~~of ~~below, providing~~$0.001 ~~separate~~per ~~opinions on the critical audit matters or on the accounts or disclosures to which they relate~~share.

~~Investment Impairment Assessment~~F-10

As described in Note 4 and Note 12 to the consolidated financial statements, the Company’s investment balance was $350,000 at September 30, 2021, after deduction of a significant impairment to the total original investment cost of $1,400,000 paid for 140,000 shares of the investee’s Series C Preferred Stock ~~initiated~~ in December 2020. Investment is tested for impairment at least annually and the determination of the fair value of the investment requires management to make significant estimates and assumptions related to the performance of the investee, a private entity. As disclosed by management, changes in these assumptions could have a significant impact on the fair value of the reported investment, the amount of any impairment charge, or both.Options

WeOn ~~identified~~July 15, 2022, the ~~Company’s~~CEO, ~~assessment~~David Tang, was granted 15,000,000 options to purchase shares at $0.01 per share. As of September 30, 2023, total options ~~investment~~granted ~~impairment~~was as15,000,000 aand ~~critical~~4,375,000 ~~audit~~was ~~matter~~vested. ~~Believing~~This ~~that~~option itwill ~~would~~be ~~not~~subject beto ina ~~the~~vesting ~~best~~schedule ~~interests~~providing offor twenty-five percent (25%) vesting after the ~~Company~~first ~~and~~twelve ~~its~~(12) ~~shareholders to~~months ~~register~~of employment and bemonthly ~~regulated~~vesting as anto ~~investment~~the ~~company~~remaining ~~under~~seventy-five percent (75%) of the ~~Investment~~shares over ~~Company~~the ~~Act,~~following thirty-six (36) months after the ~~Company~~first ~~sold~~anniversary of the ~~entire~~employment ~~investment~~commencement todate. anThese ~~individual~~stock options are exercisable ~~subsequently~~over ina ~~November~~maximum ~~2021~~period ~~and~~of ~~resulted~~10 ayears ~~significant~~from ~~loss~~the grant date. ~~Management~~The ~~determined~~weighted ~~that~~average ~~the~~grant ~~loss~~date ~~should~~fair bevalue ~~recognized~~of asoptions angranted ~~impairment to~~during the ~~investment~~year at ended September 30, ~~2021~~2022 was $0.02.

~~Our~~Compensation costs ~~primary~~associated ~~audit~~with ~~procedures~~the ~~to address management~~Company’s stock options are recognized, based on the grant-date fair value of these options, over the ~~judgment~~requisite ~~regarding~~service period, or vesting period. Accordingly, the ~~impairment~~Company recognized stock-based compensation expense of $75,000 and ~~this~~$15,822, respectively, ~~critical~~which ~~audit~~was ~~matter~~included ~~include:~~in the general and administrative expenses in the consolidated statements of operations for the years ended September 30, 2023 and 2022.

●The ~~Reviewing~~fair value of the ~~investment~~stock ~~agreement~~options ~~and~~listed ~~understanding~~above ~~the~~was ~~primary~~determined ~~purpose~~using ofthe ~~investment~~Black-Scholes ~~based~~option onpricing ~~inquiries~~model with ~~management and~~ the ~~Board~~following ~~Chairman.~~assumptions:

● Considering the Company’s internal control over financial reporting.

	September 30, 2023
Risk-free interest rate		2.99	%
Expected term		6.08 years
Expected volatility		379.35	%
Expected dividend yield		0	%

●The ~~Discussing~~following is ~~with~~a summary of the ~~Investee’s~~option ~~President/Chief~~activity ~~Executive~~for ~~Officer.~~the year ended September 30, 2023:

● Consulting with the Company’s legal counsel and evaluating the entire circumstance as well as the options that the Company might have in order to avoid becoming an Investment Company.

Options	Number of Underlying Shares		Weighted average exercise price		Weighted Average Remaining Contractual Life (years)		Aggregate Intrinsic Value
Outstanding at October 1, 2022		15,000,000	$	0.01		–	$	–
Granted		–	$	–		–	$	–
Exercised		–	$	–		–	$	–
Forfeited or expired		–	$	–		–	$	–
Outstanding at September 30, 2023		15,000,000	$	0.01		8.8	$	–
Vested and expected to vest as of September 30, 2023		15,000,000	$	0.01		8.8	$	–
Exercisable at September 30, 2023		4,375,000	$	0.01		8.8	$	–

●As ~~Evaluating~~of ~~the~~September 30, ~~reasonableness~~2023, ofunrecognized ~~management~~total ~~judgment~~compensation ~~and~~cost ~~the~~associated ~~subsequent~~with ~~events~~these options was $209,178. This expense is expected to be recognized over a weighted-average period of 2.79 years.

~~/s/ DYH & Company DYH & Company We have served as the Company’s auditor since 2017.~~F-11

~~Brea,~~NOTE 7 ~~California~~– RELATED PARTY TRANSACTIONS

~~January~~Related ~~13, 2022~~Parties

FName of related parties Relationship with the Company Yi Lung (Oliver) Lin Principal shareholder Jui Pin (John) Lin Principal shareholder, Chairman of the Board, President, and Director Jia Tian (Jeffery) Lin Former Chief Executive Officer Wen-4Piao (Jack) Lai Director Shao-Cheng (Will) Wang Former Chief Financial Officer Kuang Ming (James) Tsai Director and Chief Financial Officer Hsin-Ta (Darren) Su Director, Treasurer Hui-Chuan (Sandra) Lin Director and Secretary, daughter of Jui Pin (John) Lin David Tang Chief Executive Officer

~~GENUFOOD~~Due ~~ENERGY~~to ~~ENZYMES~~Related ~~CORPORATION~~Parties

~~CONSOLIDATED~~The Company’s ~~BALANCE~~due ~~SHEETS~~to related parties balances are as follows:

	As of			As of
	September 30, 2023			September 30, 2022
	September 30,			September 30,
Kuang Ming (James) Tsai	$	-		$	20,755
	2022			2021
Jui Pin (John) Lin		-			8,048
ASSETS
Jia Tian (Jeffery) Lin		-			2,500
CURRENT ASSETS
Shao-Cheng (Will) Wang		-			27,600
Cash and cash equivalents	$	136,400		$	9,271
Wen-Piao (Jack) Lai		-			22,210
Prepayment		14,493			25,773
Hsin-Ta (Darren) Su		707			17,189
Total Current Assets		150,893			35,044
Hui-Chuan (Sandra) Lin		-			4,529
Investment		-			350,000
David Tang		14,023			-
Total Assets	$	150,893		$	385,044
Total	$	14,730		$	102,831
LIABILITIES AND STOCKHOLDERS’ (DEFICIT) EQUITY
CURRENT LIABILITIES
Accounts payable	$	102,185		$	100,746
Accrued expenses		-			1,590
Due to related parties		102,831			3,010
Total Current Liabilities		205,016			105,346
Commitment and contingencies (Note 8)		29,226			26,226
STOCKHOLDERS’ EQUITY
Common stock; $0.001 par value; 10,000,000,000 shares authorized; 299,686,921 and 299,686,921 shares issued and outstanding as of September 30, 2022 and 2021, respectively		299,687			299,687
Additional paid-in capital		16,975,058			16,911,770
Discount on common stock		(7,241,581	)		(7,241,581	)
Accumulated other comprehensive loss		(193,558	)		(193,583	)
Accumulated deficit		(9,922,955	)		(9,522,821	)
Total Stockholders’ (Deficit) Equity		(83,349	)		253,472
Total Liabilities and Stockholders’ (Deficit) Equity	$	150,893		$	385,044

FThe related party balances are unsecured, interest-5free and due on demand.

~~GENUFOOD ENERGY~~NOTE ~~ENZYMES~~8 ~~CORPORATION~~– INCOME TAXES

~~CONSOLIDATED~~The Company ~~STATEMENTS~~has OFnot ~~OPERATIONS~~generated ~~AND~~any ~~COMPREHENSIVE~~revenue ~~LOSS~~from any source in the United States and had consolidated net loss for all the years since inception in 2010. Management believes GEEC does not have any U.S. income tax liability due. However, even though the Company does not have U.S. income tax liability, it may be required to file Form 5471 each year with the Internal Revenue Service (the “IRS”) of Department of Treasury. GEEC falls in the Category Five Filer (as a domestic corporation). The Company used to have subsidiaries: GEECIS in Sri Lanka that was established in May 2011, GESPL in Singapore that was established in February 2012, and GESTL in Thailand that was established in December 2014. The subsidiaries in Sri Lanka and Thailand were disposed in 2014 and 2016, respectively. The Singapore subsidiary has been inactive since 2016 and dissolved in January 2023.

	For the years ended September 30,
	2022			2021
REVENUE	$	-		$	-
OPERATING EXPENSES
General and administrative expenses		396,311			363,637
Total operating expenses		396,311			363,637
LOSS FROM OPERATIONS		(396,311	)		(363,637	)
OTHER INCOME (EXPENSE)
Interest income (expense)		6			(1,734	)
Impairment expense		-			(1,050,000	)
Foreign currency income (loss)		6			(511	)
Other non-operating income (expenses), net		(3,835	)		52,250
Total other expense		(3,823	)		(999,995	)
Loss before income taxes		(400,134	)		(1,363,632	)
Income tax expense		-			800
NET LOSS	$	(400,134	)	$	(1,364,432	)
OTHER COMPREHENSIVE INCOME (LOSS)
Foreign currency transaction adjustments		25			(1,548	)
COMPREHENSIVE LOSS	$	(400,109	)	$	(1,365,980	)
BASIC & DILUTED LOSS PER SHARE	$	*		$	*
WEIGHTED AVERAGE NUMBER OF ORGINARY SHARES-BASIC & DILUTED		299,686,921			215,264,348

F-12

*Internal Revenue ~~Less~~Code ~~than~~(“IRC”) Section 6038(a) requires information reporting with respect to certain foreign corporations (Form 5471) and describes the information required to be reported on this form. IRC Section 6038(b)(1) provides for a monetary penalty of $010,000 for each Form 5471 that is filed after the due date of the income tax return (including extensions) or does not include the complete and accurate information described in Section 6038(a).01 ~~per~~According ~~share~~to IRS rules, a penalty may apply to each Form 5471 which is filed after the due date of the income tax return. The penalty will be applied whether or not any tax is due on Form 1120.

~~F-6~~The Company believes that based on the current information available, it is difficult to determine whether it is probable that the Company will be charged penalties by IRS for the late filing of Form 5471 and even if it will be, it is difficult to reasonably estimate the amount of penalties that may be assessed.

~~GENUFOOD~~During the ~~ENERGY~~fiscal ~~ENZYMES~~year ~~CORPORATION~~ended September 30, 2021, the IRS imposed a $25,000 penalty on the Company for failure to file Form 5472, Information Return of a 25% Foreign-Owned U.S. Corporation or a Foreign Corporation Engaged in a U.S. Trade or Business, for the year ended September 30, 2020. The Company has engaged an outside professional advisor to seek for forgiveness of the penalty and interest thereon in the amount of $7,226, for a total of $32,226, which was still pending as of September 30, 2023.

~~CONSOILDATED~~NOTE ~~STATEMENTS~~9 OF– ~~STOCKHOLDERS’~~COMMITMENTS ~~EQUITY~~AND ~~(DEFICIT)~~CONTINGENCIES

~~FOR~~The Company ~~THE~~terminated ~~YEARS~~its ~~ENDED~~previous ~~SEPTEMBER~~virtual office agreement in Los Angeles, California and has established a new virtual office in Arcadia, California. The new arrangement is on a month-to-month basis at a cost of $200 per month. As of September 30, ~~2022~~2023, ~~AND~~the ~~2021~~Company has no material commitments under operating leases.

	Common Stock				Additional		Discount on						Accumulated Other			Total Stockholder ’s
	Number of Shares		Amount		Paid-in- Capital		common stock			Accumulated Deficit			Comprehensive Income (loss)			Equity (Deficit)
BALANCE AT SEPTEMBER 30, 2020		104,083,120	$	104,083	$	15,134,979	$	(7,241,581	)	$	(8,158,389	)	$	(192,035	)	$	(352,943	)
Shares issued for cash		180,000,000		180,000		1,605,959		-			-			-			1,785,959
Issuance of Common Stock for Debt Conversion – Current and Former Director and Officers		9,345,889		9,346		108,988		-			-			-			118,334
Issuance of Common Stock for Debt Conversion – Current and Former Consultants		3,198,076		3,198		34,306		-			-			-			37,504
Issuance of Common Stock for Debt Conversion		3,059,836		3,060		27,538		-			-			-			30,598
Foreign Currency Translation adjustment		-		-		-		-			-			(1,548	)		(1,548	)
Net Loss		-		-		-		-			(1,364,432	)		-			(1,364,432	)
BALANCE AT SEPTEMBER 30, 2021		299,686,921		299,687		16,911,770		(7,241,581	)		(9,522,821	)		(193,583	)		253,472
Stock-based compensation		-		-		63,288		-			-			-			63,288
Foreign Currency Translation adjustment		-		-		-		-			-			25			25
Net Loss		-		-		-		-			(400,134	)		-			(400,134	)
BALANCE AT SEPTEMBER 30, 2022		299,686,921	$	299,687	$	16,975,058	$	(7,241,581	)	$	(9,922,955	)	$	(193,558	)	$	(83,349	)

~~F-7~~NOTE 10 – SUBSEQUENT EVENTS

~~GENUFOOD~~Management ~~ENERGY~~has ~~ENZYMES~~evaluated ~~CORPORATION~~subsequent events pursuant to the requirements of ASC Topic 855, from the balance sheet date through the date when the consolidated financial statements were issued and determined that no subsequent events occurred that would require adjustment to or disclosure in the consolidated financial statements.

~~CONSOLIDATED STATEMENTS OF CASH FLOWS~~F-13

	For the Years Ended
	September 30,
	2022			2021
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$	(400,134	)	$	(1,364,432	)
Adjustments to reconcile net loss to net cash used in operating activities
Impairment to investment		-			1,050,000
Stock-based compensation		63,288			-
Change in operating assets and liabilities
Prepayment		11,280			(25,773	)
Accounts payable		1,507			(29,015	)
Accrued expenses		(1,590	)		14,256
Due to related parties		99,821			24,150
Commitment and contingencies		3,000			26,226
Net cash used in operating activities		(222,828	)		(304,588	)
CASH FLOWS FROM INVESTING ACTIVITIES
Payment for Hukui investment		-			(1,400,000	)
Proceeds from sale of Hukui investment		350,000			-
Net cash provided by (used in) financing activities		350,000			(1,400,000	)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from note payable – related party		-			30,000
Payment to note payable – related party		-			(120,410	)
Proceeds from issuance of common stock		-			1,785,959
Net cash provided by financing activities		-			1,695,549
EFFECT OF EXCHANGE RATE CHANGES ON CASH		(43	)		218
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS		127,129			(8,821	)
CASH AND CASH EQUIVALENTS - BEGINNING OF PERIOD		9,271			18,092
CASH AND CASH EQUIVALENTS - END OF PERIOD	$	136,400		$	9,271
SUPPLEMENTAL DISCLOSURE OF CASHFLOW INFORMATION
Cash paid for interest	$	-		$	2,271
Cash paid for income taxes	$	-		$	800
SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING ACTIVITIES:
Issuance of Common Stock for Debt Conversion – Director and Officers	$	-		$	118,334
Issuance of Common Stock for Debt Conversion – Consultants		-			37,504
Issuance of Common Stock for Debt Conversion – Promissory Note		-			30,000
Issuance of Common Stock for Debt Conversion – Promissory Note Interest		-			598
	$	-		$	186,436

299686921 526044946 false FY 0001510518 0 0001510518 2022-10-01 2023-09-30 0001510518 2024-01-09 0001510518 2023-03-31 0001510518 2023-09-30 0001510518 2022-09-30 0001510518 us-gaap:RelatedPartyMember 2023-09-30 0001510518 us-gaap:RelatedPartyMember 2022-09-30 0001510518 2021-10-01 2022-09-30 0001510518 us-gaap:CommonStockMember 2021-09-30 0001510518 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0001510518 gfoo:DiscountOnCommonStockMember 2021-09-30 0001510518 us-gaap:RetainedEarningsMember 2021-09-30 0001510518 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-09-30 0001510518 2021-09-30 0001510518 us-gaap:CommonStockMember 2021-10-01 2022-09-30 0001510518 us-gaap:AdditionalPaidInCapitalMember 2021-10-01 2022-09-30 0001510518 gfoo:DiscountOnCommonStockMember 2021-10-01 2022-09-30 0001510518 us-gaap:RetainedEarningsMember 2021-10-01 2022-09-30 0001510518 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-10-01 2022-09-30 0001510518 us-gaap:CommonStockMember 2022-09-30 0001510518 us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0001510518 gfoo:DiscountOnCommonStockMember 2022-09-30 0001510518 us-gaap:RetainedEarningsMember 2022-09-30 0001510518 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-09-30 0001510518 us-gaap:CommonStockMember 2022-10-01 2023-09-30 0001510518 us-gaap:AdditionalPaidInCapitalMember 2022-10-01 2023-09-30 0001510518 gfoo:DiscountOnCommonStockMember 2022-10-01 2023-09-30 0001510518 us-gaap:RetainedEarningsMember 2022-10-01 2023-09-30 0001510518 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-10-01 2023-09-30 0001510518 us-gaap:CommonStockMember 2023-09-30 0001510518 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0001510518 gfoo:DiscountOnCommonStockMember 2023-09-30 0001510518 us-gaap:RetainedEarningsMember 2023-09-30 0001510518 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-09-30 0001510518 gfoo:HukuiBiotechnologyCorporationHukuiMember us-gaap:SeriesCPreferredStockMember 2020-12-15 0001510518 gfoo:HukuiBiotechnologyCorporationHukuiMember us-gaap:SeriesCPreferredStockMember 2021-06-25 0001510518 gfoo:HukuiBiotechnologyCorporationHukuiMember us-gaap:SeriesCPreferredStockMember 2021-11-17 2021-11-17 0001510518 gfoo:HukuiBiotechnologyCorporationHukuiMember us-gaap:SeriesCPreferredStockMember 2021-11-17 0001510518 gfoo:HukuiSharesMember 2021-11-19 0001510518 gfoo:HukuiSharesMember 2021-11-01 2021-11-19 0001510518 gfoo:HukuiSharesMember 2022-10-01 2023-09-30 0001510518 gfoo:HukuiAgreementMember us-gaap:SeriesCPreferredStockMember 2020-09-01 2020-09-23 0001510518 gfoo:HukuiAgreementMember us-gaap:SeriesCPreferredStockMember 2020-09-23 0001510518 us-gaap:SeriesCPreferredStockMember 2020-12-15 0001510518 us-gaap:SeriesCPreferredStockMember 2020-12-01 2020-12-15 0001510518 us-gaap:SeriesCPreferredStockMember 2021-06-01 2021-06-25 0001510518 us-gaap:SeriesCPreferredStockMember 2021-06-25 0001510518 gfoo:HukuiAgreementMember us-gaap:SeriesCPreferredStockMember 2021-11-01 2021-11-17 0001510518 gfoo:HukuiAgreementMember us-gaap:SeriesCPreferredStockMember 2021-11-17 0001510518 2021-11-19 2021-11-19 0001510518 2023-02-24 0001510518 2023-02-24 2023-02-24 0001510518 2023-03-24 0001510518 2023-03-24 2023-03-24 0001510518 srt:ChiefExecutiveOfficerMember 2022-07-15 2022-07-15 0001510518 srt:ChiefExecutiveOfficerMember 2022-07-15 0001510518 us-gaap:ShareBasedCompensationAwardTrancheOneMember 2023-09-30 0001510518 us-gaap:StockOptionMember gfoo:VestingMember 2022-10-01 2023-09-30 0001510518 gfoo:VestingMember 2022-10-01 2023-09-30 0001510518 us-gaap:StockOptionMember 2022-10-01 2023-09-30 0001510518 us-gaap:StockOptionMember 2021-10-01 2022-09-30 0001510518 gfoo:YiLungOliverLinMember 2022-10-01 2023-09-30 0001510518 gfoo:JuiPinJohnLinMember 2022-10-01 2023-09-30 0001510518 gfoo:JiaTianJefferyLinMember 2022-10-01 2023-09-30 0001510518 gfoo:WenPiaoJackLaiMember 2022-10-01 2023-09-30 0001510518 gfoo:ShaoChengWillWangMember 2022-10-01 2023-09-30 0001510518 gfoo:KuangMingJamesTsaiMember 2022-10-01 2023-09-30 0001510518 gfoo:HsinTaDarrenSuMember 2022-10-01 2023-09-30 0001510518 gfoo:HuiChuanSandraLinMember 2022-10-01 2023-09-30 0001510518 gfoo:DavidTangMember 2022-10-01 2023-09-30 0001510518 gfoo:KuangMingJamesTsaiMember 2023-09-30 0001510518 gfoo:KuangMingJamesTsaiMember 2022-09-30 0001510518 gfoo:JuiPinJohnLinMember 2023-09-30 0001510518 gfoo:JuiPinJohnLinMember 2022-09-30 0001510518 gfoo:JiaTianJefferyLinMember 2023-09-30 0001510518 gfoo:JiaTianJefferyLinMember 2022-09-30 0001510518 gfoo:ShaoChengWillWangMember 2023-09-30 0001510518 gfoo:ShaoChengWillWangMember 2022-09-30 0001510518 gfoo:WenPiaoJackLaiMember 2023-09-30 0001510518 gfoo:WenPiaoJackLaiMember 2022-09-30 0001510518 gfoo:HsinTaDarrenSuMember 2023-09-30 0001510518 gfoo:HsinTaDarrenSuMember 2022-09-30 0001510518 gfoo:HuiChuanSandraLinMember 2023-09-30 0001510518 gfoo:HuiChuanSandraLinMember 2022-09-30 0001510518 gfoo:DavidTangMember 2023-09-30 0001510518 gfoo:DavidTangMember 2022-09-30 0001510518 us-gaap:RelatedPartyMember 2023-09-30 0001510518 us-gaap:RelatedPartyMember 2022-09-30 0001510518 2019-10-01 2020-09-30 0001510518 2020-10-01 2021-09-30 xbrli:shares iso4217:USD iso4217:USD xbrli:shares gfoo:Segment xbrli:pure

F-8

GENUFOOD ENERGY ENZYMES CORP NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

NOTE 1 – GENERAL ORGANIZATION AND BUSINESS

Since its inception, the Company has always been in the development stage and never generated significant revenues. The Company is currently developing business in Electric Vehicle Charge station. The Company has engaged in business agreements and development with various parties.

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The Company’s consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“US GAAP”) and pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”).

Principle of Consolidation

The consolidated financial statements include the accounts of GEEC and its wholly-owned subsidiary GESPL. All significant inter-company accounts and transactions have been eliminated in consolidation. The wholly-owned subsidiary of the Company did not have business activities during the year ended September 30, 2022 and 2021.

Use of Estimates

The preparation of the consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

F-9

Concentrations of Credit Risk

Cash and Cash Equivalents

The Company considers all highly liquid instruments with original maturities of three months or less when acquired to be cash equivalents. As of September 30, 2022 and 2021, the Company did not have cash equivalents. The Company’s cash was denominated in United States Dollars (“USD”) or New Taiwan Dollars (“TWD”) and was placed with banks in the United States of America and Taiwan.

Fair Value of Financial Instruments

● Level 1 inputs are quoted prices available for identical assets and liabilities in active markets. ● Level 2 inputs are observable for the asset or liability, either directly or indirectly, including quoted prices for similar assets and liabilities in active markets or other inputs that are observable or can be corroborated by observable market data. ● Level 3 inputs are less observable and reflect our own assumptions.

The Company’s financial instruments consist principally of cash and cash equivalents, accounts payable and accrued expenses and due to related parties. The carrying amounts of such financial instruments in the accompanying consolidated balance sheets approximate their fair values due to their relatively short-term nature. It is management’s opinion that the Company is not exposed to any significant currency or credit risks arising from these financial instruments.

Foreign Currency Translation and Transactions

The reporting and functional currency of GEEC is the USD. The functional currency of GESPL, a wholly owned subsidiary of GEEC, is the Singapore Dollar (“SGD”).

F-10

Transactions denominated in currencies other than the functional currency are translated into the functional currency at the exchange rates prevailing at the dates of the transactions. The resulting exchange difference, presented as foreign currency transaction loss, is included in the accompanying consolidated statements of operations.

Business Segments

The Company operates in only one segment.

Net Income (Loss) Per Share

The Company calculates net loss per share in accordance with ASC Topic 260, “Earnings per Share.” Basic loss per share is computed by dividing the net loss by the weighted-average number of common shares outstanding during the period. Diluted income per share is computed similar to basic loss per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common stock equivalents had been issued and if the additional common shares were dilutive. There were no potential dilutive debt or equity instruments issued and outstanding at any time during the years ended September 30, 2022 and 2021.

Discounts on Common Stock

Common stock issued lower than the Company’s par value is treated as common stock issued under discounts. The portion of the discount is shown separately as a deduction from the Company’s account of common stock on the Company’s consolidated financial statements.

Stock-Based Compensation

The Company accounts for its stock-based compensation in which the Company obtains employee services in share-based payment transactions under FASB ASC Topic 718, Compensation – Stock Compensation, which requires the Company to expense the cost of employee services received in exchange for an award of equity instruments based on the grant date fair value of such instruments over the vesting period.

Income Taxes

Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is recorded to reduce the Company’s deferred tax assets to the amount that is more likely than not to be realized.

The Company considers positive and negative evidence when determining whether a portion or all of its deferred tax assets will more likely than not be realized. This assessment considers, among other matters, the nature, frequency and severity of current and cumulative losses, forecasts of future profitability, the duration of statutory carry-forward periods, its experience with tax attributes expiring unused, and its tax planning strategies. The ultimate realization of deferred tax assets is dependent upon its ability to generate sufficient future taxable income within the carry-forward periods provided for in the tax law and during the periods in which the temporary differences become deductible. When assessing the realization of deferred tax assets, the Company has considered possible sources of taxable income including (i) future reversals of existing taxable temporary differences, (ii) future taxable income exclusive of reversing temporary differences and carry-forwards, (iii) future taxable income arising from implementing tax planning strategies, and (iv) specific known trend of profits expected to be reflected within the industry.

F-11

The Company recognizes a tax benefit associated with an uncertain tax position when, in its judgment, it is more likely than not that the position will be sustained upon examination by a taxing authority. For a tax position that meets the more-likely-than-not recognition threshold, the Company initially and subsequently measures the tax benefit as the largest amount that the Company judges to have a greater than 50% likelihood of being realized upon ultimate settlement with a taxing authority. The Company’s liability associated with unrecognized tax benefits is adjusted periodically due to changing circumstances, such as the progress of tax audits, case law developments and new or emerging legislation. Such adjustments are recognized entirely in the period in which they are identified. The Company’s effective tax rate includes the net impact of changes in the liability for unrecognized tax benefits and subsequent adjustments as considered appropriate by management. The Company classifies interest and penalties recognized on the liability for unrecognized tax benefits as income tax expense.

There were no current and deferred income tax provision recorded for the years ended September 30, 2022 and 2021 since the Company is in developing stage and did not generate any revenues in the two fiscal periods.

Recent Accounting Pronouncements

The Company considers the applicability and impact of all Accounting Standards Updates (“ASUs” or “ASU”) on the Company’s consolidated financial statements. Updates not listed below were assessed and determined to be either not applicable or are expected to have minimal impact on the Company’s consolidated financial position or results of operations. Recently issued ASUs that the Company feels may be applicable to the Company are as follows:

In August 2020, the FASB issued Accounting Standards Update No. 2020-06, Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40). The subtitle is Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity. This ASU addresses complex financial instruments that have characteristics of both debt and equity. The application of this ASU would reduce the number of accounting models for convertible debt instruments and convertible preferred stock. Limiting the accounting models would result in fewer embedded conversion features being separately recognized from the host contract as compared with current GAAP. Convertible instruments that continue to be subject to separation models are (1) those with embedded conversion features that are not clearly and closely related to the host contract, that meet the definition of a derivative, and that do not qualify for a scope exception from derivative accounting and (2) convertible debt instruments issued with substantial premiums for which the premiums are recorded as paid-in capital. To date, no such bifurcation has been necessary. Management is evaluating the potential impact. This ASU becomes effective for fiscal years beginning after December 15, 2023.

In March 2020, the FASB issued Accounting Standards Update No. 2020-03, Codification Improvements to Financial Instruments. There are seven issues addressed in this update. Issues 1 through 5 were clarifications and codifications of previous updates. Issue 3 relates only to depository and lending institutions and therefore would not be applicable to the Company. Issue 6 was a clarification on determining the contractual term of a net investment in a lease for purposes of measuring expected credit losses, an issue not applicable to the Company. Issue 7 relates to the regaining control of financial assets sold and the recordation of an allowance for credit losses. The amendment related to issues 1, 2, 4 and 5 become effective immediately upon adoption of the update. Issue 3 becomes effective for fiscal years beginning after December 15, 2019. Issues 6 and 7 become effective on varying dates that relate to the dates of adoption other updates. Management’s initial analysis is that it does not believe the new guidance will substantially impact the Company’s financial statements.

F-12

NOTE 3 – GOING CONCERN

As of September 30, 2022 and 2021, the Company had an accumulated deficit of $9,922,955 and $9,522,821, respectively. To date, the Company’s cash flow requirements have been primarily met through proceeds received from sales of Common Stock and investment. These and other factors raise substantial doubt about the Company’s ability to continue as a going concern. These consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets and liabilities that may result in the Company not being able to continue as a going concern.

The Company sold the 140,000 Hukui Shares for $350,000 cash on November 19, 2021. The proceeds have been used for operation expenses. Management is currently seeking additional funds for future operation.

NOTE 4 – INVESTMENT

Pursuant to that certain Series C Preferred Shares Subscription Agreement dated September 23, 2020 between the Company and Hukui (the “Hukui Agreement”), the Company agreed to purchase an aggregate 200,000 Series C Preferred Shares, at $10.00 per share, for an aggregate investment of $2,000,000, in a series of three closings from December 15, 2020 through June 30, 2022. On December 15, 2020, the Company purchased 80,000 shares of Series C Preferred Stock at $10.00 per share, for a total purchase price of $800,000; and on June 25, 2021, the Company purchased an additional 60,000 shares of Series C Preferred Stock at $10.00 per share, for a total purchase price of $600,000. The total $1,400,000 investment consists of less than 20% of Hukui’s total equity with no significant control over or influence on Hukui. The investment is recorded at cost.

On November 17, 2021, the Company entered into a stock purchase agreement to sell all 140,000 Hukui Shares at $2.50 per share for a total of $350,000, The sale was completed on November 19, 2021, resulting in loss of $1,050,000. The Company recognized impairment loss of the market value of the shares of $1,050,000 for the year ended September 30, 2021.

NOTE 5 – STOCKHOLDERS’ EQUITY (DEFICIT)

The Company is authorized under its articles of incorporation, as amended, to issue 10,000,000,000 shares of Common Stock, par value $0.001 per share.

Issuance of Common Stock

On December 15, 2020, the Company completed a private offering of its Common Stock. The Company sold 107,000,000 shares of its Common Stock to 34 individuals at a purchase price of $0.01 per share, for gross proceeds of $1,070,000, before allocating certain expenses associated with the offering in the amount of $5,852 as adjusted paid-in capital.

Effective March 31, 2021, the Company issued an aggregate 6,399,965 shares of its Common Stock to certain of its directors, officers, employees and a consultant, who converted accrued and unpaid compensation in the aggregate amount of $94,398. Of this amount, (i) $37,998 was with respect to amounts accrued during fiscal year 2020 and was converted at a rate of $0.05 per share into an aggregate 759,965 shares of its Common Stock; and (ii) $56,400 was with respect to amount accrued during fiscal year 2021 through March 31, 2021 and was converted at a rate of $0.01 per share into an aggregate 5,640,000 shares of its Common Stock.

F-13

During the year ended September 30, 2021, one of the Company’s shareholders made a loan to the Company in the principal amount of $30,000, primarily to pay our expenses. The loan bore simple interest at a rate of 4% per annum and was payable as to both principal and interest on the maturity date of April 9, 2021. On the maturity date, the holder of the note converted the outstanding principal, together with accrued and unpaid interest of $598, into 3,059,836 shares of the Company’s Common Stock, at the rate of $0.01 per share.

On June 15, 2021, the Company sold and issued 63,000,000 shares of Common Stock to 18 individuals, at purchase price of $0.01 per share, from a private offering of its Common Stock (the “Spring 2021 Offering”). The gross proceeds were $630,000, before allocating certain expenses associated with the offering in the amount of $7,230 as adjusted paid-in capital.

On July 15, 2021, the Company completed the Spring 2021 Offering of its Common Stock, on which date it sold and issued additional 10,000,000 shares of its Common Stock to five individuals at a purchase price of $0.01 per share, for gross proceeds of $100,000, before allocating certain expenses associated with the offering in the amount of $959 as adjusted paid-in capital.

Effective September 30, 2021, the Company issued an aggregate 6,144,000 shares of its Common Stock to certain of its directors, officers, employees and a consultant, who converted accrued and unpaid compensation in the aggregate amount of $61,440.

Stock Options

On July 15, 2022, the CEO, David Tang, was granted 15,000,000 options to purchase shares at $0.01 per share. As of September 30, 2022, total options granted was 15,000,000 and none was vested. This option will be subject to a vesting schedule providing for twenty-five percent (25%) vesting after the first twelve (12) months of employment and monthly vesting as to the remaining seventy-five percent (75%) of the shares over the following thirty-six (36) months after the first anniversary of the employment commencement date. These stock options are exercisable over a maximum period of 10 years from the grant date. The weighted average grant date fair value of options granted during the year ended September 30, 2022 was $0.02.

Compensation costs associated with the Company’s stock options are recognized, based on the grant-date fair value of these options, over the requisite service period, or vesting period. Accordingly, the Company recognized stock-based compensation expense of $63,288 and $0, respectively, which was included in the general and administrative expenses in the consolidated statements of operations for the years ended September 30, 2022 and 2021.

The fair value of the stock options listed above was determined using the Black-Scholes option pricing model with the following assumptions:

	September 30, 2022			September 30, 2021
Risk-free interest rate		2.99	%		–
Expected term		6.08 years			–
Expected volatility		379.35	%		–
Expected dividend yield		0	%		–

The following is a summary of the option activity for the year ended September 30, 2022:

Options	Number of Underlying Shares		Weighted average exercise price		Weighted Average Remaining Contractual Life (years)		Aggregate Intrinsic Value
Outstanding at October 1, 2021		–	$	–		–	$	–
Granted		15,000,000	$	0.01		–	$	–
Exercised		–	$	–		–	$	–
Forfeited or expired		–	$	–		–	$	–
Outstanding at September 30, 2022		15,000,000	$	0.01		9.8	$	375,000
Vested and expected to vest as of September 30, 2022		15,000,000	$	0.01		9.8	$	375,000
Exercisable at September 30, 2022		–	$	–		–	$	–

As of September 30, 2022, unrecognized total compensation cost associated with these options was $236,712. This expense is expected to be recognized over a weighted-average period of 3.79 years.

F-14

NOTE 6 – RELATED PARTY TRANSACTIONS

Related Parties

Due to Related Parties

The Company’s due to related parties balances are as follows:

	September 30, 2022		September 30, 2021
Kuang Ming (James) Tsai	$	20,755	$	1,000
Jui Pin (John) Lin		8,048		1,510
Jia Tian (Jeffery) Lin		2,500		-
Shao-Cheng (Will) Wang		27,600		-
Wen-Piao (Jack) Lai		22,210		500
Hsin-Ta (Darren) Su		17,189		-
Hui-Chuan (Sandra) Lin		4,529		-
Total	$	102,831	$	3,010

The related party balances are unsecured, interest-free and due on demand.

NOTE 7 – INCOME TAXES

The Company has not generated any revenue from any source in the United States and had consolidated net loss for all the years since inception in 2010. Management believes GEEC does not have any U.S. income tax liability due. However, even though the Company does not have U.S. income tax liability, it may be required to file Form 5471 each year with the Internal Revenue Service (the “IRS”) of Department of Treasury. GEEC falls in the Category Five Filer (as a domestic corporation). The Company used to have subsidiaries: GEECIS in Sri Lanka that was established in May 2011, GESPL in Singapore that was established in February 2012, and GESTL in Thailand that was established in December 2014. The subsidiaries in Sri Lanka and Thailand were disposed in 2014 and 2016, respectively, and the Singapore subsidiary has been inactive since 2016.

Internal Revenue Code (“IRC”) Section 6038(a) requires information reporting with respect to certain foreign corporations (Form 5471) and describes the information required to be reported on this form. IRC Section 6038(b)(1) provides for a monetary penalty of $10,000 for each Form 5471 that is filed after the due date of the income tax return (including extensions) or does not include the complete and accurate information described in Section 6038(a). According to IRS rules, a penalty may apply to each Form 5471 which is filed after the due date of the income tax return. The penalty will be applied whether or not any tax is due on Form 1120.

The Company believes that based on the current information available, it is difficult to determine whether it is probable that the Company will be charged penalties by IRS for the late filing of Form 5471 and even if it will be, it is difficult to reasonably estimate the amount of penalties that may be assessed.

F-15

During the fiscal year ended September 30, 2021, the IRS imposed a $25,000 penalty on the Company for failure to file Form 5472, Information Return of a 25% Foreign-Owned U.S. Corporation or a Foreign Corporation Engaged in a U.S. Trade or Business, for the year ended September 30, 2020. The Company has engaged an outside professional advisor to seek for forgiveness of the penalty and interest thereon in the amount of $4,226, for a total of $29,226, which was still pending as of September 30, 2022.

NOTE 8 – COMMITMENTS AND CONTINGENCIES

The Company terminated its previous virtual office agreement in Los Angeles, California and has established a new virtual office in Arcadia, California. The new arrangement is on a month-to-month basis at a cost of $200 per month. As of September 30, 2022, the Company has no material commitments under operating leases.

NOTE 9 – SUBSEQUENT EVENTS

The Company announced that on October 26, 2022, it entered into three Charging Station Site Host Agreements (the “Agreements”) with two institutions (the “Site Hosts”), respectively, pursuant to which the Site Hosts agree to allow the Company to install its electric vehicle charging stations at the locations set forth in the Agreements (the “Charging Stations”). Under the Agreements, the Company agrees to share its revenue generated by the sales of electricity at the Charging Stations with the Site Hosts.

The foregoing description of the Agreements does not purport to be complete and is subject to, and qualified in its entirety by reference to the Agreements.

Management has evaluated subsequent events pursuant to the requirements of ASC Topic 855, from the balance sheet date through the date when the consolidated financial statements were issued and determined that no subsequent events occurred that would require adjustment to or disclosure in the consolidated financial statements.

F-16

215264348 299686921 false FY 0001510518 0 0001510518 2021-10-01 2022-09-30 0001510518 2023-01-11 0001510518 2022-03-31 0001510518 2022-09-30 0001510518 2021-09-30 0001510518 2020-10-01 2021-09-30 0001510518 us-gaap:CommonStockMember 2020-09-30 0001510518 us-gaap:AdditionalPaidInCapitalMember 2020-09-30 0001510518 gfoo:DiscountOnCommonStockMember 2020-09-30 0001510518 us-gaap:RetainedEarningsMember 2020-09-30 0001510518 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-09-30 0001510518 2020-09-30 0001510518 us-gaap:CommonStockMember 2020-10-01 2021-09-30 0001510518 us-gaap:AdditionalPaidInCapitalMember 2020-10-01 2021-09-30 0001510518 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-10-01 2021-09-30 0001510518 us-gaap:RetainedEarningsMember 2020-10-01 2021-09-30 0001510518 us-gaap:CommonStockMember 2021-09-30 0001510518 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0001510518 gfoo:DiscountOnCommonStockMember 2021-09-30 0001510518 us-gaap:RetainedEarningsMember 2021-09-30 0001510518 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-09-30 0001510518 us-gaap:AdditionalPaidInCapitalMember 2021-10-01 2022-09-30 0001510518 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-10-01 2022-09-30 0001510518 us-gaap:RetainedEarningsMember 2021-10-01 2022-09-30 0001510518 us-gaap:CommonStockMember 2022-09-30 0001510518 us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0001510518 gfoo:DiscountOnCommonStockMember 2022-09-30 0001510518 us-gaap:RetainedEarningsMember 2022-09-30 0001510518 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-09-30 0001510518 us-gaap:SeriesCPreferredStockMember 2020-12-01 2020-12-15 0001510518 us-gaap:SeriesCPreferredStockMember 2021-06-01 2021-06-25 0001510518 us-gaap:SeriesCPreferredStockMember 2021-11-01 2021-11-17 0001510518 us-gaap:SeriesCPreferredStockMember 2021-11-17 0001510518 gfoo:HukuiBiotechnologyCorporationMember us-gaap:SeriesCPreferredStockMember 2021-11-10 2021-11-19 0001510518 us-gaap:SeriesCPreferredStockMember 2021-11-10 2021-11-19 0001510518 gfoo:HukuiAgreementMember us-gaap:SeriesCPreferredStockMember 2020-09-01 2020-09-23 0001510518 gfoo:HukuiAgreementMember us-gaap:SeriesCPreferredStockMember 2020-09-23 0001510518 us-gaap:SeriesCPreferredStockMember 2020-12-15 0001510518 us-gaap:SeriesCPreferredStockMember 2021-06-25 0001510518 gfoo:HukuiAgreementMember us-gaap:SeriesCPreferredStockMember 2021-11-01 2021-11-17 0001510518 gfoo:HukuiAgreementMember us-gaap:SeriesCPreferredStockMember 2021-11-17 0001510518 2021-11-01 2021-11-19 0001510518 gfoo:PrivateOfferingMember 2020-12-05 2020-12-15 0001510518 gfoo:PrivateOfferingMember 2020-12-15 0001510518 2020-10-01 2021-03-31 0001510518 2021-03-31 0001510518 us-gaap:CommonStockMember 2021-03-31 0001510518 us-gaap:CommonStockMember 2020-10-01 2021-03-31 0001510518 2021-06-15 0001510518 gfoo:PrivateOfferingMember 2021-06-15 0001510518 2021-06-01 2021-06-15 0001510518 2021-07-01 2021-07-15 0001510518 2021-07-15 0001510518 srt:ChiefExecutiveOfficerMember 2022-07-01 2022-07-15 0001510518 srt:ChiefExecutiveOfficerMember 2022-07-15 0001510518 us-gaap:StockOptionMember 2021-10-01 2022-09-30 0001510518 gfoo:YiLungOliverLinMember 2021-10-01 2022-09-30 0001510518 gfoo:JuiPinJohnLinMember 2021-10-01 2022-09-30 0001510518 gfoo:JiaTianJefferyLinMember 2021-10-01 2022-09-30 0001510518 gfoo:WenPiaoJackLaiMember 2021-10-01 2022-09-30 0001510518 gfoo:ShaoChengWillWangMember 2021-10-01 2022-09-30 0001510518 gfoo:KuangMingJamesTsaiMember 2021-10-01 2022-09-30 0001510518 gfoo:NanYaoJakeChanMember 2021-10-01 2022-09-30 0001510518 gfoo:HsinTaDarrenSuMember 2021-10-01 2022-09-30 0001510518 gfoo:HuiChuanSandraLinMember 2021-10-01 2022-09-30 0001510518 gfoo:KuangMingJamesTsaiMember 2022-09-30 0001510518 gfoo:KuangMingJamesTsaiMember 2021-09-30 0001510518 gfoo:JuiPinJohnLinMember 2022-09-30 0001510518 gfoo:JuiPinJohnLinMember 2021-09-30 0001510518 gfoo:JiaTianJefferyLinMember 2022-09-30 0001510518 gfoo:JiaTianJefferyLinMember 2021-09-30 0001510518 gfoo:ShaoChengWillWangMember 2022-09-30 0001510518 gfoo:ShaoChengWillWangMember 2021-09-30 0001510518 gfoo:WenPiaoJackLaiMember 2022-09-30 0001510518 gfoo:WenPiaoJackLaiMember 2021-09-30 0001510518 gfoo:HsinTaDarrenSuMember 2022-09-30 0001510518 gfoo:HsinTaDarrenSuMember 2021-09-30 0001510518 gfoo:HuiChuanSandraLinMember 2022-09-30 0001510518 gfoo:HuiChuanSandraLinMember 2021-09-30 0001510518 2019-10-01 2020-09-30 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure

Filing Compare · Genufood Energy Enzymes Corp.